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The goal of the research was to synthesize magnetic polymeric nanoparticles 
(MPNPs) under 100 nm in diameter, for future drug delivery applications. The thesis is 
divided into two main sections. In the first section, a quantitative, and comprehensive 
description of the top-down synthesis techniques available for poly(lactide-co-glycolide) 
(PLGA) and magnetic polymeric nanoparticles (MPNPs) formation is provided, as well 
as the techniques commonly used for nanoparticle characterization. In the second part, a 
novel way to form MPNPs is presented. The emulsion evaporation method was selected 
as the method of choice to form poly(lactide-co-glycolide) (PLGA) nanoparticles with 
entrapped magnetite (Fe3O4) in the polymeric matrix, in the presence of sodium dodecyl 
sulfate (SDS) as a surfactant. The magnetite, a water soluble compound, was surface 
functionalized with oleic acid to ensure its efficient entrapment in the PLGA matrix. The 
inclusion of magnetite with oleic acid (MOA) into the PLGA nanoparticles was 
accomplished in the organic phase. Synthesis was followed by dialysis, performed to 
eliminate the excess SDS, and lyophilization. The nanoparticles obtained ranged in size 
between 38.6 nm and 67.1 nm for naked PLGA nanoparticles, and from 78.8 to 115.1 nm 
for MOA entrapped PLGA nanoparticles. The entrapment efficiency ranged from 57.36% 







CHAPTER 1. INTRODUCTION 
January 2005, FDA approves ABRAXANE® for breast cancer treatment, the first 
nanoparticle system for drug delivery [1, 2]. This system, based on nanoparticle 
Albumin-bound (nab®) Paclitaxel, showed better and faster rate of shrinking tumors in 
460 patients with metastic breast cancer, almost double compared with solvent-based 
Taxol®. The application of nanotechnology to the health market is significant, 
considering the extensive research developed in this area during the last 20 years.  
A basic requirement for the use of nanoparticles and other synthetic systems as 
drug delivery systems for human therapy is their biodegradability and biocompatibility. 
Another challenge for the use of nanoparticles as drug delivery systems is to minimize 
their side effects in the biological system in which dispersed. A controlled size 
distribution (monodisperse distribution of size), for accurate drug administration, is a 
central need for the use of nanoparticles in drug delivery systems. Moreover, the absence 
of toxic residues in the final nanosystem is required, and therefore stronger restrictions to 
the type of methods used for nanoparticles formation exist. Additionally, the stability of 
the nanoparticles should be addressed if parenteral administration of the nanoparticle is 
used. The aggregation process due to dispersion forces (i.e. electrostatic, hydrogen 
bonding, hydrophilic/hydrophobic, steric-Van der Waals) is the principal drawback of 
nanoparticle use in drug delivery. Therefore, the understanding of the complexity of the 
nanosystem, the biological system, and the interactions between the two is a basic 
requirement for successful implementation of new nano-systems designed for drug 
delivery.  
 The goal of the present research was to form nanoparticles from a preformed 
polymer (poly(lactide-co-glycolide)) with entrapped magnetite. The thesis is divided in 
two main sections. The first section contains a review of PLGA and magnetic polymeric 
nanoparticles (MPNPs) synthesis and characterization. A detailed description of the 
important parameters affecting the nanoparticle size is also provided. The second section 
of the thesis is focused on the entrapment of magnetite into the PLGA matrix. The 
formation process of MPNPs nanoparticles by emulsion evaporation method, the effect of 
surfactant, and the magnetite entrapment results are explained in detail. The selection of 
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the method, materials, and processing parameters to form MPNPs (Chapter 3) is based on 
the extensive literature cited in the first section of the thesis (Chapter 2), as follows. 
1.1. Method Selection 
 Two main procedures can be followed to form polymeric nanoparticles, namely 
top-down and bottom-up techniques. The top-down methods use size reduction to obtain 
controlled-size nanoparticles. This size reduction is based on the application of strong 
shear stress by wave sound emission (sonication), high pressure (microfluidization), and 
high speed agitation (homogenization). The bottom-up methods start from individual 
molecules to form nanoparticles, by polymerization. The polymerization methods 
commonly used are emulsion polymerization (water in oil, oil in water, and 
polymerization in bicontinuous structures), dispersion polymerization, and interfacial 
polymerization [3]. Monomers, initiators, additives, and solvent are the basic chemical 
components used in the polymerization methods. The main drawbacks of the bottom-up 
methods are the presence of residual sub-products in the final nanoparticles that can 
impart toxicity to the nanoparticles, the difficulty in the prediction of polymer molecular 
weight, affecting the biodistribution and release behavior of the drug from the 
nanoparticle; and the possibility for drug inhibitions due to interactions, or cross reactions 
of the drug with activated monomers and H+ ions present during polymerization [4]. To 
overcome these limitations, top-down methods were developed using naturals and 
synthetic polymers. The emulsion evaporation, salting out, nanoprecipitation, and 
emulsion diffusion are the main top-down methods used to form polymeric nanoparticles. 
During the last years, significant modifications of these methods have been developed 
(see Chapter 2 for details) in an attempt to avoid the use of toxic solvents and surfactants, 
to improve drug entrapment efficiency and nanoparticle stability, and to more efficiently 
use energy in droplet size reduction. All these methods involve two liquid phases, the 
organic phase which can dissolve the polymer and the other hydrophobic components, 
and the continuous aqueous phase.   
Each synthesis method has advantages and disadvantages as described in detail in 
Chapter 2. Emulsion evaporation, was selected as the method of choice in the present 
research due to its advantages described as follows. The versatility and flexibility of the 
method allows for the use of different polymers and solvents. Emulsion evaporation 
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permits higher polymer concentration per batch production improving the nanoparticle 
yield by batch. It can be used for entrapment of hydrophobic and hydrophilic drugs. The 
hydrophobic drugs use oil in water (o/w) emulsion. The hydrophilic drugs require the use 
of double emulsion (w/o/w), and the first aqueous phase dissolves the hydrophilic drug. 
The fast evaporation rate of the solvent permits a reduction in the processing time [4, 5, 
6, 7]; moreover the evaporation rate may be used to control the nanoparticle size as 
compared with other methods where evaporation follows the nanoparticle formation. 
1.2. Materials Selection 
1.2.1. Polymer (PLGA) 
A wide spectrum of synthetic and natural polymers is available for nanoparticle 
formation, but their biocompatibility and biodegradability are the major limiting factors 
for their use in the drug delivery area. Natural polymers are more restricted due to 
variation in their purity. Also, some natural polymers require crosslinking, which can 
inactivate the entrapped drug [8]. Synthetic polymers, on the other hand, offer better 
reproducibility of the chemical characteristics of the synthesized nanoparticles as 
compared to the natural polymers. Synthetic polymers from the ester family, such as 
poly(lactic acid), poly(β-hydroxybutyrate), poly(caprolactone), poly(dioxanone), or other 
families such as poly(cyanoacrylates), poly(acrylic acid), poly(anhydrides), poly(amides), 
poly(ortho esters), poly(ethylene glycol),  and poly(vinyl alcohol) are suitable for drug 
delivery due to their biodegradability, special release profiles and biocompatibility [9].  
Poly(lactide-co-glycolide acid) (PLGA), from the ester family, has been widely 
used in the biomedical industry as a major components in biodegradable sutures, bone 
fixation nails and screws [10, 11]. It is a well-characterized polymer, its degradation sub-
products are non toxic, it provides controlled drug release profiles by changing the PLGA 
copolymer ratio which affects the crystallinity (low crystallinity, more amorphous 
polymer means more fast degradation) of PLGA [9, 10, 11, 12, 13]. For these reasons, 
PLGA has been selected as the polymer of choice in the present research. PLGA of 
different molecular weights (from 10 kDa to over 100 kDa) and different copolymer 
molar ratios (50:50, 75:25, and 85:15) is available on the market. Molecular weight and 
copolymer molar ratio influence the degradation process and release profile of the drug 
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entrapped. In general, low molecular weight PLGA with higher amounts of glycolic acid 
offer faster degradations rates [13, 14].   
1.2.2. Solvent (Ethyl Acetate) 
The top-down method requires the dissolution of the polymer in the aqueous or 
organic phase. The solvent election is restricted to the method used; for example, 
nanoprecipitation and emulsion diffusion use water-soluble solvents (i.e. acetone, benzyl 
alcohol), and emulsion evaporation requires water immiscible solvents. The method 
selected to form the nanoparticles was emulsion evaporation, in which the polymer 
(PLGA) was dissolved in the organic phase (solvent). The chlorinate solvents have been 
extensively used with this method to dissolve the PLGA (i.e. methylene chloride, 
dichloromethane, chloroform), but their toxicity and inflammability are of concern [15, 
16]. A solvent that could be used as an alternative to chlorinate solvents is ethyl acetate. 
The low toxicity, low boiling point (77 °C) and inflammability are the main advantages 
of using ethyl acetate to dissolve the polymer. Because ethyl acetate is partially water 
soluble however, it is required to saturate the solvent with water before emulsification [7, 
17].  
1.2.3. Surfactant (SDS) 
The stability of the organic droplet (ethyl acetate and PLGA) in water, during the 
emulsification step, is insured by the addition of surfactants. A wide spectrum of 
surfactants are available for emulsion stabilization, ionic surfactants (cationic, anionic, 
zwitterionic) and nonionic surfactants. The nonionic surfactants are macromolecules 
formed by copolymers or tripolymers (amphiphilic) which can form stable micelles due 
to the hydrophobic hydrophilic interactions with the two phases. The anionic and cationic 
surfactants use electrostatic interactions to stabilize emulsions. The major nonionic 
surfactants used in the emulsion evaporation method are poly(vinyl alcohol) (PVA), 
poloxamer and poloxamines family, pluronic family (F68, F127, and others), sodium 
cholate, and tween 80. The formation of amphiphilic PLGA molecule has been studied to 
eliminate the surfactant addition during the emulsification step; this is accomplished by 
the attachment of a hydrophilic polymer (covalent link) to hydrophobic PLGA. Some of 
the common hydrophilic polymers used are poly(ethylene glycol) (PEG), chitosan, and 
poly(ethylene oxide) (PEO) [18, 19]. Anionic or cationic surfactants permit formation of 
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micelles under 100 nm [20, 21] because of the electrostatic interaction (and other 
properties like value of packing number, HLB value, surface tension, and morphology). 
Sodium dodecyl sulfate (SDS), an anionic surfactant, was selected because it has high 
HLB value (40) and forms micelles with sizes ranging between 20 to 150 nm in oil in 
water emulsion [7, 21, 22].  
1.3. Processing Parameters 
 The method and material selection, as well as the synthesis parameters play an 
important role in forming nanoparticles of controlled physical and chemical properties. 
Process parameters like phase volume ratio, sonication time and amplitude, amount of 
surfactant, PLGA concentration, evaporation conditions, and purification play a key role 
in determining the final nanoparticle size. Synthesis parameters were selected as follows. 
The phase volume ratio used was 20%, value based on previous works [7, 23, 24]. In the 
sonication step (droplet size reduction), two main parameters were controlled, the 
amplitude and the sonication time. The amplitude, defined as the peak to peak 
displacement at the probe tip, and the sonication time were selected based on the work of 
Landfester, K. [25], which showed that amplitudes over 30% formed small nano-droplets 
for a sonication time of 500 seconds. The sonication time selected was 10 minutes with 
39% amplitude, which were proven experimentally to form small size nanoparticles (See 
Chapter 3). The PLGA concentration used was 5 %w/v (mg PLGA/ml ethyl acetate) 
based on previous published studies [23, 24, 26]. Dialysis was selected as a purification 
method to reduce the excess of SDS as opposed to ultracentrifugation, because of the 
aggregation of the nanoparticles observed when centrifugation was used. The time of 
dialysis and number of washes was based on the published work of Jeong et al. [27, 28]. 
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CHAPTER 2. SYNTHESIS AND CHARACTERIZATION OF 





Synthetic polymers and natural macromolecules have been extensively researched 
as colloidal materials for nanoparticle production designed for drug delivery. Synthetic 
polymers have the advantage of high purity and reproducibility over natural polymers. 
Among the synthetic polymers, the polyesters family (i.e. poly(lactic acid) (PLA), poly(e-
caprolactone) (PCL), poly(glycolic acid) (PGA)) are of interest in the biomedical area 
because of their biocompatibility and biodegradability properties. In particular, 
poly(lactide-co-glycolide) (PLGA) has been FDA approved for human therapy [1].  
The size and size distribution of the PLGA nanoparticles and magnetic polymeric 
nanoparticles (MPNPs) among other physical characteristics, are affected by the 
technique used for the nanoparticle production and the pertinent synthesis parameters, i.e. 
PLGA molecular weight, the addition of active components, surfactants, and other 
additives [2-8]. The current review is designed to present the reader with comprehensive 
information on PLGA nanoparticle synthesis, control of nanoparticle properties (i.e. size, 
size distribution, zeta potential, morphology, hydrophobicity/hydrophilicity, drug 
entrapment) by manipulation of the synthesis parameters, methods for NPMPs synthesis, 
and methods available for nanoparticle characterization. The words nanoparticles and 
nanospheres will be used interchangeably in this review based on the term preferably 
used by the cited authors; both terms denote particles smaller than 1 µm (1000 nm).  
A number of reviews published in the literature focused on polymeric 
nanoparticle synthesis in general and PLGA nanoparticles in particular [7, 9-16]. The 
current review differs from the aforementioned reviews in several ways. First, it focuses 
specifically on PLGA nanoparticles, covering topics such as synthesis, size control and 
characterization. Second, it addresses in detail all top-down techniques available for 
PLGA nanoparticle formation. Third and last, in-depth discussions of available methods 
                                                 
1 Reprinted with permission from “Brill Academic Publishers”  
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to control the size, size distribution, surface charge, and other nanoparticle properties are 
also presented.  
2.2. Synthesis of PLGA Nanoparticles  
Methods available for PLGA nanoparticle synthesis can be divided into two 
classes: bottom-up and top-down techniques. The bottom-up techniques such as emulsion 
or microemulsion polymerization, interfacial polymerization, and precipitation 
polymerization, employ a monomer as a starting point. Emulsion evaporation, emulsion 
diffusion, solvent displacement, and salting out are top-down techniques, in which the 
nanoparticles are synthesized from the pre-formed polymer. Table 1 summarizes the 
nanoparticles characteristics (size, nanoparticle yield) formed by different methods 
(emulsion diffusion, salting out, nanoprecipitation, emulsion evaporation, dialysis, 
solvent diffusion), as a function of important parameters (polymer concentration, 
copolymer ratio, polymer molecular weight, surfactant concentration, solvent used, phase 
volume ratio). The data is catalogued according to the method used for nanoparticle 
formation.  
2.2.1. Emulsion Diffusion Method  
In this synthetic scheme, the polymer (PLGA) is dissolved in an organic phase 
(e.g., benzyl alcohol, propylene carbonate, ethyl acetate), which must be partially 
miscible in water. The organic phase is emulsified with an aqueous solution of a suitable 
surfactant (i.e. anionic sodium dodecyl sulfate (SDS), non-ionic polyvinyl alcohol (PVA), 
or cationic didodecyl dimethyl ammonium bromide (DMAB), under stirring. The 
diffusion of the organic solvent and the counter diffusion of water into the emulsion 
droplets induce polymer nanoparticle formation [11].  
Important parameters that affect the nanoparticle size synthesized by emulsion 
evaporation are: PLGA copolymer ratio, polymer concentration, solvent nature, 
surfactant polymer molecular weight, viscosity, phase ratios, stirring rate, solvent nature, 
temperature and flow of water added.  
• Lactide/glycolide ratio 
The common PLGA copolymer ratios (lactide/glycolide molar ratio) used are 
50:50 and 75:25. The difference detected in nanoparticles size is minimal when different 
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copolymer ratios are used. Konan et al. [17] obtained nanoparticles with a mean size of 
93 nm for 50:50 PLGA and 95 nm for 75:25 PLGA. 
• PLGA concentration  
The data obtained by Kwon et al. [18] showed the effect of PLGA concentration 
on the nanoparticle size. For an increased PLGA concentration from 1% to 4% w/v, an 
increase in the mean nanoparticle size from 205 nm to 290 nm was observed (Figure 2.1); 
PVA concentration was maintained at 2.5% w/v, and the solvent used was propylene 
carbonate (PC) in all experiments. The work of Lee et al. [19] showed similar results. At 
a fixed agitation (homogenizer speed 15000 RPM and agitator speed 400 RPM), the 
mean nanoparticle size obtained was 120 nm for 1% w/v PLGA, and 230 nm for 5% w/v 
PLGA. The solvent used was ethyl acetate, and the surfactant was 5% of Pluronic F-127 
in aqueous suspension.  
 
Figure 2.1. Effect of PLGA concentration on the mean particle size of PLGA 
nanoparticles (PVA concentration of 2.5 % w/v). Reproduced from Ref. Kwon et al. 
[18]  
• Solvents (organic phase) 
The nature of the organic phase affects the final nanoparticle size. This is clearly 
shown by Choi et al. [20]. Ethyl acetate, methyl ethyl ketone, propylene carbonate, and 
benzyl alcohol were used to dissolve the PLGA (75:25 with a molecular weight from 75 
to 120 kDa), and the continuous phase contained the surfactant poloxamer 188. The 
smaller nanosphere size was 120 nm when ethyl acetate was used, and it was close to the 
 
11 
nanosphere size obtained with methyl ethyl ketone, 125 nm. The highest size 
nanoparticles of 260 nm were obtained with benzyl alcohol as the organic solvent. The 
experiments were carried out under a constant PLGA concentration of 2% w/v. 
• Thermodynamic parameters  
Choi et al. [20] studied the exchange solvent ratio, solubility, and polymer-solvent 
interaction in a quest for the right method to decrease nanoparticle size. The PLGA 
concentration used was 2 mg/ml, with four different solvents (ethyl acetate, methyl ethyl 
ketone, propylene carbonate, and benzyl alcohol). Ethyl acetate solvent formed the 
smallest nanospheres (approx. 120 nm in size). The authors suggest that solvents with 
low exchange ratio, ratio between diffusion from solvent to water and vice versa, and 
high polymer-solvent interaction parameter form small nanoparticles due to small 
supersaturation region produced.  
• Surfactants (or stabilizer) 
A wide variety of surfactants can be used for stabilization of the organic droplets, 
which contain the polymer. The effect of PEG, tween 80, gelatin, dextran, pluronic L-63, 
PVA, and DMAB as surfactants (for nanoparticle stabilization) was evaluated by Kwon 
et al. [18]. PVA and DMAB (a cationic surfactant) were the only surfactants that formed 
nanoparticles with the emulsion diffusion method. The smaller mean size of PLGA 
nanoparticles was obtained when DMBA was used (Figure 2.2.a). The mean size was 76 
nm for a concentration of 2% w/v of DMAB. The mean PVA nanoparticle size was 210 
nm for 5% w/v. When the DMAB concentration was increased from 2 to 4% w/v, a slight 
decrease in size of the nanosphere was noticed (from 80 nm to 75 nm). The smaller 
nanoparticle size formed with DMAB is attributed to the more pronounced surface 
tension reduction as compared with PVA, 22 dyne/cm at 10-2 % w/v for DMAB versus 37 
dyne/cm at 10-1 % w/v for PVA (Figure 2.2.b).  
Ravi Kumar et al. [21] studied the effect of PVA, and a mix of PVA and chitosan 
(needed to form positive charges over the surface of the nanospheres) in an attempt to 
improve the entrapment efficiency of DNA (DNA has negative charges allowing its 
migration to the external phase due to the repulsion with the negative charges of PLGA 





Figure 2.2. a. The influence of surfactant on the mean size of PLGA nanoparticles. 
b. Surface tension of DMAB and PVA solution as a function of concentration (wt%). 
Reproduced from Ref. Kwon et al. [18].  
When PVA was used alone, the mean nanoparticle size was 111.7 ± 4.2 nm. The 
addition of chitosan alone did not allow formation of nanospheres, so the addition of a 
blend of PVA and chitosan was crucial for the formation of stable nanospheres with a 
positive surface charge. In a further work, Ravi Kumar et al. [22] prepared two surfactant 
blends and tested the DNA transfection in vivo. The first blend contained chitosan and 
PVA, and the second blend was a mix of chitosan, PVA, and PEG. The mean size was 
180 ± 11 nm for both systems, with a zeta potential of 10 mV for the former, and 7 mV 
for the latter. They attributed the decrease of zeta potential to PEG chains present in the 
second blend, but there is no mention if there is a statistical difference between the data 
points. 
• Viscosity of continuous and discontinuous phase 
The viscosity of the continuous and discontinuous phase is an important 
parameter to take into account because it affects the diffusion process, a key step in 
forming smaller nanoparticles. Ahlin et al. [23] prepared dispersed phases with different 
viscosities by changing the PLGA molecular weight. A solution of 5% w/w PLGA in 
benzyl alcohol had viscosities of 0.03 Pa s, 0.036 Pa s, and 0.046 Pas for 50:50 PLGA 




Nanoparticles with mean size of 175 nm, 220 nm, and 280 nm, were obtained by 
increasing viscosity of the organic solution from 0.03 to 0.046 Pa s. The viscosity of the 
continuous phase was determined to be 1.5 Pa s, 5 Pa s, and 13 Pa s for 10%, 15% and 
20% w/w of aqueous PVA solution, respectively. The mean size of nanoparticles 
synthesized with 10% of PVA was 310 nm and 170 nm with 20% PVA. The conclusion 
reached was that the size of the nanoparticles increases with an increase in the viscosity 
of the dispersed phase, whereas a decrease in the nanoparticle size was observed for a 
more viscous continuous phase. Other polymers with the same viscosity should be 
studied for an accurate analysis of the viscosity effect on the nanoparticle size. 
• Homogenizer speed and agitation speed 
The homogenization of the oil-in-water emulsion is another important step in 
forming smaller nanospheres. Lee et al. [19] evaluated the effect of homogenizing speed 
(when the organic phase is added to the aqueous suspention). The speed range tested was 
from 5000 to 15000 RPM for a suspension with 5% w/v of PVA for a fixed time (7 min). 
A mean size of 200 nm was obtained for speeds up to 11500 RPM, and at higher 
revolutions (22000 RPM) the mean nanoparticle size decreased up to 120 nm with no 
further decrease in size at higher RPM.  
Agitation is applied during the addition of excess of water to improve solvent 
diffusion and nanosphere precipitation. The nanoparticle size was reduced from 115 nm 
to 90 nm when the agitation speed was increased from 200 RPM to 600 RPM; increasing 
the agitation speed further to 1000 RPM did not affect the particle size [19]. In the work 
of Ravi Kumar et al. [21, 22], nanoparticles of 884 ± 17 nm mean size were synthesized 
when the emulsion was not homogenized and no additional water was added. When 
homogenization was included, the mean size decreased to 403 ± 8 nm. The mean size 
was further improved to 181 ± 3 nm by stirring at 1000 RPM and applying 
homogenization at 13500 RPM. In the studies mentioned above there is no description of 
the system hydrodynamics which could affect the nanosphere size, so the process scale 
up and reproducibility of the experiment should be complicated and reconsidered. 
• Addition rate of water  
The addition rate of water to allow the solvent diffusion was studied by Kwon et 
al. [18]. No significant size difference was detected for water added at 0.03 mL/s and 16 
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mL/s. When DMAB was used, the mean size was 76 nm and 78 nm at 0.03 mL/s and 16 
mL/s, respectively. When PVA was used, the mean size was 220 nm and 204 nm, for 
0.03 mL/s and 16 mL/s, respectively. 
• Temperature of the water added for solvent diffusion  
An important size reduction of the nanoparticles can be achieved by careful 
control of the water temperature added to improve the diffusion of the solvent. Kwon et 
al. [18] worked with PVA (5% w/v) and DMAB (2% w/v) with a constant water addition 
rate of 16 mL/s. For both surfactants, the mean size of nanoparticles was decreased with 
an increase in the temperature of the water added. For DMAB, the smaller size obtained 
was 65 nm (polydispersity of 0.056 ±0.019) at 60 °C, and the larger size was 78 nm 
(polydispersity of 0.023 ±0.012) at 25 °C. For PVA, the smaller size obtained was 170 
nm (polydispersity of 0.063 ±0.034) at 60 °C, and the higher size was 204 nm 
(polydispersity of 0.064 ±0.028) at 25 °C. The main drawback of this approach is the 
effect of the water temperature on the polymer structure, because the Tg (glass transition 
temperature) of PLGA is lower than 60 °C. It is important to understand the effect of 
temperature on the polymer matrix when the working temperature is 60 °C and higher. 
• Cryoprotectant  
The most common way to stabilize a preparation of nanospheres is lyophilization. 
The sample is pre-frozen at low temperatures to form small crystals of water, important 
in that the water crystal disrupts the stabilizer shell around the particle, which results in 
clustering in the nanoparticle resuspension. Konan et al. [17] worked with trehalose as a 
lyoprotectant to preserve the nanoparticle size after lyophylization. The weight ratio used 
was of 2:1 trehalose to nanoparticles. The nanospheres size varied from 120 nm to 140 
nm with the addition of trehalose for the 50:50 PLGA copolymer ratio, and from 125 nm 
to 200 nm for the 75:25 PLGA copolymer ratio. The re-suspension was carried in 
different mediums (distilled water, phosphate buffer saline (PBS), fetal bovine serum 
(FBS), human plasma, waymouth grouth) by 30 seconds of manual agitation. The only 
re-suspension media that showed increase in size was human plasma (from 125 nm to 
155 nm for nanospheres prepared with 50:50 PLGA copolymer ratio). Ahlin et al. [24] 
worked with the same ratio of nanoparticles to trehalose (1:2 w/w for nanoparticles to 
trehalose) for entrapment of enalaprilat. The mean nanoparticle size before lyophilization 
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was 204 ± 6 nm. Nanoparticles undergoing lyophilization without trehalose measured 
283 ± 65 nm. The nanoparticle mean size was 255 ± 30 nm and 210 ± 12 nm for 
nanoparticle to trehalose ratios of 1:1 and 1:2, respectively. The PI for the three 
resuspensions was higher (0.9 ± 0.09, 0.91 ± 0.15, and 0.59 ± 0.11 for 0, 1:1, and 1:2) 
compared to the sample before lyophilization (0.13 ± 0.1). This suggested that the 
aggregation is reduced with the increase of trehalose amount, but it is not eliminated.  
• Drug entrapment 
The drug entrapment affects the final nanosphere mean size and stability over 
time. This effect can be positive, reducing the mean size of nanospheres, or negative, 
increasing the mean nanospheres size. Ahlin et al. [24] entrapped enalaprilat, which was 
dissolved in the organic phase, benzyl alcohol. The free drug nanospheres had a mean 
size of 183 ± 5 nm. The nanospheres with entrapped drug had a mean size of 204 ± 6 nm. 
The effect of the drug on the nanoparticle stability, defined as the size variation as a 
function of time, was also studied. The mean size after 15 days for the free drug 
nanosphere was almost constant (181 ± 6 nm), and for the nanospheres with the 
entrapped drug was 730 ± 200 nm. This data suggests that the diffusion of enalaprilat 
drug from PLGA matrix induced formation of PLGA nanoparticle clusters, increasing the 
final mean nanoparticle size.  
A positive effect of the drug entrapped on the nanoparticle size is shown in the 
work of Konan et al [17]. Benzyl alcohol was the organic phase used and meso-tetra(p-
hydroxyphenyl)porphyrin (p-THPP) was the drug. The preparation with 50:50 copolymer 
ratio and free drug nanospheres had a size of 124 ± 2 nm. When the drug was 
incorporated, the size was reduced to 93 ± 0 nm for a theoretical loading of 15%. The 
samples with 75:25 copolymer ratio and free drug nanospheres had a mean size of 132 ± 
12 nm. The addition of the drug decreased the size to 95 ± 6 nm for a theoretical loading 
of 15%. Both copolymer ratios showed a mean size increase with further increases in 
theoretical loading of drug. It should be highlighted that increases in the theoretical drug 
loading decreases the entrapment efficiency. The higher entrapment efficiency (76.3% 
±1.4%) was for the 5% theoretical drug loading.  
Advantages (A)/Disadvantages (D) 
• (A) The use of non highly toxic solvents (i.e. benzyl alcohol) 
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• (A) Reduced energy consumption because it only requires mild stirring. The 
process does not require high stress shear (i.e. sonication or 
microfluidization) 
• (D) The requirement of large amounts of water for nanoparticles formation 
• (D) Large time of emulsion agitation 
• (D) The size is highly sensitive to polymer concentration if the process does not 
use shear stress for size reduction (high speed agitation or sonication)  
• (A/D) Suitable for hydrophobic active components. The hydrophilic 
components have a high migration tendency due to the diffusion of the 
polar solvent to the aqueous phase and therefore the drug entrapment 
efficiency is low 
2.2.2. Salting Out Method 
In this synthesis method, the polymer is dissolved in the organic phase, which 
should be water-miscible, like acetone or tetrahydrofuran (THF). The organic phase is 
emulsified in an aqueous phase, under strong mechanical shear stress. The aqueous phase 
contains the emulsifier and a high concentration of salts which are not soluble in the 
organic phase. Typically, the salts used are 60% w/w of magnesium chloride hexahydrate 
[25, 26] or magnesium acetate tetrahydrate in a ratio of 1:3 polymer to salt [27]. Contrary 
to the emulsion diffusion method, there is no diffusion of the solvent due to the presence 
of salts. The fast addition of pure water, to the o/w emulsion, under mild stirring, reduces 
the ionic strength and leads to the migration of the water-soluble organic solvent to the 
aqueous phase inducing nanosphere formation [5]. The final step is purification by cross 
flow filtration or centrifugation to remove the salting out agent. Common salting out 
agents are electrolytes (sodium chloride, magnesium acetate, or magnesium chloride) or 
non-electrolytes, such as sucrose [14].  
Important parameters to be considered are: polymer concentration and molecular 
weight, stirring rate and time, nature and concentration of surfactant and solvent, and 
cryoprotectans. 
• Polymer concentration 
This method is more robust than emulsion-diffusion technique because the mean 
size is not highly sensitive to increments in polymer concentration. Konan et al. [25] 
 
17 
varied the PLGA concentration from 10% to 25% w/w. The mean size of 150 nm was 
constant up to a polymer concentration as high as 17% w/w. At concentrations higher 
than 20% w/w the size of the nanoparticles increased (to 300 nm for 25% w/w).  
• Polymer molecular weight and copolymer molar ratio 
The PLGA molecular weight impacts the final mean nanosphere size. In general, 
higher molecular weight forms higher mean size nanoparticles. The change in 
nanoparticle size was evaluated as the composition and molecular weight of PLGA was 
varied (12000 to 48000 for 50:50 PLGA; 12000 to 98000 Da for 75:25 PLGA). For the 
nanospheres with 50:50 PLGA, the mean size ranged from 102 ± 4 nm to 154 ± 17 nm 
for 12000 Da and 48000 Da, respectively. For the 75:25 PLGA, the nanoparticle mean 
size ranged from 132 ± 3 nm to 152 ± 25 nm for 12000 Da and 98000 Da, respectively. 
For the same molecular weight, the two copolymer ratio (50:50 and 75:25 with free 
carboxylic end groups) formed nanospheres with similar sizes (125 ± 9 nm compared 
with 132 ± 3 nm, respectively) [25]. 
• Solvent 
The solvent plays an important role in the formation and mean size of the 
nanoparticles. Konan et al. [25] obtained different nanosphere sizes with acetone and 
THF. Smaller nanoparticles were obtained when THF was used. The samples using THF 
formed nanospheres in the range of 102 ± 4 nm to 166 ± 5 nm, and the mean size for the 
samples with acetone range from 120 ± 7 nm to 210 ± 66 nm. Acetone was used by 
Zweers et al. [26]. The mean nanoparticle size formed was 230 nm (polydispersity index 
(PI) of 0.09), and 139 nm (polydispersity index (PI) of 0.19) for PLGA and PEO-PLGA, 
respectively. 
• Surfactant 
The PVA family is widely used as surfactant for the preparation of PLGA 
nanoparticles. Konan et al. [25] tested two types of PVA: Mowiol® 4-88 (87.7% 
hydrolyzed with molecular weight of 26,000 Da), and Mowiol® 3-83 (82.6% hydrolyzed 
with molecular weight of 18,000 Da). PVA Mowiol® 3-83 was most efficient in lowering 
the size of the nanoparticles to 148 nm (±5 nm) in a concentration of 15% w/w. Zweers et 
al. [26] used PVA 80% hydrolyzed with molecular weight of 10 kDa, and the 
concentration in the aqueous suspension was 2 wt.%. The mean size obtained was 230 
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nm with PI of 0.09. The PVA or Mowiol® 4-88 were used by Eley et al. [27] to make 
nanoparticles with a normal size distribution between 400 to 1100 nm, as obtained by 
light scattering laser spectrophotometry. 
• Stirring rate and time 
The size can be controlled by stirring rate and time. This was shown by Konan et 
al. [25]. The stirring speed was varied from 2000 to 13500 RPM (figure 2.3), and the 
stirring time tested varied from 5 to 50 min. At 13500 RPM, nanospheres with a mean 
size of 155 nm were formed using THF as a solvent, with 17% w/w of polymer 
concentration, and 10% w/w of PVA. Nanoparticles sizes under 200 nm were obtained at 
8000 RPM; no statistical analysis was provided to detect the significance of these 
differences. At an optimum stirring time of 15 minutes, nanospheres of 140 nm mean size 
were formed; no significant decrease in the mean size was notices after 25 minutes (the 
total size increment was 8 nm up to 45 minutes of stirring).  
• Cryoprotectants in freeze-drying 
The lyophilization step must be carried out in the presence of cryoprotectants to 
preserve the mean nanoparticle size obtained in the formation process. The sugar family 
is widely used as cryoprotectant. Konan et al. [25] tested trehalose, mannitol, glucose, 
and lactose. All lyoprotectants showed a good size preservation with just a slightly size 
increment for lyoprotectant to nanoparticles mass ratio over 0.5 (size was increased from 
135 nm to 150 nm). The sample without cryoprotectant had a mean size of 480 nm after 
resuspension. 
Advantages(A)/Disadvantages(D) 
• (A) Reduced energy consumption because it only requires normal stirring. The 
process does not require high stress shear (i.e. sonication or 
microfluidization) 
•  (A) Low time consuming process 
• (D) The main drawback is the requirement of purification step for salting out 
agent elimination, which is in higher amounts (at least three times more 





Figure 2.3. Influence of the stirring rate on the main nanoparticle size (Aqueous 
phase: 10% (w/w) of Mowiol 4-88 and 60% (w/w) MgCl2, organic phase: 17% (w/w) 
of polymer in THF (mean ± SD, n=3). Reproduced from ref. Konan et al. (2002)  
•  (A/D) Suitable for hydrophobic components because the salting out agent is 
water soluble 
•  (A/D)The use of not highly toxic, but explosive, solvents (i.e. acetone, THF) 
2.2.3. Nanoprecipitation (Solvent Diffusion, or Solvent Displacement) Method 
Typically, this method is used for hydrophobic drug entrapment, but it has been 
adapted for hydrophilic drugs as well. Polymer and drug are dissolved in a polar, water-
miscible solvent such as acetone, acetonitrile, ethanol, or methanol. The solution is then 
poured in a controlled manner (i.e. drop-wise addition) into an aqueous solution with 
surfactant. Nanoparticles are formed instantaneously by rapid solvent diffusion. Finally, 
the solvent is removed under reduced pressure.  
Important parameters to be considered are: polymer/surfactant ratio, polymer 
concentration, surfactant nature and concentration, solvent nature, viscosity, additives, 
active component, and phase injection. 
• Polymer concentration 
The polymer concentration is maintained in the range of 1% w/v up to 10% w/v. 
Prakobvaitayakit and Nimmannit [28] tested three different concentrations of 50:50 
PLGA for nanosphere formation. The nanoparticle mean size was 190 nm for 1 % w/v, 
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and the size increased to 238.9 nm for 10% w/v. Govender et al. [29] used a 
concentration of 1% w/v to synthesize nanospheres of 157.1 ± 1.9 nm in size. Csaba et al. 
[30] worked with a polymer concentration of 5 % w/v to form nanoparticles with a size 
range from 161 ± 7 nm to 269 ± 11 nm. This size range is correlated to the presence of 
different polymers in the polymer blend used (detailed in the surfactant section). Niwa et 
al. [31] worked with two different concentrations of 0.39% w/v and 0.44 % w/v, and the 
mean size was 195 ± 34 nm and 283 ± 37 nm, respectively. In another work, Niwa et al. 
[32] used 0.77% w/v PLGA forming nanospheres with a mean size of 224 ± 14 nm. 
Ameller et al. [33] worked with a concentration of 2% w/v and obtained nanospheres 
with a mean size of 260 ± 50 nm, approximately (0.1 %w/w of poloxamer 188 was in the 
aqueous phase); a significant size reduction (approximately, 80 ± 20 nm for the same 
concentration) was achieved when PLGA was grafted to PEG (5 kDa) (no poloxamer in 
the aqueous phase) suggesting that the hydrophilic lattices provided by PEG stabilized 
the nanoparticles; the PLGA aggregation was reduced during nanosphere formation 
reducing the nanosphere mean size. The trend was maintained for other two polymers 
used, poly(D,L-lactide) (PLA) and poly(ε-caprolactone) (PCL), which were covalently  
grafted with PEG (5 kDa). 
• Polymer molecular weight and copolymer ratio 
The polymer molecular weight affects the size more significantly than the 
copolymer ratio, as follows. Niwa et al. [31] worked with different molecular weights, 
and copolymer ratios. The PLGA 50:50 with a MW of 66475 Da formed nanospheres 
with a size of 338 ± 67 nm, which was similar to the nanospheres size of 85:15 PLGA 
with a MW of 66671 Da, measuring 385 ± 51 nm in size. The 85:15 PLGA with a MW of 
127598 Da formed nanospheres with mean size of 637 ± 40 nm. These nanospheres were 
prepared with a mix of chloroform and acetone for the entrapment of indomethacin.  
• Solvent nature 
The selection of good solvents to form smaller nanoparticles and to improve the 
entrapment efficiency of the active component is a complex and an important process. 
There is no clear definition of the ‘best solvent’ for this method. Niwa et al. [31] used a 
mix of organic solvents (acetone, methanol, dichloromethane, or chloroform) to dissolve 
PLGA and drugs (indomethacin and 5-fluorouracil). The size of the 85:15 PLGA 
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nanoparticles of two molecular weights (12279 Da and 66671 Da) changed when the mix 
of solvents was altered from 0.5:5:5 ml to 0.5:25:5 ml (dichloromethane /acetone 
/methanol). The first mix of solvents formed nanospheres with a mean size of 283 ± 37 
nm and 213 ± 13 nm for the two molecular weights tested, and the second one formed 
nanospheres of 195 ± 34 nm, and 207 ± 13 nm. The reduction in size with increased 
acetone concentration is attributed to the reduction in the surface tension of the 
dichloromethane solution in the presence of acetone. The formation process performed 
with dichloromethane or chloroform formed nanospheres 1 µm and bigger in size. 
Acetone is commonly used alone for the preparation of nanospheres. Ameller et 
al. [33, 34] obtained a mean size nanoparticles of 258 ± 97 nm with zeta potential of -
53.4 ± 0.5 mV. Prakobvaitayakit and Nimmannit [28] formed nanospheres with a mean 
size varying from 190 nm to 643.9 nm. Panagi et al. [35] formed nanospheres with mean 
size of 154 ± 23.5 nm, polydispersity of 0.489, and zeta potential of 45.1 ± 1.9 mV with 
the same solvent. Oster et al. [36] obtained a mean size of 152 ± 3 nm and zeta potential 
of 35 ± 3 mV. 
Saxena et al. [37] added methanol to acetonitrile (in which PLGA was dissolved) 
for a good dissolution of the active component. The mean size was 357 ± 0.21 nm with 
zeta potential of -16.3 ± 1.5 mV. The higher zeta potential (less negative) is attributed to 
the presence of PVA over the nanosphere surface. 
Csaba et al. [38] worked with ethanol (organic phase) for the polymer 
nanoprecipitation. The mean size of the nanospheres (PLGA 50:50) obtained was 191.5 ± 
7.1 nm. Other works used acetonitrile as the organic solvent. For example, Govender et 
al. [29] prepared nanospheres with a size of 157.1 ± 1.9 nm with acetonitrile. 
• Surfactant 
A variety of surfactants are used for nanoparticle formation and stabilization. The 
surfactant can be anionic, cationic or nonionic. Surfactants in the poloxamer and 
poloxamines family, formed with polyoxiyethylene and polyoxypropylene, are 
commonly used in nanoparticle synthesis. Surfactants of different HLB values can be 
obtained by varying the amount of monomers; less ethylene oxide monomers and more 
propylene oxide monomers form surfactants with lower HLB values. Csaba et al. [38] 
used poloxamer and poloxamines blended with PLGA in the organic phase. The samples 
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formed with more hydrophobic surfactants (HLB of 1 and 2.5) had an increased final size 
of up to 333.7 ± 82.1 nm for a mass ratio PLGA:surfactant of 50:75 mg/mg. The lower 
size nanoparticle formed was 159.8 ± 6.5 nm for the blend PLGA:Pluronic® F68 (HLB 
value of 29) of 50:75 mg/mg. Pluronic® F68 has shorter ethylene oxide chains and larger 
propylene oxide chains compared with the other surfactants tested. Ameller et al. [34] 
used poloxamer 188 with a concentration of 0.1% w/w forming PLGA nanospheres of 
262 ± 52 nm mean size. The zeta potential obtained was -11 mV.  
Another important surfactant used is PVA. Niwa et al. [31] tested different 
concentrations of PVA. The range tested was from 0.5 % to 2 % of PVA in the aqueous 
suspension leading to nanoparticle formation with a mean size of 300 nm (not significant 
difference in the range tested). Saxena et al. [37] obtained mean nanoparticle size of 357 
± 0.21 nm using 88 - 89 % hydrolyzed PVA. 
• Additives 
Certain compounds can improve the stability and size of the nanoparticles (fatty 
acids, short chains of carbons). Additionally, they can affect the entrapment efficiency of 
the active component. Govender et al. [29] found that fatty acid incorporation affected 
the entrapment efficiency of the active component (procaine hydrochloride and procaine 
dihydrate, water soluble drugs) reducing the nanoparticles mean size. The authors added 
caprylic acid, (molar ratio of 1:1 and 1:3), lauric acid (molar ratio of 1:1 and 1:3), PLA 
oligomers (molar ratio of 1:1), and poly(methyl methacrylate-co-methacrylic acid) 
(PMMA-MA) (molar ratio of 5:1). Lauric acid in a molar ratio of 1:1 increased the drug 
content from 11% to 34.8%, and the nanoparticle size was reduced from 157.1 ± 1.9 nm 
to 118.8 ± 1.4 nm (p value <0.05). With the 3:1 molar ratio, the size was lower (55.8 ± 
1.5 nm) but the morphology was altered (irregular shape). Zeta potential showed a slight 
increase from -49.2 ±0.7 mV to -44.1 ± 1.8 mV. The longer carbon chain of lauric acid 
(in comparison to that of caprylic acid) was associated with the improvement in the 
nanoparticle characteristics. 
• Active component entrapment 
Entrapment of active components has an important effect on the final nanospheres 
final size; as a general rule, entrapment of hydrophobic active components leads to 
formation of smaller nanospheres, as compared to the entrapment of hydrophilic 
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components. The interaction between solvent, polymer and active component must be 
taken into account to improve the drug loading and the drug entrapment efficiency. 
The entrapment of procaine hydrochloride (with a pH of 5.8 for aqueous solution) 
was found to increase the nanoparticle size from 157.1 ± 1.9 nm to 209.5 ± 2.7 nm for a 
theoretical drug loading of 0% to 10%, respectively. The drug content increased from 0.2 
to 4.6% w/w when the theoretical drug loading was increased from 1% to 10% w/w, but 
the entrapment efficiency decreased from 14.5% to 6.3% [29]. Although, they reduced 
the nanosphere mean size by change of the aqueous pH (buffer at pH 9.3), the size for 
PLGA alone was 123.6 ± 2.3 nm, and for nanospheres with 10% w/w theoretical drug 
loading, the size was 186.5 ± 2.3 nm. In both cases, the entrapment formed bigger 
nanospheres in the presence of the drug, as compared with the PLGA alone. The 
nanospheres size was reduced with the entrapment of procaine dehydrate. When the 
theoretical drug loading of procaine dyhidrate was increased up to 10% w/w, the mean 
size was reduced from 157 ± 1.9 nm to 56.2 ± 1.9 nm. The drug entrapment efficiency 
ranged from 36.2% up to 44.1% [29]. 
The entrapment of plasmids in PLGA nanoparticles increased the nanoparticle 
size, which can be observed in the work developed by Csaba et al. [30] as depicted in 
Figure 2.4. The organic solvent used to dissolve the polymer blends was methylene 
chloride, and the polymer blends were PLGA: poloxamer and PLGA:poloxamine in a 
ratio of 50:50 mg/mg. Plasmid DNA encoding green fluorescent protein with CMV 
promoter (pEGFP-C1) in an aqueous solution was added to the organic phase. The mean 
size of naked PLGA nanospheres was 191 ± 7 nm with a polydispersity index (PI) of 
0.046 and zeta potential of -60.1 ± 7.4 mV. When plasmid was added to the preparation 
with PLGA alone, the final size was 234 ± 13 nm with PI of 0.187 and zeta potential of -
72.7 mV. The addition of plasmid increases the size all samples tested, but the exception 
was for poloxamine Tetronic® 904 (HLB of 14.5 and molecular weight of 6700). This 
sample showed a reduction of size from 168 ± 9 nm to 161 ± 7 nm, without and with 
plasmid, respectively. The zeta potential decreased from -38.4 ± 3.3 mV to -54.1 ± 2 mV 




Figure 2.4. TEM micrographs of blank and plasmid-loaded (A) PLGA: poloxamer 
(Pluronic F68) and (B) PLGA:poloxamine (Tetronic 908) blend nanoparticles. 
Reproduced from Ref. Csaba et al. [30].  
Saxena et al. [37] found that the retention of the ICG-NaI into the polymeric 
matrix was less than ICG because of the more hydrophilic nature of ICG-NaI. As a result 
of the lower retention of ICG-NaI, all further discussions will only consider ICG 
formulations. The mean nanoparticle size decreased with increasing concentration of ICG 
from 405 ± 0.05 nm with 1% w/w of drug to 307 ± 0.08 nm with 10% w/w of drug, and 
the nanoparticle recovery was improved from 48% to 65.3%, respectively. The drug 
entrapment was reduced from 9.92% to 1.14% and the drug content decreased from 
0.21% to 0.17% with increasing amounts of ICG (1% w/w to 10% w/w). When the drug-
polymer ratio was reduced drastically to 0.125% w/w, the drug entrapment increased to 
74.47%. The drug content was 0.2%, and the nanoparticle recovery was slightly 
decreased to 45.7% for the lower drug concentration.  
• Phase injection 
The organic phase addition to the continuous aqueous phase should be controlled 
and constant, by mild stirring, to assure a uniform distribution and diffusion. 
(A) Blank    plasmid-loaded 
(B) Blank    plasmid-loaded 
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Prakobvaitayakit and Nimmannit [28] used a constant flow rate of 0.3 ml/min with 
mechanical stirring of 750 RPM. In the Govender et al. [29] work, they reported a drop 
wise organic phase addition. The stirring was done by a magnetic stirrer. The same 
procedure was followed by Saxena et al. [37]. Csaba et al. [30, 38] used vortex agitation 
for mixing both phases getting a fast organic phase dispersion and further moderate 
magnetic stirring. Other works using fast organic phase dispersion is that by Ameller et 
al. [33, 34]. 
Advantages (A)/Disadvantages (D) 
• (A) The use of non highly toxic solvents (i.e. acetone). 
• (A) Reduced energy consumption because it only requires regular stirring. 
The process does not require high stress shear (i.e. sonication or 
microfluidization). 
• (A) Additives can be used for nanoparticle size reduction. 
• (D) The solvent is removed by evaporation (time consuming). 
• (D) The main drawback is the requirement of drugs that are highly soluble 
in polar solvents (i.e. acetone, ethyl acetate), but they should be slightly 
soluble in water to minimize losses during solvent diffusion. The drug can 
diffuse to the aqueous phase reducing the drug entrapped in the PLGA 
nanospheres [39].  
• (D) The drug loading efficiency is lower for the hydrophilic drugs than 
hydrophobic ones because of their poor interaction (hydrophobic 
interaction) with the polymer leading to diffusion of the drug during the 
solvent displacement from the polymer in the organic phase to the external 
aqueous environment [15].  
• (D) Nanoparticle size is very much affected by the polymer concentration; 
higher nanoparticle sizes are obtained at higher polymer concentrations. 
2.2.4. Emulsion Evaporation Method 
Emulsion evaporation is the oldest method used to form polymeric nanoparticles 
from preformed polymers. The method is based on the emulsification of an organic 
solution of the polymer in an aqueous phase followed by the evaporation of the organic 
solvent. The polymer is dissolved in a suitable solvent (e.g., ethyl acetate, chloroform, 
 
26 
methylene chloride). The organic phase or aqueous phase is poured into the continuous 
phase (aqueous or organic phase) in which a surfactant is dissolved to impart stability to 
the emulsion. Emulsification is carried out under high-shear stress to reduce the size of 
the emulsion droplet (directly related with the final size of the nanoparticles). The process 
of emulsification is followed by evaporation of the organic solvent under vacuum, which 
leads to polymer precipitation and nanoparticle formation. 
Normal emulsions oil in water (o/w) or water in oil (w/o) and double emulsions 
(w/o/w) can be used to accommodate the entrapment of active components with different 
properties. The o/w emulsion is used for entrapment of hydrophobic compounds, whereas 
w/o/w double emulsion is used for the entrapment of hydrophilic compounds. The 
method is widely used for microencapsulation because it is easy to scale up, it doesn’t 
require high shear stress, and it can be adjusted (by use of the double emulsion method) 
to encapsulate water soluble drugs [40-44]. 
The formation of the emulsion is a key aspect of this method [45], considering 
that the size of the emulsion droplet is directly related to the final nanoparticle size. 
Emulsions can be classified in microemulsions, miniemulsions (or nanoemulsions), and 
macroemulsions. The microemulsions are transparent and thermodynamically stable 
emulsions, with droplets mean sizes from 20 to 50 nm, obtained by conjugation of 
surfactant, solvent and co-surfactant. Microemulsions are thermodynamically stable due 
to the entropic effect of smaller droplets [46, 47]. The size of mini or nanoemulsions is in 
the order of 40 to 500 nm [48, 49]; high shear stress and enough surfactant amounts are 
needed to make stable nanoemulsions. Nanoemulsions are kinetically stable and the 
surfactant is used in the most efficient way [48]. The macroemulsion droplet size is in the 
micrometer range; macroemulsions are formed by mild stirring and surfactant addition 
for stability. Macroemulsions are unstable over time, so they tend to aggregate.  
The procedure followed to form a miniemulsion involves the use of surfactants 
and the application of mechanical stirring with high RPM, high pressure or sonication, as 
well as the addition of hydrophobic components that act as a suppressant agent against 
Ostwald ripening (migration of small droplets to bigger ones) [50]. The effect of 
sonication on the droplet size was studied by Landfester et al. [51], and it showed that the 
amplitude of wavelength should be over 20% with 600 to 800 seconds of sonication to 
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form a stable miniemulsions with no more droplet size changes. The main draw-back of 
sonication is the lack of monodispersity of the emulsion formed [52].  
Mason and Bibette [53, 54] showed that the application of laminar shear rate 
flow, as opposed to sonication, can result in a monodisperse droplet size. The formation 
of monodisperse viscous droplets in viscoelastic complex fluids by the application of 
shear stresses with laminar flows was experimentally studied. The emulsion was sheared 
in a thin gap of two glasses under a uniform shear flow to form a uniform droplet size 
distribution in the nanometer range by adjustment of the gap in where the sample is 
placed [53, 55, 56]. Some requirements must be met, such as the phases must be 
viscoelastic, and the initial emulsion droplets must be rather big in size (5 to 10 µm) for a 
monodisperse miniemulsion to result.  
Advantages (A)/Disadvantages (D) 
• (A) The use of non highly toxic solvents (i.e. ethyl acetate) 
• (A) Additives can be used for nanoparticle size reduction 
• (A) Suitable for hydrophilic (double emulsions) and hydrophobic active 
components. 
• (D) High consumption of energy by the necessity of high stress shear (i.e. 
sonication or microfluidization) 
• (A/D) The solvent is removed by evaporation (energy consumption), but 
the process time for solvent removal is reduced (special with fast 
evaporation with vacuum) 
• (A/D) The addition of active component affects the final size of 
nanoparticles 
2.2.4.1. Oil in Water Emulsion Method (Single Emulsion) 
The method is based on the emulsification of an organic solution which contains 
the polymer and the active component in an aqueous phase, followed by the evaporation 
of the organic solvent. Different surfactants such as PVA, SDS, Pluronic F68 can be 
dissolved in the aqueous phase. The size reduction of the emulsion droplet is done by 
sonication or microfluidization for miniemulsion formation. The evaporation step is 
required to eliminate the organic solvent present in the organic phase. This leads to the 
precipitation of the polymer as nanoparticles with a diameter in the nanometers range.  
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Important parameters to be considered are: polymer molecular weight and 
concentration, copolymer ratio and end groups, surfactant nature, phase ratio, solvent 
nature, evaporation rate, drug entrapment, additives, shear stress, and sterilization. 
• Polymer concentration 
Polymer concentration is an important parameter to consider when forming 
nanoparticles. Julienne et al. [57] worked with 85:15 PLGA, MW of 87000 Da, and 88% 
hydrolyzed PVA in a fixed concentration of 0.5% w/v. Nanoparticles formed under these 
conditions at four PLGA concentrations, 0.79%, 2.5%, 5%, and 7.5% w/v had a mean 
size of 220, 178, 177, and 236 nm, respectively.  
• Polymer molecular weight 
Usually, the increase in molecular weight leads to formation of nanospheres of 
significantly bigger size, but the entrapment of active components reduces this effect. 
Panyam et al. [58] formed PLGA nanospheres (theoretical loading of dexamethasone was 
20 % w/w) with a size of 260 nm (PI of 0.115) and 270 nm (PI of 0.228) for PLGA with 
molecular weight of 103,000 Da and 143,000 Da, respectively.  
• Copolymer ratio and end groups 
Different copolymer ratios have been tested with no significant difference in the 
mean nanospheres size. Panyam et al. [58] tested three different proportions of lactide 
molar ratios for the entrapment of dexamethasone. The 100% lactide polymer formed 
nanospheres with a mean size of 260 nm (PI of 0.255), which was the same for the 
sample with 75% of lactide, but the PI decreased to 0.115 with the decrease in the lactide. 
The sample with 50 % slightly increased the mean size to 270 nm with a PI of 0.228. Zeta 
potential varied from -23.9 ± 3.5 mV to -19.6 ± 1.5 mV, respectively. There is no 
mention of statistical analysis to detect significant differences in the parameters analyzed. 
Another important factor was the effect of end groups on the mean size. Samples 
prepared with ester end groups formed nanospheres with an average size of 740 nm (PI of 
0.394); the mean size for acid PLGA end group was 240 nm (PI of 0.225). The PLGA 
used was 50:50 with a molecular weight of 12000 and 10000 Da, respectively.  
• Surfactant 
Many options of surfactant can be used for nanosphere formation by emulsion 
evaporation. Julienne et al. [57] tested PVA, methylcellulose (MC), gelatin, and lecithin. 
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For PVA, the concentrations tested were 0.1%, 0.2%, and 0.5% w/v. The size varied from 
342 nm to 291 nm. When MC was used, the mean size obtained varied from 1880 nm to 
1950 nm for the same concentrations. At a fixed surfactant concentration of 0.5% w/v, a 
PLGA concentration of 2% w/v and a phase ratio of 20% v/v (organic to aqueous phase), 
the mean sizes obtained were 288, 2013, 1400, and 298 nm for PVA, MC, gelatin, and 
lecithin, respectively.  
The surfactant type is critical in forming small and stable nanospheres. Moreover, 
when the target applications of the nanoparticles are in the biomedical area, the presence 
of toxic surfactant residues over the surface of the nanospheres is of concern. To address 
this concern, researchers looked to find other surfactants, biodegradable and 
biocompatible to form nanoparticles. Mu and Feng (2003) use vitamin E TPGS (d-α-
tocopheryl polyethylene glycol 1000 succinate), amphiphile molecule due to the presence 
of PEG chains) as a surfactant. Different surfactant concentrations were tested, from 15 
mg/ml to 60 mg/ml. The smaller size nanoparticles were formed at a surfactant 
concentration of 60 mg/ml, measuring in size 567.4 ± 362.6 nm when 85:15 PLGA of a 
molecular weight of 90 to 120 kDa was used. 
• Phase ratios 
The phase ratio (organic to aqueous solvent) plays an important role in controlling 
the size of the nanospheres. In general, the lower ratio of organic-aqueous phase produces 
nanoparticle of smaller size. Juliene et al. [57] showed the effect with different ratios. At 
three organic:aqueous ratios, 10%, 25%, and 40% v/v nanoparticles of 106.8 nm (CV 
43.1%), 111.2 nm (CV 29.4%), and 130.5 nm (CV 16.5) were formed. The samples were 
formed in the presence of 8 % w/v of PVA.  
• Solvent 
Several organic solvents can be selected based on two criteria, (1) the PLGA must 
be soluble in this solvent, and (2) the solvent must be completely immiscible with the 
aqueous phase. Solvents from the chlorinate family have been widely used in the 
emulsion evaporation method. Julienne et al [57] used methylene chloride to form PLGA 
nanospheres with a mean size of 177 nm (CV of 32%). The same solvent was used by 
Pietzonka et al. [59] with a mean size of 400 to 500 nm. Song et al. [60] used a mix of 
dichloromethane and acetone (8:2 v/v) and formed nanospheres with a mean size of 117 
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± 40 nm. Panyam et al. [58] used chloroform to dissolve the PLGA, and the drug 
(dexamethasone) was dissolved in methanol to form nanoparticles of a mean size of 240 
nm (PI of 0.225).   
• Evaporation rate 
Fast evaporation of the organic solvent under vacuum is more efficient in forming 
smaller nanoparticles. Chung et al. [61, 62] compared vacuum solvent evaporation at 160 
mmHg and normal evaporation at 760 mmHg as two methods to form microspheres of 
albumin-loaded poly L-lactide (LPLA) and poly D-lactide (DPLA). The fast rate of 
evaporation produced a mean particle size around 30% smaller than the mean particle 
size obtained under a normal rate of evaporation. The reduction in particle size coupled 
with the low glass transition (Tg) and melting temperature (Tm) of PLGA polymer (i.e. Tg 
of 25.7 °C for 50:50 PLGA with molecular weight of 5 to 15 kDa) makes the vacuum 
evaporation method indispensable in the formation of PLGA nanoparticles.  
• Drug entrapment 
In emulsion evaporation, as in other synthesis methods, entrapment of highly 
hydrophobic drugs tends to reduce the size of the nanospheres. This fact is clearly 
observed in the work of Mu and Feng [63]. Paclitaxel, an active drug used in breast 
cancer therapy is added at a 2.4% w/w concentration to form nanoparticles of an average 
size of 272.5 ± 169.5 nm in the presence of vitamin E TPGS as a surfactant. The samples 
without paclitaxel formed nanospheres with a mean size of 914.8 ± 380.1 nm and 699.3 ± 
286.9 nm for 60 mg/ml and 15 mg/ml of vitamin E TPGS, respectively. Other paclitaxel 
concentrations (0.62% and 0.83% w/w) were tested, but the mean size was higher than 
that obtained with 2.4% w/w. The entrapment efficiency was 50.4% with a recovery yield 
of 41.7%. 
The solubility of the drug in water is the main drawback in forming smaller size 
nanospheres and improving the drug entrapment efficiency. This effect was shown by the 
study of Song et al. [60] where the pH (aqueous phase) effect on the drug solubility was 
reflected on the drug loading and the size of the nanospheres (Figure 2.5). The higher 
drug (U-86983, anti-proliferative agent) entrapment efficiency was for basic pH (over 8) 
due less solubility at basic pHs. The drug load increased from 5.4% to 20.4%, and the 
entrapment efficiency increased from 28.2% to 84.3% by increasing the pH. Although, 
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there is high improvement in entrapment efficiency by increasing the pH (linear relation), 
the nanosphere mean size showed different pattern. The low pH (6.5) formed nanosphere 
with mean size of 142 ± 36 nm, and the mean size for higher pH (8.14) was 144 ± 37 nm. 
The smaller size was for pH 7.5 with an average of 88 ± 41 nm, and entrapment 
efficiency of 56.9%. The entrapment of the drug U61431F was done for pH 4 and 4.5. 
The sample with pH 4 formed nanospheres with mean size of 109 ± 41 nm, and 
entrapment efficiency of 86.1%. The pH 4.5 formed nanospheres with mean size of 115 ± 
42 nm, and entrapment efficiency of 77.5%.  
 
 
Figure 2.5. Efficiency of drug (U-86983) entrapment into PLGA nanoparticles by 
changing the pH of the aqueous phase from neutral to basic. Reproduced from Song 
et al. [60]. 
• Additives 
Addition of hydrophobic additives can improve the nanosphere size, the drug 
entrapment efficiency, and release profile. Song et al. [60] tested wax (PLGA/wax of 
80/20%) and palmitate (PLGA/palmitate of 80/20%) to improve the release profile 
(reduce the burst effect, fast initial drug release) of the drug U-86983 (an anti-
proliferative agent). The mean size for the wax sample was 105 ± 38 nm, which was 
almost the same with the palmitate sample (107 ± 30 nm). The entrapment efficiency was 
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higher for the wax sample (85.3%) as compared with the palmitate sample (80%), but the 
burst effect was not reduced (around 40% of drug release in the first day). 
• Shear stress 
The emulsion formation requires a strong agitation to reduce the droplet size. This 
highly impacts the nanoparticles size. Julienne et al. [57] tested two methods of shear 
stress (mechanical stirring, high pressure homogenizer). They tested two homogenizer 
pressures of 100 and 200 bars (high pressure homogenizer). The mean size obtained was 
178 nm (CV of 22%) and 188 nm (CV of 38%) for 100 and 200 bars, respectively. There 
is a favorable impact in the size reduction when the emulsion is homogenized with a high 
pressure homogenizer compared with just high stirring (10000 RPM). The nanosphere 
mean size with stirring was 288 nm (CV 37%), and the mean size for nanosphere using 
homogenization (high pressure of 300 bars) was 231 nm (CV of 21%). The samples used 
PVA at 5% w/v and phase ratio of 20%.  
• Sterilization 
The effect of sterilization on nanosphere size was evaluated by Song et al. [60]. 
The sterilization was done by γ- irradiation at 2.5 Mrad doses for nanospheres with 2 
aminochromone drug family. The mean size slightly changed from 123 ± 38 nm before 
irradiation to 149 ± 43 nm after irradiation. The drug release was the same for both 
preparations, and the nanoparticles uptake was slightly increased from 13.4 µg/10 mg to 
15.4 µg/10 mg artery, before and after irradiation.   
2.2.4.2. Double Emulsion (w/o/w) Method 
The first step of the double emulsion method is the formation of a water in oil 
(w/o) emulsion where the aqueous solution contains the hydrophilic active component 
and the organic phase contains PLGA and a suitable surfactant (Span 80, pluronic F 68, 
and others) with a low HLB. The miniemulsion is formed under strong shear stress (i.e. 
sonication, microfluidization, high speed homogenization). Next, the water in oil in water 
(w/o/w) emulsion formation is sonicated or homogenized for droplet size reduction. This 
second size reduction should be controlled to minimize the hydrophilic active component 
diffusion to the external aqueous phase. Evaporation, the final step, is used to remove the 
organic solvent. Evaporation is done under vacuum to avoid polymer and active 
component damage, and to promote final nanoparticle size reduction. 
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The main drawback of the double emulsion method is the large size of the 
nanoparticles formed and the leakage of the hydrophilic active component [64], 
responsible for low entrapment efficiencies. The coalescence and Ostwald ripening [65, 
66] are the two important mechanisms that destabilize the double emulsion droplets, and 
the diffusion through the organic phase of the hydrophilic active component is the main 
mechanism responsible of low levels of entrapped active component [64]. One strategy 
followed by Song et al. [60] to reduce the nanoparticle size was to apply a second strong 
shear rate. The leakage effect can be reduced by using a high polymer concentration, and 
a high polymer molecular weight, accompanied by an increase in the viscosity of the 
inner water phase, and an increase in the surfactant molecular weight [60, 67].  
Important parameters to be considered are: polymer/surfactants ratio, polymer 
concentration, surfactant nature, viscosity, solvent nature, shear stress, evaporation, 
additives, and first/second phase ratios.  
• Polymer molecular weight and copolymer ratio 
An interesting effect of nanosphere size reduction against molecular weight 
increase is shown by Prabha and Labhasetwar [68]. The molecular weights tested were 
12, 53, and 143 kDa for 50/50 copolymer ratio, and the mean size achieved were 563 ± 6, 
685 ± 40, and 375 ± 22 nm, respectively. The zeta potential was -17.8 ± 1.0 mV, -16.6 ± 
1.4 mV, and -11.5 ± 3.4 mV, respectively. The PLGA copolymer ratio tested were 75:25 
and 50:50 (molecular weight of 53 kDa) with mean size of 485 ± 11 nm and 685 ± 40 
nm. The zeta potential was -16.6 ± 1.4 mV, and -18.2 ± 3.8 mV, respectively. The 
polymer concentration was maintained at 3 %w/v. 
• Solvent  
The chlorinate family is widely used for nanosphere preparation with double 
emulsion. Aukunuru et al. [69] used methylene chloride to dissolve PLGA, and entrapped 
a 19-mer antisense oligonucleotide (PS-ODN). The mean size obtained was 252 ± 3.4 nm 
with zeta potential of -12.98 ± 1.8 mV. Dillen et al. [70] used dichloromethane and 
formed nanospheres with a size of 209.5 ± 2.5 nm before freeze drying. The same solvent 
was used by Vandervoort et al. [71] with mean size of 204 ± 4 nm. Yan et al. [72] used 
ethyl acetate to dissolve PLGA, and insulin was added to the first aqueous solution. The 
smaller nanosphere size was 149.2 nm (PI of 0.09). 
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• Surfactant  
Two surfactants are needed in double emulsion evaporation method, a 
hydrophobic surfactant for the first emulsion and a hydrophilic surfactant for the second 
emulsion. Vandervoort and Ludwig [73] evaluated a series of stabilizers against PVA. 
The stabilizers used were methylcellulose (MC), hydroxy-ethylcellulose (HEC), hydroxy-
propylcelluloose (HPC) hydroxyl-propylmethylcellulose (HPMC), gelatin type A and B, 
carbomer (Carbopol® 980) and poloxamer (Lutrol® F68). The stabilizers used alone 
formed nanoparticles up to 3.2 µm with an exception for Carbopol® 980- and Lutrol® 
F68, which formed nanospheres with a size of 400 nm. In the presence of PVA, 
nanospheres under 1 µm were formed. The lower mean size was obtained by using a mix 
of the stabilizer (the concentration used was equivalent to the same viscosity of 1% PVA) 
and PVA. The mix of PVA with Carbopol and poloxamer were exceptions because the 
blend of carbopol and PVA showed a slightly increase in mean size (420 nm), and the 
blend of poloxamer and PVA showed no variation on the mean size. Zeta potential varied 
from +14 mV to -50 mV for all preparations. Almost all formulation showed negative 
values with the exception of gelatin type A, showing a zeta potential of +13 mV.  
Another work dealing with PVA use as a surfactant in the second emulsion is that 
by Yan et al. [72]. PVA concentration was varied to study the entrapment of insulin in 
PLGA nanoparticles (molecular weight of 11000 Da). The PVA concentrations tested 
were 0.4%, 0.7%, and 1% w/v. The mean size was reduced from 266.7 nm (PI of 0.15 
nm) to 149.2 nm (PI of 0.09), and the entrapment efficiency was improved from 19.3% 
(±4.2%) to 42.8% (±1.5%) by increasing the PVA concentration from 0.4 to 1% w/v. The 
insulin concentration for the higher entrapment efficiency was 3.048 mg/mL, the 
surfactant concentration was 1% w/v, and polymer concentration was 50 mg/mL.  
Prabha and Labhasetwar [68] tested different PVA concentrations, varying from 
0.5% to 2%. The 2% PVA samples formed smaller nanospheres size, 270 ± 1 nm with a 
PI of 0.2 (±0.01). They also quantified the amount of PVA bounded to the nanosphere 
surface and found that this amount was directly correlated to the amount of surfactant 
used in the preparation. The lower PVA concentration formed nanospheres with 2.2% ± 
0.2% w/w PVA bounded, and the 5% PVA sample formed nanospheres with 5.3% ± 
0.7% w/w PVA over the surface. 
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Aukunuru et al. [69] used a PVA concentration of 5% in the continuous phase. It 
was found that zeta potential increased to less negative values when the PVA 
concentration increased. Prabha and Labhasetwar [68] showed an increase in zeta 
potential from -31.3 ± 1.6 mV to -6.5 ±1.7 mV for PVA concentrations from 0.5% to 2%. 
Aukunuru et al. [69] obtained zeta potential value of -12.98 ± 1.8 mV. Sahoo et al. [74] 
showed a similar effect of PVA. The PVA concentration was varied from 0.5% w/v to 
5% w/v. The mean size varied from 522 nm to 380 nm, and the zeta potential varied from 
-15.4 ± 0.8 mV to -8 ± 2.3 mV, respectively.  
Yan et al. [72] studied the entrapment of insulin in PLGA nanoparticles 
(molecular weight of 11000 Da). The effect of surfactant concentration (poloxamer 188) 
on the nanoparticle size was tested. The lowest mean size obtained for 1% w/v of 
poloxamer 188 was 149.2 nm with a polydispersity index of 0.09, and the entrapment 
efficiency was 42.8% ± 1.5%. The large size obtained of 266.7 nm (PI of 0.15 and 
entrapment efficiency of 19.3% ± 4.2%) was for 0.4% w/v of poloxamer 188. 
• Drug entrapment 
Dillen et al. [75] showed a slight increase in the nanosphere size from 234.7 nm to 
238.1 nm, when the drug ciprofloxacin was added. When boric acid was added to the first 
aqueous suspension to acidify and improve the drug entrapment, the size increased 
slightly from 234.7 nm to 239 nm and the entrapment efficiency was improved from 
61.7% to 62.6%. The improvement was greater (79.9%) when the number of 
homogenization cycles was increased from one to three. The entrapment of hydrophilic 
drugs is improved by using high molecular weight of PLGA and high molecular weight 
of first surfactant, which results in a higher inner phase viscosity. Song et al. [60] tested 
two different molecular weights of PLGA (58 and 102 Da). The lower molecular weight 
resulted in an entrapment efficiency of 24.8% and 9.2% for a PLGA concentration of 3% 
and initial theoretical drug (bovine serum albumin, BSA) of 10%, and for a PLGA 
concentration of 6% with 14 % of BSA, respectively. The entrapment efficiencies were 
improved to 68% and 74.8% for high molecular weight, under the same conditions. The 





• Shear stress 
High shear stress for droplet size reduction is a basic requirement to make small 
nanoparticles by double emulsion. Homogenization by microfluidization has been used 
and found to affect the size of the nanoparticles as a function of the pressure and number 
of cycles. Dillen et al. [75] tested one and three cycles with a fixed pressure of 50 bars. 
The mean size obtained for one cycle was 234.7 nm, and the mean size was reduced to 
188.7 nm with three cycles. Vandervoort et al. [71] tested the effect of pressure and 
homogenization cycles forming a wide spectrum of nanoparticle sizes and entrapment 
efficiencies. The size reduction was achieved by an increase in the homogenization 
pressure and cycles. The lowest PLGA nanoparticle size was for the PVA and PVA 
mixed with carbopol (204 ±4 nm, and 205 ±5 nm, respectively) with 500 bar and three 
cycles. The drug entrapment decreased with an increase in homogenization pressure and 
cycles; the PVA sample varied from 61.5% ±12.4% to 20% ±8.2%, and the PVA mixed 
with carbopol varied from 41.8% ±12.1% to 20.8% ±8.4% for the entrapment of 
pilocarpine HCl. 
• Sterilization 
Sterilization is an important step to obtain a suitable system to be used in vivo. 
Dillen et al. [75] observed that nanoparticle size increased from 255.8 nm to 295.1 nm 
following gamma irradiation for sterilization purposes. This effect of slight increment of 
size is similar to that showed by Song et al. [60] with single emulsion method. 
2.2.5. Important Modifications of Traditional Methods 
The methods detailed above are the main methods extensively employed in the 
synthesis of PLGA nanoparticles for different purposes. There is a continuous effort to 
improve the nanoparticle size (size reduction), to reduce the polydispersity index, to 
better entrap the active components (hydrophilics and hydrophobics), and to reduce the 
potential toxicity of the different components involved. These efforts stimulated research 
and discovery of new methods, based on slight modifications of standard methods, and 
the application of new synthesis steps in the PLGA nanoparticles formation. The use of 
microfluidizers, dialysis, spray drying, and mix of standard techniques are examples of 




2.2.5.1. Membrane Emulsion Evaporation Method 
The aqueous and organic phases are separated by a membrane which has a 
defined pore diameter and distribution. The organic phase is forced through the pores to 
form an organic droplet which is detached from the membrane by a certain movement of 
the aqueous phase. The membrane has a hydrophobic or hydrophilic behavior as a 
function of the disperse phase (aqueous or organic solvent) [76]. This can lead to very 
uniform size distribution of nanoparticles, but the main drawback is the bigger size 
obtained compared to normal emulsion evaporation method [77]. The pore diameter 
affects the final size of the nanoparticles, and there is a relation pore to droplet diameter 
of 1:3 [78]. There are a number of criteria that have to be met in order to obtain 
nanoparticles in the nanometer range: the membrane must have a pore diameter between 
100 and 200 nm, the applied pressure difference should be slightly greater than the 
critical pressure, the contact angle should be as small as possible, and the surfactant 
should be adsorbed fast at the oil water interface [76]. SPG (Shirasu Porous Glass) and 
PTFE (poly(tetrafluoroethylene)) are the main membranes used in this technique [79].  
2.2.5.2. Spray Dry Method for Water in Oil 
Pamujula et al. [80] developed a method to improve the entrapment efficiency of 
hydrophilic drugs. An emulsion was formed between the organic phase and water. The 
organic phase, consisted of a mix of dichloromethane and chloroform, containing the 
polymer, and lipophilic surfactant L-α-phosphatidylcholine. The aqueous phase contained 
the drug (amifostine). The final emulsion was injected in a standard 0.7 mm nozzle 
blowing into a chamber with hot air (55 °C). The mean size obtained was 257 nm (182-
417 nm) and 240 nm (182-417 nm) for preparations with 40% w/w and 100% of 
theoretical drug loading, respectively. The main advantage of this method is the high 
entrapment efficiency for hydrophilic drugs, which were 90.9% ± 0.16% and 100.03% ± 
2.01% for the same preparations.  
2.2.5.3. Spryer Solvent Displacement with Dialysis and Freeze Dryer Stabilization 
Kim et al. [81] modified the solvent displacement as follows. The organic phase 
was injected into an aqueous solution by a nozzle and the solvent removed by dialysis. 
The drug addition (paclitaxel) was done after dialysis, by adsorption onto the nanosphere 
surface. The system was stabilized by the addition of an aqueous solution of pluronic F-
 
38 
68 and subsequently freeze dried. The solvent used in the organic phase (discontinuous) 
was tetraglycol. For the PLGA concentration tested, 0.5 wt% to 5 wt% the nanosphere 
mean size obtained were in the range of 150 nm to over 1.4 µm. The maximum 
entrapment efficiency was 28.5% ± 3.3% and loading amount of 9.4% ± 1.4 wt% for 
PLGA nanospheres formed with 0.05 wt% of paclitaxel-ethanol solution. A limitation of 
this procedure is the strong dependence of the nanosphere size with respect to the 
polymer concentration.  
2.2.5.4. Double Emulsion with Emulsion Diffusion 
Cegnar et al. [82] modified the normal emulsion solvent evaporation method. The 
evaporation step, required for the solvent elimination, was changed by the addition of 
large amounts of distilled water to promote the diffusion of the solvent from the polymer 
(organic phase) to the aqueous suspension to improve the energy consumption. PVA was 
used as surfactant in the emulsion, and it was added to the second aqueous phase, in low 
concentrations (0.3% w/v), to avoid aggregation. Ethyl acetate was used as the organic 
solvent. The excess of PVA was reduced by centrifugation and wash steps with distilled 
water. Four 50:50 PLGA polymers (free carboxyl end groups with 12 and 48 kDa, and 
esterified carboxyl end group with 12 and 48 kDa) were employed to entrap cystatin, a 
cysteine protease inhibitor. The free carboxyl end group with 42 kDa 50:50- PLGA led to 
mean sizes varying from 300 nm to 350 nm with a polydispersity index of 0.3, and zeta 
potential of -30 mV. The free carboxyl end groups PLGA incorporated higher amounts of 
cystatin than esterified carboxyl end groups (free carboxyl end groups: for the 12 kDa 
was 57 ± 8%, and for 42 kDa was 35 ± 8%; esterified carboxyl end groups: for the 12 
kDa was 12 ± 4%, and for the 42 kDa was 14 ± 6%).  
In a further work, Cegnar et al. [83] optimized different parameters to obtain 
smaller nanoparticles with maximum cystatin activity into the matrix. The parameters 
tested were stirring rate (from 5000 to 15000 RPM), solvent (ethyl acetate and a mix of 
dichloromethane with acetone, DCMA), stirring with sonication, and polymer type. The 
stirring with sonication formed the smaller particles with slight difference for both 
solvents tested. The mean nanosphere size were 254 ± 16 nm and 235 ± 19 nm for ethyl 
acetate and DCMA preparations, respectively. The reduction in the cystatin activity was 
more pronounced with the mix of acetone and DCM (30%) compared with ethyl acetate 
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(15%). Therefore, a mix of sonication and mild stirring in ethyl acetate was applied to 
preserve up to 85% of cystatin activity. The mean nanoparticle size was 180 ± 9 nm for 
free carboxylic end group PLGA with molecular weight of 12 kDa. Best drug loading and 
entrapment efficiencies were obtained for the PLGA polymer with free carboxylic end 
groups, 2.6% ± 0.2% and 57% ± 8%, respectively.  
2.2.5.5. Dialysis Method for Modified PLGA 
This is a simple method that can be used for the preparation of nanoparticles with 
block-copolymers, graft copolymers, and amphiphilic materials [84, 85]. Typically, this 
method consists of using a dialysis device in which the organic solution is placed. The 
organic solution, containing the polymer and the lipophylic active component is dialyzed 
for at least 12 hours against distilled water to remove the organic solvent and the free 
active component. 
Jeon et al. [84] investigated the effect of different solvents on the size of PLGA 
nanoparticles formed and release of norfloxacin. PLGA copolymer ratios used were 
85:15, 75:25, and 50:50 with molecular weight of 48.4, 47.5, and 40.1 kDa, respectively. 
The experiments were developed with low PLGA concentration (0.2% w/v) suggesting 
that the mean size of nanospheres obtained by this method is highly sensitive to polymer 
concentration. The solvents studied were acetone, dimethylsulfoxide (DMSO), 
dimethylacetamide (DMAc), and dimethylformamide (DMF). The lowest mean size 
obtained was for DMF with 50:50 PLGA with 183 ± 70.6 nm (number average), and the 
drug content was 9.74 wt % with a loading efficiency of 10.8 wt %. The highest drug 
content (12.97 wt%) and loading efficiency (14.9 wt%) was for the 50:50 PLGA in 
DMAc, but the nanoparticle size obtained was higher (over 300 nm).  
The solvent effect was further studied by Jeong et al. [85], who looked at different 
solvents (acetone, tetrahydrofuran (THF), DMF, DMAc, and DMSO). The lowest size 
nanosphere obtained was 200.4 ± 133 nm in the presence of DMAc as organic solvent 
(Figure 2.6). The nanoparticle sizes (number average) varied from 421.2 nm to 276.9 nm 
for 85:15 and 75:25 copolymer ratios, respectively. It should be noted that the entrapment 





Figure 2.6. Scanning electron microphotographs of 50:50 PLGA nanoparticles 
prepared from (a) DMAc or (b) acetone as a function of the initial solvent. 
Reproduced from ref. Jeong et al. [85]. 
The study of testosterone-free surfactant PLGA nanoparticles was done by Jeong 
et al. [86]. They compared the dialysis method with solvent diffusion method in terms of 
PLGA nanoparticle size. The nanoparticles mean size obtained by dialysis method was 
732.8 ± 190.7 nm with a drug loading of 8.5 wt% and an entrapment efficiency of 46.4 
wt% using acetone. For DMF, the mean size was 164.1 ± 32.5 nm with a drug loading of 
9.1 wt% and entrapment efficiency of 50.1 wt%. The solvent diffusion was done with 
acetone, and the mean size was 81.3 ± 10.4 nm with a drug loading of 11.2 wt% and 
entrapment efficiency of 63.1 wt%. The release profile for testosterone differed for each 
preparation suggesting that drug release is related more to the nanoparticle size than 
active component concentration and that it is regulated by diffusion pathways more than 
polymer degradation. Nanoparticle synthesized using the acetone-solvent displacement 
method was released faster than the nanoparticles prepared with the dialysis method 
(almost 100% after 3 days for the former, and almost 60% for the latter).  
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A further work of Jeong et al. [87] studied the addition of PLA-poly(ethylene 
glycol) diblock copolymer to the organic phase with dissolved PLGA. The organic 
solvent used was dimethylformamide. The organic solution was placed in a dialysis tube 
with a cutoff of 12,000 g/mol. The mean nanoparticle size (number average) was 295.3 ± 
171.3 nm and 307.6 ± 27.2 nm for the PLGA and PLGA/(PLA-PEG) blend, respectively. 
The entrapment of adriamycin-HCl (ADR) increased the mean size to 307.6 ± 27.2 nm 
and 348.4 ± 176.6 nm for 1:1 and 1:2 PLGA/ADR weight ratio, respectively. Poly(L-
lysine)-grafted-PLGA polymer was another modification done to PLGA by Jeong et al. 
[88, 89] to obtain an amphiphilic polymer suitable for micelle formation under 
dissolution in water. The polymer concentration used was 0.4% w/v. The mean size 
ranged from 149.6 ± 4.8 nm to 69.4 ± 2.8 nm for 3% or 8% of polymer grafting, 
respectively.  
2.3. Magnetic Polymeric Nanoparticles (MPNPs) 
There are numerous methods available to form magnetic polymeric nanoparticles 
(MPNPs), divided in two main classes, 1) polymerization techniques, starting with a 
monomer, and 2) chemical and physical entrapment of magnetite in a preformed polymer. 
Polymerization methods include emulsion or microemulsion polymerization, interfacial 
polymerization, precipitation polymerization, and suspension polymerization. When a 
preformed polymer is the starting material, the methods used are impregnation of 
magnetite in the polymer matrix, polymer immobilization onto inorganic magnetite, 
incorporation of magnetite by precipitation, and others. 
2.3.1. Polymerization Methods 
The materials resulting from the inclusion of magnetite (inorganic material) into a 
polymer matrix (organic material) are usually named polymer latexes [128, 129] or 
nanocomposites [130]. Both names, the first originating from colloidal chemistry and the 








Table 2.1. Summary of important parameters for PLGA nanoparticles formation 
 









































PVA at 10, 
15, 20% w/w 
Benzyl 
alcohol 


















10/20 na. Estrogen na. 
Approx. 200 







ED 5% w/w 50/50 12 
PVA at 10, 
15, 20% w/w 
Benzyl 
alcohol 






ED 20 70/30 na. 















































SO 20% w/w na. na. PVA Acetone na. 65 
Coumarin-
6 






SO 2%wt. 57/43 11.4 
PVA at 2 
wt.% 























4.96  11.8   
8.22 









































NP 4.4 85/15 
66, 
127 





































1.62   
5.42   
15.0 































1.5:2   2:5) 
Acetone and 
water 











NP 33.3 50/50 20 
PVA at 1% 
w/v or span 
80 (100 mg) 
Acetone+Me










19.5     











NP 40 50/50 na. 










NP 7.74 85/15 105 














NP 2.5% w/v 50/50 
40 to 
75 





























NP 10 to 100 50/50 na. 
Pluronic F68 
(0.25%) 
Acetone 10 / 25 na. 
Itraconazol
e 
0.2 to 1.8 190 to 644 na. na.  
 
44 



































NP 20 na. 75 
poloxamer 
188 (1%) 
















4.2,   4.2,   
33.3 









0.21,    


























Nile red or 
coumarin-6 



















































30% w/v 50/50 7 PVA 7.5% 
water/chl-

















EEV 24.2 50/50 
143,  
12,   
10 


























DCM  and 
water 
na. na. Paclitaxel na. 
369.1±80.8 
552±81.4 



























































EEV na. 50/50 
40-
75 
PVA 2% and 
TPGS 0.03% 
w/v 










































































DEV 30 50/50 143 






































































DEV 200 50/50 na. 
Pluronic 10% 
and 1% 
Ethyl acetate na. na. 
Recombina
nt Bet v1 
4 































































DEV 100 52/48 40 




































































60.0      
31.5       
6.8 








DESD 50 50/50 
12   
12    
48 










12±4   













to 5% w/v 
75/25 90 
















Notes: The data presented in the table is classified in function of the method. The main parameters presented are: polymer concentration in mg PLGA/ml of solvent; PLGA copolymer molar ratio; PLGA molecular 
weight (M.W.); surfactant concentration; solvent in the organic phase; phase volume ratio; nanoparticle yield (% of final nanoparticle obtained as a function of the initial amounts of components); active component 
used in the formulation; initial concentration of drug in the discontinuous phase; nanoparticle size, drug entrapment efficiency (drug entrapped / initial amount added); nanoparticle loading (amount of drug related 
to the amount of PLGA nanoparticle).  When the units are different, they are detailed in the cells.  
Abbreviations used:      *: Polydispersity index (0 to 1)  BLP25: MUC1 lipopeptide 
 E.D.: emulsion diffusion    DiO: 3'3-dioctadecyloxacarbocyanine perchlorate BSA: bovine serum albumin 
 S.O.: Salting out      (fluorescent dye)   DMF: dimethylformamide 
 N.P.: nanoprecipitation or solvent diffusion  BSP: Betamethasone Sodium phosphate THF: tetrahydrofuram 
 EEV: Emulsion evaporation (single emulsion)  ICG: Indocyanine green (free of sodium iodide) AN: acetonitrile  
 DEV: Double emulsion evaporation   ICG-NaI: Indocyanine green sodium iodide EAc: athyl acetate  
 Dya: Dialysis method, free of surfactant  chl-met: mix of chloroform and methanol  DCM: dichloromethane 
 SDO: Solvent diffusion in oil    MPLA: monophosphoryl lipid A  DXM: dexamethasone 
 NS: nanosphere  TMR-dextran: Tetramethylrhodamine conjugated dextran Met-chlor: Methylene chloride 
 DESD: Double emulsion with solvent diffusion  TPGS: vitamin E succinate with polyethyleneglycol 1000    
 SDya: spray injection and dialysis  Polymer concentration is based on the organic phase    
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Examples of this are the addition of 1 wt% of multiwalled carbon nanotubes to 
polystyrene to improve the tensile strength of polystyrene by at least 25% [131], the 
application of cellulose whiskers (nanocrystals) as mechanical reinforcing agents for low 
thickness polymer electrolytes for lithium batteries [132], or the use of iron oxides and 
ferrites to form conducting polymers [129].  
Several monomers have been used to form the shell surrounding a magnetic 
nanoparticle by polymerization techniques. Sauzedde et al. [128, 133] worked with 
polystyrene (PS), poly N-isopropylacrylamide (NIPAM) and poly S/N-
isopropylacrylamide (PNIPAM) to form a stable nanoparticle by precipitation 
polymerization. The maximum magnetite adsorbed was 1.24 g/g for PNIPAM, and the 
hydrodynamic diameter of the nanoparticles formed was 450 nm at 20 °C. When the 
adsorption was carried out at 40 °C, the mean size decreased to 215 nm, but the magnetite 
adsorbed decreased as well to 0.95 g/g.   
Dresco et al. [134] used a single inverse microemulsion by seed copolymerization 
of methacrylic acid, hydroxyethyl methacrylate and cross-linker to form magnetic 
nanoparticles. Nanoparticles in the range of 80 to 320 nm were obtained. Arias et al. 
[135] used anionic polymerization to synthesize a shell of poly(ethyl-2-cyanoacrylate) 
with a magnetite core. The core/shell nanoparticles obtained were spherical in shape and 
measured around 144 nm (± 15 nm) with a polymer shell of 30 nm (approx.), for an 
initial weight ratio of 4 to 3 between monomer to magnetite. Landfester and Ramirez 
[136] studied miniemulsion polymerization technique as a way to form magnetic 
polymeric nanoparticles. The nanospheres made from polystyrene matrix with entrapped 
magnetite measured in average 60 nm, and the entrapment efficiency of magnetite ranged 
from 19.4% to 34.7% as measured by thermogravimetric measurements. Zheng et al. 
[137] used the same method to improve the magnetite content and the nanoparticle size 
distribution. The final nanoparticle mean size was around 120 nm as measured by DLS. 
Different ratios of magnetite/styrene monomers were tested. The lowest particle diameter 
(102 nm) was observed for the 1/1 ratio, and the highest diameter (128 nm) was for the 
1/3 ratio. The magnetic content was found to change proportionally to the amount of 
magnetite used for the preparation of the magnetic core polymeric shell system, ranging 
from 27 to 55 %.  
 
48 
The polymerization techniques have the advantage of forming well controlled 
magnetic core polymeric shell nanoparticles, by close monitoring the magnetite to 
polymer ratio, as compared to other methods. A limitation of the polymerization 
techniques is that the polymeric shell, in some cases, is not thick enough to transport a 
suitable amount of drug [130, 138]. Other drawbacks are the risk of residual additives and 
the possibility of interactions or cross-reactions between the drug and the polymer during 
the polymerization process, leading to drug inactivation [117]. 
2.3.2. Chemical and Physical Entrapment of Magnetite 
2.3.2.1. Chemical Entrapment and Surface Modification of Magnetite 
Another procedure used to form polymeric latexes or nanocomposites is the 
attachment of preformed polymers to magnetite by chemical reaction. The polymer is 
formed previously and added to the magnetite synthesis or formed magnetite. 
Burke et al. [130] worked with polyethylene, polystyrene and polyisobutylen to 
form a suitable polymeric shell for magnetic nanoparticles (called nanocomposites). The 
previously formed polymers were added to iron pentacarbonyl and kerosene to form the 
core/shell nanoparticle. The average size varied from 8 nm to 50 nm with a core size 
range of 3 nm to 45 nm. The iron content varied from 21 to 61 % wt %. In general, a 
smaller size distribution of nanoparticles was observed for polyethylene and 
polyisobutylene as compared to polystyrene shell nanocomposites. 
2.3.2.2. Physical Entrapment 
In the physical entrapment techniques (top-down techniques), the starting 
materials are the polymer and magnetite. No chemical reactions are involved in the 
process; magnetite is entrapped into the polymeric matrix by hydrophobic-hydrophilic, 
electrostatic, or steric interaction. 
Emulsion evaporation, emulsion diffusion, salting out, nanoprecipitation or 
solvent displacement, are some of the common methods used to form nanoparticles from 
preformed polymers. These methods can be adapted to entrap magnetite. Jeong et al. 
[139] entrapped magnetite into a preformed polymer (PLGA) by the emulsion diffusion 
method. The nanoparticles obtained had an average size of 120 nm. Lee et al. [19] 
entrapped magnetite in PLGA by nanoprecipitation. The magnetite was suspended in 
acetone after the PLGA dissolution (150 mg), and the initial magnetite concentration 
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(theoretical loading) was 3.33 % w/w (related to PLGA weight). The nanoparticle size 
obtained ranged from 120 nm to 230 nm for PLGA concentration varied from 1% to 5%, 
respectively. 
Emulsion evaporation is one of the oldest methods used with preformed polymers, 
and it has been extensively used to entrapment numerous drugs [63, 72, 121]. 
Hydrophilic compounds (normal magnetite) can be modified by adding a layer of oleic 
acid to the surface to ensure its entrapment in the PLGA (hydrophobic polymer) matrix 
by emulsion evaporation method. 
2.3.3. Surface Modification  
Surface modification is pursued not only to ensure effective magnetite entrapment 
in PLGA, but also in an attempt to improve stability of the magnetic nanoparticles, to 
increase their circulation half life, and improve the nanoparticle cellular uptake. Zaitsev 
et al. [140] used methacrylic acid for magnetite coating. The size of the nanoparticles 
formed was 5.7 nm. Dextran coated magnetite nanoparticles have been researched by 
Lacava et al. [141], who focused on long term retention of the particles in the liver and 
spleen. Magnetite nanoparticles with an average size of 9.4 nm were obtained. The use of 
triblocks copolymer is yet another approach to improve the stability of magnetite. Harris 
et al. [138] synthesized a triblock copolymer which was adsorbed onto the magnetite 
surfaces. The mean size of the nanoparticles was 8.7 nm (SD 2.7 nm). The amount of 
entrapped magnetite ranged from 6.9 to 45.4 wt%.  
 The incorporation of poly(ethylene glycol) (PEG) on the magnetite surface is 
another approach to improve stability and increase the circulation half life. Kim et al. 
[142] obtained nanoparticles of 4.2 nm in size. Gupta and Curtis [143] studied the effect 
of PEG coated magnetite on human fibroblasts cells suggesting that the cellular uptake is 
improved compared with unmodified magnetite. The size of the magnetite coated 
nanoparticles was around 40 -50 nm in diameter. Goodarzi et al. [144] used citric acid for 
surface modification to obtain a suitable aqueous suspension of magnetite. The size range 
ranged from 5 to 13 nm. The amount of citric acid attached to the surface was around 
30% in weight as determined by thermogravimetric analysis (TGA).  
 Surfactants were used to stabilize magnetite and to form hydrophilic or 
hydrophobic magnetic nanoparticles. The adsorption of surfactants on the magnetite 
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surface was studied by Korolev et al. [145]. Oleic, stearic, and linoleic acids were tested 
in CCl4, and oleic acid in hexane. A higher amount of oleic acid was adsorbed for both 
solvents on the magnetite surface as compared to stearic and linoleic acids, suggesting a 
better performance for this fatty acid. The nanoparticle size obtained varied between 5.7 
nm and 9.3 nm, depending on the temperature. Montagne et al. [146] worked with oleic 
acid for stabilization of water-oil emulsion of maghemite (Fe3O2) ferromagnetic fluid. 
Wooding et al. [147] studied the effect of different carboxylic acids (C6 to C18) on the 
stability of surface modified magnetite in aqueous suspension for one and two surfactant 
layers. The surface covered was between 21 to 38 Å2. Along the same lines, the addition 
of fatty acids (oleic acid, dodecanoic acid, etc.) was found to improve the stability of 
magnetite in aqueous and organic suspension. Xu et al. [131] used N-oleoylsarcosine to 
form a double layer on the magnetite surface by changing the amount of surfactant added 
to the suspension. The nanoparticle size varied between 8.1 nm and 20.7 nm. Landfester 
and Ramirez [136] used oleic acid to form a hydrophobic magnetite which was 
suspended in octane. The nanoparticle size was around 20 nm. A different approach was 
followed by Jain et al. [148], who mixed two surfactants to entrap a suitable drug. The 
first one was oleic acid which was attached to the magnetite surface. The second 
surfactant was Pluronic F-127 which was added to the system magnetite-oleic and stirred 
over night. The optimum composition was 70.1 wt% magnetite, 15.4 wt% oleic acid, and 
14.5 wt% Pluronic F-127 determined by TGA. The drug (doxorubicin) loaded into the 
system was 8.2 ± 0.5 wt% with an entrapment efficiency of 82%. 
Another option for magnetite surface modification is the incorporation of ligands 
like folic acid [149], proteins like HIV-1 tat peptide [150], or poly ethylene glycol (PEG) 
[142, 149], which was found to improve the half-life by limiting the mononuclear 
phagocyte system (MPS) uptake. 
2.4. Characterization  
2.4.1. Morphology 
The methods most broadly used to characterize nanoparticle morphology are 
transmission electron microscopy (TEM), scanning electron microscopy (SEM), 
cryogenic transmission electro microscopy (cryo-TEM) and atomic force microscopy 
(AFM). TEM is used for shape, aggregation, and internal details. It is common to use a 
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negative staining with phosphotungstic acid solution (3% w/v, adjusted to pH 4.7 with 
KOH) [115]. Panyam et al. [108, 116] used negative staining with uranyl acetate for 
TEM. SEM is used for surface characterization (shape, distribution, aggregation) with a 
layer of gold [117] or nanoparticles alone [59, 60, 80, 81, 99]. Cryo-TEM is used to 
observe the micellar formation of PLGA-g-PEG [118]. Dailey et al. [119] used AFM to 
visualize three different formulation (PVA grafted PLGA polymer with different amounts 
of carboxymethyl cellulose) on mica with and without nickel chloride pretreatment. Ravi 
Kumar et al. [22] and Saxena et al. [37] used AFM for size and morphology of 
nanoparticles. Moreover, a three D image of one nanoparticle was obtained by Feng et al. 
[101]. 
2.4.2. Size and Size Distribution 
Dynamic light scattering is the most widely technique used to determine size and 
size distribution. One of the most common used techniques is photon correlation 
spectroscopy at room temperature with water as suspension medium [17, 87, 116, 120]. 
Typically, the suspension is previously sonicated to reduce aggregation if the sample is a 
re-suspension of nanoparticles. Panyam and Labhasetwar [121] used TEM to determine 
the mean size of the nanoparticles. The same equipment is used to determine mean size 
and size distribution. The turbidity measurements are used to evaluate droplet size 
changes and aggregation during emulsification and evaporation [117]. 
2.4.3. Surface Properties 
Laser doppler anemometry is used to measure the zeta potential, an important 
parameter when considering the stability of the nanoparticles [30, 34, 103, 105, 119] in 
vitro. The more negative or positive values of zeta potential are related to more stable 
particles; more repulsion between particles reduce the particle aggregation.  For chemical 
characterization, Fourier transform infrared spectroscopy (FT-IR) is used when there is 
surface modification by the attachment of special components [122]. Gref et al. [123] 
used two-dimensional electrophoresis to determine the plasma protein adsorbed onto the 
nanoparticles surface. The surface hydrophobicity was measured by the binding constant 
of Rose Bengal [74].  
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2.4.4. Active Component Entrapment 
The entrapment into the nanoparticles is described by two important parameters: 
theoretical drug loading, which is the ratio between mass of drug used in synthesis and 
mass of polymer used in synthesis, and nanoparticle recovery, which is the ratio between 
mass of nanoparticles recovered and mass of polymer and drug used in synthesis. The 
drug content is calculated by the ratio of mass of drug in nanoparticles to mass of 
nanoparticles recovered, and the drug entrapment by the ratio of mass of drug in 
nanoparticles to mass of drug used in synthesis [17, 31, 120]. The quantitative 
determination of active component entrapped in nanoparticles is done by extraction of the 
drug. The polymer dissolution in a suitable solvent (acetonitrile, ethyl acetate, and others) 
is required, washing steps with distilled water, and purification. The drug concentration 
of the final suspension can be measured by ultraviolet spectroscopy at defined 
wavelength (related to the active component) or HPLC. When the target is the 
quantification of surfactant attached to the surface, the thermo-gravimetric analysis is 
used [50]. 
2.4.5. Other Techniques 
Gel permeation chromatography is suitable to determine the molecular weight of 
the polymers used for nanoparticle formation and for studies of degradation [87, 124]. 
Dailey et al. [119] studied degradation by measuring the lactic and glycolic acid present 
in the supernatant at different time intervals with a UV spectrophotometer. When the 
nanoparticles are tested in vitro, flow cytometry is used to determine the cell association 
in 3’3-dioctadecyloxacarbocyanine perchlorate (DiO) [98]. H-NMR is commonly used 
when the target is the identification of a specific structure in the nanoparticle and polymer 
blends [38, 125], but Chognot et al. [126] used to determine the molecular weight (Mn 
and Mw) of MPEO. To determine the PVA residues on the nanoparticles, a colorimetric 
method is used [17, 116] with measurements at 644 nm. Desgouilles et al. [127] used a 
small angle neutron scattering to investigate the nanoparticle structure. The sample was 
diluted in deuterium oxide (D2O), and the sample-to-detector distance was 1.62 or 4.62 m 
with incident wavelengths of 6 or 15 Å. For porosity measurements, the true density was 
calculated with helium pycnometer equipment by Murakami et al. [94], and the formula 
used was Porosity = (1-(apparent density/true density))*100. The crystallinity of polymer 
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and drugs are estimated by x-ray diffraction [17, 58, 70] or using differential scanning 
calorimetry [70]. A common method used to determine the crystallinity of the polymer 
and drug entrapped is done by x-ray diffraction [17, 101]. 
2.5. Conclusions 
Many methods are available to synthesize PLGA nanoparticles, starting with a 
preformed polymer. Each has its advantages and disadvantages, but the principal 
selection criteria should be the chemical characteristics of the active component and its 
interactions with the organic solvents, polymer, and surfactant, as well as the final use of 
the nanoparticles. Polymerization methods are widely employed for magnetic polymeric 
nanoparticles (MPNPs) synthesis as compared with methods based on preformed 
polymers. The final application of MPNPs is the limiting factor in selecting the adequate 
synthesis method. For example, the potential toxicity of chemical compounds (initiators, 
residual monomers, and additives) needed in some polymerization techniques limits the 
use of these methods in formation of nanoparticles for drug delivery applications.  
The methods based on diffusion of the organic solvent to form the PLGA 
nanoparticles are limited to low polymer concentration to maintain a nanoparticle mean 
size of 200 nm. Methods that involve solvent evaporation are more time consuming and 
expensive, but are less sensitive to changing the polymer concentration. Emulsion 
evaporation, in particular, can be used for entrapment of hydrophilic (w/o/w emulsion) or 
hydrophobic (w/o emulsion) drugs, which is an advantage. The salting-out method is 
suitable for formation of nanoparticles at higher polymer concentration, but the involved 
purification process is a limitation of the synthesis method. Surfactant concentration, 
polymer concentration, polymer molecular weight, solvents, surfactant concentrations, 
and phase ratios play an important role in controlling the size of the nanoparticles in all 
methods available for nanoparticles formation. There are important advances in 
understanding the mechanisms involved and possible manipulation of the nanoparticle 
characteristics and the improvement in the drug entrapment efficiency by carefully 
controlling these parameters. 
The availability of different characterization techniques makes the detailed 
analysis of the nanoparticle system possible. The nanoparticles size is affected by many 
parameters and researchers are continually attempting to decrease the average 
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nanoparticle size. Synthesis of PLGA nanoparticles smaller in size than 100 nm is not 
common by the methods detailed above; however, the advantages of smaller sizes should 
be studied in depth (i.e. nanoparticles designed for intracellular use should be smaller 
than nanoparticles designed for extra cellular use).  
The magnetic polymeric nanoparticles (MPNPs) are synthesized by 
polymerization methods. The size range is from 30 nm to over 100 nm. The common 
structure of the MPNPs is a magnetic core with a polymer shell. The amount of magnetite 
entrapped ranged from 10 %wt. to 35% wt. The use of preformed polymer to entrap 
magnetite is limited, and nanoprecipitation is the only top-down method employed in 
forming MPNPs.  
Formation of nanoparticles that can interact with the human body and can modify 
their responses based on changes in the environment is the next research step in the field. 
Several questions will be addressed to reach this goal, such as the addition of new 
polymers to form grafted PLGA, surface modification by adding new polymers or 
ligands, as well as the creation of nanoparticles with new properties for modulated 
responses and a better performance.  
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CHAPTER 3. SYNTHESIS OF POLY(DL-LACTIDE-CO-
GLYCOLIDE) NANOPARTICLES WITH ENTRAPPED 
MAGNETITE 
3.1. Introduction 
Biosensor development [1], imaging [2, 3], bio-separation [4], hyperthermia [5, 
6], drug delivery [1, 7], targeted diagnostics and therapy [8] are some of the many 
biomedical areas where magnetic nanoparticles could be of relevant use. Magnetic-
polymeric nanoparticles (MPNPs), made from organic and inorganic components, have 
unique characteristics due to the specific properties of the blend. The constituents of a 
MPNP play different roles: the polymeric matrix acts as a shell, reservoir, and vehicle for 
the active component, whereas magnetite is the component which makes targeting 
possible by external magnetic field manipulation. MPNPs can be used for delivery of 
active components such as drugs [7, 9, 10, 11], vaccines [12], proteins [13], DNA [14, 
15, 16], antisense oligonucleotides [17], enzymes [18], and others.  
In biomedical applications, synthetic polymers and natural macromolecules have 
been extensively researched as colloidal materials for the MPNPs production. Synthetic 
polymers have the advantage of high purity and reproducibility over the natural 
polymers. Among those, the polymers in the polyesters family are of interest because of 
their biocompatibility and biodegradability to nontoxic metabolites. Poly(lactide-co-
glycolide) (PLGA) is a polyester that has been FDA approved for human therapy [19, 
20]. 
The mainly technique used to form a magnetic core with a polymer shell is 
polymerization which is known as bottom up technique. Another interesting approach is 
the top down techniques due to the advantages discussed in chapter 1. In the top-down 
techniques, the starting materials are the polymer and magnetite. No chemical reactions 
are involved in the process; magnetite is entrapped into the polymeric matrix by 
hydrophobic-hydrophilic, electrostatic, or steric interaction. 
The common top-down methods using preformed polymers are emulsion 
evaporation, emulsion diffusion, salting out, nanoprecipitation or solvent displacement. 
These methods can be adapted to entrap magnetite. Jeong et al. [21] entrapped magnetite 
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into a preformed polymer (PLGA) by the emulsion diffusion method. The nanoparticles 
obtained had an average size of 120 nm. Lee et al. [22] entrapped magnetite in PLGA by 
nanoprecipitation. The magnetite was suspended in acetone after the PLGA dissolution 
(150 mg), and the initial magnetite concentration (theoretical loading) was 3.33 % w/w 
(related to PLGA weight). The nanoparticle size obtained ranged from 120 nm to 230 nm 
for PLGA concentration varied from 1% to 5%, respectively. The emulsion evaporation 
is one of the oldest methods used with preformed polymers, and it has been extensively 
used to entrapment numerous drugs [23, 24, 25, 26]. The versatility of emulsion 
evaporation method permits to entrap magnetite by double emulsion due to the 
hydrophilic behavior of magnetite, although hydrophilic compounds (normal magnetite) 
can be tailored to hydrophobic compounds by addition of a surfactant layer (oleic acid) to 
the particle surface. This magnetite surface modification ensures its entrapment in the 
PLGA (hydrophobic polymer) matrix by emulsion evaporation method.  
3.2. Objectives 
The aim of this research was to synthesize PLGA nanoparticles with entrapped 
magnetite in the polymeric matrix, by emulsion evaporation method. Single emulsion 
evaporation was the technique used for the entrapment of surface modified magnetite 
with oleic acid (MOA). The nanoparticles were characterized in terms of size and size 
distribution with dynamic light scattering (DLS). The magnetite entrapment efficiency 
was measured by colorimetric method for free iron (Fe3+) detection. The sodium dodecyl 
sulfate remaining in the nanospheres after dialysis was calculated by thermogravimetric 
analysis (TGA), and the morphology of the particles was visualized with Transmission 
Electron Microscopy (TEM).  
3.3. Materials and Methods 
3.3.1. Materials 
 Poly(DL-lactide-co-glycolide) (PLGA) 50:50, with a molecular weight of 5,000 – 
15,000, PLGA 50:50, with a molecular weight of 45,000-75,000, and PLGA 85:15 with a 
molecular weight of 90,000 -120,000 were purchased from Sigma Aldrich (Sigma 
Chemical Co, St Louis, MO). Sodium dodecyl sulfate of 99% purity (20% w/v) was 
obtained from Amresco (Amresco inc., Solon, OH). Ethyl acetate at 99% of purity was 
acquired from EMD chemicals (EMD chemicals Inc., Gibbstown, NJ), and hydrochloric 
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acid 32 -38% was purchased from Fisher Chemical (Fisher Scientific International, 
Fairlawn, NJ). Oleic acid, trehalose, iron oxide, and potassium ferrocyanide were 
purchased from Sigma Aldrich (Sigma Chemical Co, St Louis, MO). Magnetite (Fe3O4) 
was obtained from the Center for Advanced Microstructures and Devices (CAMD). 
3.3.2. Nanoparticles Preparation 
3.3.2.1. Hydrophobic Magnetite 
 Magnetite was prepared by coprecipitation of ferrous salts (Fe(II) and Fe(III)) by 
addition of excess of ammonium hydroxide. The attachment of oleic acid to the surface 
was done after the formation of magnetite by addition of 15 ml of 20 %wt aqueous 
solution of oleic acid and 10% ammonium hydroxide. The solution was stirred with a 
magnetic bar for 30 minutes at 80 °C in an oil bath. Following stirring, the solution was 
placed on a magnet and washed three times, twice with distilled water and once with 
ethanol. The solution was dried with nitrogen for two hours and stored for further use. 
3.3.2.2. Single Emulsion Evaporation with Hydrophobic Magnetite 
PLGA nanoparticles were prepared using emulsion evaporation method. 
Typically, 125 mg of PLGA was dissolved in 2.5 ml of ethyl acetate. The magnetite-oleic 
acid (MOA) was suspended in ethyl acetate and sonicated for 10 min in an ice bath and it 
was added to the organic phase at two concentrations, 4% and 8% w/w (relative to 
PLGA). The organic phase was poured into to 2 mg/ml of aqueous SDS solution 
(distilled water saturated with ethyl acetate), and the emulsion was stirred with a 
homogenizer Ultra Turrax T18 (IKA Works Inc., Wilmington, NC) for 3 minutes at 
12000 RPM. The emulsion was sheared with sonication in an ice bath at 4 to 6 °C using a 
probe-type sonicator VC505 (Vibracell, Sonic & Materials Inc., Denbury, CT) for 10 
minutes in pulse mode (38% of amplitude). The organic solvent was evaporated with a 
rotoevaporator (Buchi R-124, Buchi Analytical Inc, New Castle, DE) for 7 min under 
vacuum (40 mmHg). After nanospheres formation, the purification (extraction of excess 
of SDS) was done by dialysis with a Spectra/Por® (Spectrum Laboratories Inc., Rancho 
Dominguez, Ca) membrane of a 100 kDa molecular weight cut off. The dialysis process 
was done with distilled water with three washes. Washes for the low molecular weight 
PLGA were performed at 20 °C (tg is 25.7 °C). The first one was for two hours, the 
second one was for 8 hr, and the last one was over night. The amount of distilled water 
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was 1.5 l each time. Finally, the nanoparticles were pre-frozen at – 80 °C for three hours 
followed by lyophilization for 48 hours at -41 °C under 110 mmHg of vacuum (freezone 
4.5, Labconco Corporation, Kansas City, Missouri) in the presence of trehalose. The final 
samples were injected with nitrogen (to avoid degradation due to humidity, hydrolysis) 
and stored at 4 °C.  
3.3.3. Nanoparticles Characterization 
3.3.3.1. Morphology and Size 
Transmission electron microscope (TEM) JEOL 100-CX (JEOL USA Inc, 
Peabody, MA) was used for morphology studies. The aqueous dispersion (one drop) was 
placed over a copper grid of 400 mesh with carbon film. The droplet was reduced after 5 
min with a filter paper to eliminate the excess of nanoparticles. Finally, the sample was 
air dried prior to placing it in the TEM. 
3.3.3.2. Size and Zeta Potential 
Diffraction light scattering was used for size and polydespesity index 
measurements (Zetasizer nano ZS, Malvern instruments Inc, Southborough, MA). 
Typically, a sample of 1.5 ml was placed in a cuvette at a concentration of 0.3 mg/ml. 
The measurements were done at 25°C. The viscosity and refraction index of the 
continuous phase were set equal to those specific to water. Zeta potential measurements 
were done with a disposable capillary cell with a volume of 1 ml. The mean value was 
determined using a mono-modal distribution. 
3.3.3.3. Colorimetric Method for Iron Content 
The magnetite with oleic acid entrapped into the polymeric matrix was measured 
by detection of free iron (Fe3+) with a UV/vis spectrophotometer Genesys 6 (Thermo 
Spectronic Corp., Rochester, NY), colorimetric method, that uses the prussian blue 
reaction. The calibration curve was done with iron oxide at 99.999% of purity and 
potassium ferrocyanide solution at 4% w/v. Typically, a certain amount of PLGA 
nanospheres with entrapped MOA (10 mg) was digested with hydrochloric acid at 6 N (1 
ml) for two hours or until the residue was white. A dilution step was added (10 ml) to 
insure that the concentration was in the calibration plot range. The solution formed a 
white-yellow color. Next, 0.3 ml of sample was reacted with equal amount of potassium 
ferrocyanide for 15 min. The absorbance was measured at 700 nm. To determine the 
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magnetite content, a final correction was applied to the iron content of magnetite (molar 
ratio of 72.4%).  
3.3.3.4. Thermogravimetric Analysis 
The sample was placed in the furnace of TGA 2950 thermogravimetric analyzer 
(TA instruments, New Castle, DE) over an aluminum pan under a nitrogen atmosphere to 
avoid oxidation. The temperature was varied from 25 to 600 °C with increments of 5 °C 
per minute.  
3.3.3.5. Statistical Analysis 
Data collected were analyzed by SAS software. The test performed was analysis 
of variance (ANOVA) with Tukey-kramer adjustment. P<0.05 was considered 
significant. The proc mixed procedure was used to analyze the interaction between the 
process parameters (molecular weight, MOA addition, and sonication amplitude) and 
their effect in the nanoparticle size. 
3.4. Results and Discussions 
3.4.1. Single Emulsion Evaporation with Hydrophobic Magnetite 
3.4.1.1. Morphology and Magnetite Distribution into the Polymeric Matrix 
The magnetite with oleic acid (MOA) nanoparticles analyzed by TEM showed a 
spherical shape with a narrow size distribution (Figure 3.1). The aggregation present in 
MOA was due to the solvent elimination prior to TEM analysis and to natural clustering 
of MOA.   
 The TEM pictures of the MPNPs formed with 4% MOA theoretical loading 
showed a good distribution and a small size of the nanoparticles. The presence of MOA 
into the polymeric matrix is identified by the black dots over the grey background 
representing the PLGA (Figure 3.2). A clear visual difference between 4% and 8% MOA 
theoretical loading was not possible by TEM. Figures 3.3 and 3.4 show MOA 
nanoparticle surrounded by PLGA. MOA aggregation affects the size and PI of PLGA 
nanoparticle with entrapped MOA. The distribution and density of MPNPs can be 
observed in Figure 3.5. MOA distribution into PLGA nanoparticles can be appreciated in 







Figure 3.1. Surface modified magnetite with oleic acid (MOA). The MOA 




Figure 3.2. PLGA (molecular weight (M.W.) 45 to 75 kDa) nanospheres with 4% 
MOA theoretical loading. The black circles are showing the MOA entrapped in the 
polymeric matrix. Clustering was observed, and some PLGA nanoparticles are 








Figure 3.3. PLGA (M.W. 45 to 75 kDa) nanospheres with 8% MOA theoretical 
loading. The black dots represent MOA entrapped in PLGA nanospheres.  
 
 
Figure 3.4. Nanoparticles formed with PLGA M.W. of 45 to 75 kDa with 4% w/w of 
MOA theoretical loading. The big dark sphere (inside the dotted circle) manifests 












Figure 3.5. Low molecular weight PLGA nanospheres with 4% w/w of MOA 




Figure 3.6. Medium molecular weight PLGA (40 to 75 kDa) nanosphere with 4% 
w/w of MOA theoretical loading. The magnetite is clearly showed in the center of 





3.4.1.2. The Effect of Synthesis Parameters on Nanoparticle Physical 
Characteristics 
• Surfactant concentration 
The study of the surfactant concentration effect on the nanoparticle size was 
performed for the low molecular weight PLGA 5 to 15 kDa (Figure 3.7). Three 
distinctive regions were observed. Region A: For a SDS concentration lower than the 
critical micelle concentration (CMC), 1.2 mg/ml for SDS [27], the mean nanoparticle size 
decreased from 69.1 nm (0.4 mg/ml SDS) to 45.6 nm (1.2 mg/ml SDS). The 
polydispersity index (PI) decreased with increasing SDS concentration from 0.170 to 
0.227 in the same range. The decrease in size and PI can be explained by the decrease in 
the surface tension with increasing surfactant concentrations up to the CMC. The 
availability of the surfactant molecules at higher concentrations, required for stabilization 
of the smaller emulsion droplets created during sonication, is another reason for the 
improved size and size distribution in this region. Region B: At SDS concentrations 
higher than CMC, smaller particles were formed as a result of SDS molecules 
availability, as well. Although the size decreased, the polydispersity index (PI) of the 
formed nanoparticles increased with increasing SDS concentration. The increase of the PI 
suggests that the excess SDS was responsible for aggregation of the nanoparticles by 
interactions between the SDS polar heads and cluster formation. Region C: Ultimately, 
the aggregation due to the excess surfactant was responsible for an increase in the size 
and the PI of the nanoparticles when the SDS concentration exceeded a threshold of 7 
mg/ml (Figure 3.7). 
Nanoparticle aggregation due to the excess surfactant was apparent in the 
nanoparticle size distribution curves (Figure 3.8) for a SDS concentration of 4.8 mg/ml 
(Figure 3.8-b) with PLGA of low molecular weight. The main  peak was at 37 nm, a 
second peak (size range of 200 to 900 nm), and a third pick (over 4 µm) were present, 
which impacted the polydispersity index; whereas at SDS concentrations of 1.2 mg/ml a 
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Figure 3.7. Effect of SDS concentration on the size and polydispersity index of 
PLGA nanospheres (PLGA 5% w/v, molecular weight of 5 to 10 kDa, and 
copolymer molar ratio of 50:50), n = 2 
• PLGA concentration 
The study of different PLGA concentrations was completed for low molecular weight 
PLGA (5 to 15 kDa). The increase from 5% to 15 % w/v in the PLGA concentration 
resulted in an increase in the nanoparticle size (Figure 3.9) for SDS concentrations of 2 
mg/ml and 4 mg/ml. For a SDS concentration of 2% mg/ml, there was a slight increase in 
size from 38.6 nm to 52.7 nm, and for 4% SDS, the nanoparticle size increased from 36.1 
to 41.6 nm. The increase in size, however small, suggested that the amount of surfactant 
was not enough to maintain the stability of the droplets and coalescence of the droplets 
occurred. The nanoparticle size improved when the SDS concentration increased from 
2% to 4% w/v for all polymer concentrations tested (from 5 to 15% w/v). The results also 
showed that it was possible to increase the polymer concentration three fold (from 5 to 15 
% w/v) without forming particles over 100 nm in size. This finding is important because 
an increase in the polymer concentration is directly related to an increase in the efficiency 
of the nanoparticle synthesis. 
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Size Distribution by Intensity
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Figure 3.8. Size distribution and undersize curve for PLGA nanoparticles. Three 
runs at 25 °C with detector at 70°. a was PLGA 50:50 with molecular weight of 40 to 
75 kDa and a SDS concentration of 1.2 mg/ml. b was PLGA 50:50 with molecular 
weight of 5 to 15 kDa and SDS concentration of 4.8 mg/ml  
• Sonication amplitude 
The sonication effect on size was evaluated with two different amplitudes at a SDS 
concentration of 2 mg/ml for naked PLGA nanoparticles. Amplitudes of 30% and 39% 
were evaluated (Table 3.1), showing a small decrease in the PLGA nanoparticles size for 



























Figure 3.9. Effect of PLGA and SDS concentration on the nanospheres size (PLGA 
molecular weight of 5 to 10 kDa, copolymer molar ratio of 50:50) 
The amplitude in sonication is defined as peak to peak displacement at the probe 
tip, which is maintained constant during sonication. The percentages of amplitude are in 
function of the maximum displacement. The random process of droplet disruption and 
fusion during sonication improved the nanoparticle size for all polymer molecular 
weights (amplitude 39%). 
Table 3.1. Size of PLGA nanospheres as a function of sonication wave amplitude  
  Sonicated with 30% amplitude Sonicated with 39% amplitude 
MW (kDa)  
(L:G ratio) 
5 to 15 
(50:50) 
40 to 75 
(50:50) 
90 to 126 
(75:25) 
5 to 15 
(50:50) 
40 to 75 
(50:50) 
90 to 126 
(75:25) 
Size (nm) 39.4±1.7 66.8±1.8 70.6±0.3 38.6±0.2 63.3±0.3 67.1±0.5 
PI  0.285±0.016 0.107±0.008 0.121±0.01 0.217±0.018 0.127±0.003 0.127±0.005 
ζ (mV)  -28.0±3.7 -31.4±4.6 -39.7±2.9 -19.2±4.6 -26.3±1.3 -27.1±2.9 
* n=3 for all samples 
The nanoparticles size reduction with increasing the sonication amplitude was 
higher for the medium and high molecular weight (5.3% and 5%) as compared with the 
nanospheres of low molecular weight (2.03%). However, the decrease in size with 
increasing sonication amplitude was not significant for the three molecular weights tested 
(p values of 0.9768, 0.0542, and 0.3065 for low, medium and high PLGA molecular 
weight, respectively). Not only the size, but also the PI was affected by the sonication 
amplitude. A better PI was observed for the low molecular weight (5 to 15 kDa) PLGA 
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with increasing the sonication amplitude. The medium (40 to 75 kDa) and high (90 to 126 
kDa) molecular weights had similar PIs (close to 0.1), and indicator of monodisperse 
suspension, for both sonication amplitudes.  
• Effect of MOA size on the final MPNP size and size distribution   
To evaluate the effect of MOA size on the final MPNPs size, MOA was sonicated 
before it was added to the nanosphere preparation. At constant amplitude of 39%, the 
sonication time tested was 2 and 10 minutes. The final size of MPNPs was affected 
(Table 3.2) by sonication time.  
Table 3.2. Effect of sonication time of MOA on the PLGA nanosphere with 
magnetite entrapped in the polymeric matrix    
  MOA sonicated for 2 min   MOA sonicated for 10 min 
Molecular size PI Ζ  size PI ζ 
weight (kDa) nm a.u. mV  nm a.u. mV 
4% magnetite        
5 to 15 (50:50) 109.2±2.4 0.321±0.024 -39.5±1.7  87.2±0.8 0.297±0.006 -28.5±3.9 
40 to 75 (50:50) 87.5±4.1 0.270±0.019 -49.9±23.9  81.8±6.1 0.222±0.06 -26.9±2.9 
90 to 126 (75:25) 84.0±0.7 0.234±0.006 -49.6±11.1  78.8±0.3 0.172±0.017 -33.6±1.9 
8% magnetite        
5 to 15 (50:50) 138.7±10.5 0.299±0.076 -38.9±2.5  115.1±1.0 0.320±0.019 -36.1±4.4 
40 to 75 (50:50) 100.0±1.9 0.268±0.008 -39.2±4.3  93.0±1.4 0.249±0.01 -34.1±3.2 
90 to 126 (75:25) 96.8±1.3 0.258±0.003 -38.1±3.4   107.4±4.9 0.258±0.004 -37.6±3.1 
* MOA suspension in ethyl acetate. n = 3, and the amplitude of sonication was 39%  
The size of nanospheres with 4% of MOA theoretical loading was improved from 
109.2 nm to 87.2 nm for the low molecular weight sample. The medium and high 
molecular weight showed a reduction in size of 5.7 nm and 6 nm, respectively. Moreover, 
the PI was lower for all 4% MOA preparations after 10 minutes of sonication. It was 
obvious that the size decrease in the MOA accomplished by increasing the sonication 
time, which was associated with an improvement in the final MPNP characteristics for 
low, medium, and high PLGA molecular weight at 4% of MOA.  
When the nanospheres were prepared with 8% of MOA theoretical loading, with 
low molecular weight PLGA (5 to 15 kDa), the size was reduced from 138.7 nm to 115.1 
nm. The MPNPs size decreased from 100 nm to 93 nm for the medium molecular weight 
PLGA (40 to 75 kDa). However, the size of the MPNPs formed with high molecular 
weight PLGA (90 to 126 kDa) increased by 10.6 nm, while the PI remained constant. In 
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general, a strong shear stress applied to the MOA suspension reduced the size the MOA 
clusters naturally occurring and therefore improved the MPNP size.  
• Polymer molecular weight 
The particle size, size distribution, and zeta potential were measured after 
nanoparticle formation for three PLGA molecular weights (MW): low MW 5-15 kDa, 
medium MW 40-75 kDa, and high MW 90-126 kDa (Table 3.3). The nanoparticle size 
was found to increase with the polymer molecular weight, from 38.6 nm to 67.1 nm. The 
size distribution improved for high MW PLGA (PI of 0.127) as compared to low MW 
PLGA (PI of 0.217). The results are consistent with the literature, where a direct 
relationship is defined between the polymer molecular weight and the nanoparticle size 
(for naked PLGA nanoparticles). The differences in nanoparticle size between low and 
medium PLGA molecular weight, and low and high PLGA molecular weight, were 
significant (both p values < 0.05 (0.0001)). The difference between medium and high 
PLGA molecular weight was not significant (p value > 0.05 (0.9455)).  
• Magnetite concentration 
The amount of magnetite entrapped in the polymeric matrix was found to affect 
the final mean size of the polymeric nanoparticle (Table 3.3). The addition of magnetite 
increased the size and size distribution of the nanoparticles (Figure 3.10). 
When 4% magnetite was entrapped into the matrix, the size increased from 38.6 
nm to 87.2 nm (for low MW) and from 67.1 to 78.8 nm (for high MW). The increase in 
the nanoparticle size was even more evident when 8% magnetite was entrapped into the 
polymeric matrix. The size increment was higher for low molecular weight PLGA as 
compared to the medium and high molecular weight PLGA, with a maximum size of 
115.1 nm for low MW PLGA. The difference in size was significant for all combinations 
of MOA entrapped (0%, 4%, and 8%) and for all three PLGA molecular weights (P 
values < 0.05). 
The increase in size observed for all MW PLGA can be explained by the 
hydrophobic interactions between the oleic acid tails belonging to two or more partially 
covered magnetic particles. These interactions could be responsible for magnetite 
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Figure 3.10. PLGA nanoparticles size and polydispersity measured by DLS (at 70°, 
25 °C). n = 3 
Table 3.3. Mean size, polydispersity index, and zeta potential of nanoparticles for 
different molecular weights and magnetite concentration BEFORE dialysis 
MW (kDa) Size (nm) PI ζ (mV) 
0% magnetite    
5 to 15 (50:50) 38.6±0.2 0.217±0.018 -19.2±4.6 
40 to 75 (50:50) 63.3±0.3 0.127±0.003 -26.3±1.3 
90 to 126 (75:25) 67.1±0.5 0.127±0.005 -27.1±2.9 
4% magnetite    
5 to 15 (50:50) 87.2±0.8 0.297±0.006 -28.5±3.9 
40 to 75 (50:50) 81.8±6.1 0.222±0.060 -26.9±2.9 
90 to 126 (75:25) 78.8±0.3 0.172±0.017 -33.6±1.9 
8% magnetite    
5 to 15 (50:50) 115.1±1.0 0.320±0.019 -36.1±4.4 
40 to 75 (50:50) 93.0±1.4 0.249±0.010 -34.1±3.2 
90 to 126 (75:25) 107.4±4.9 0.258±0.004 -37.6±3.1 




Table 3.4. Mean size, polydispersity index, and zeta potential of nanoparticles for 
different molecular weights and magnetite concentration AFTER dialysis 
MW (kDa) Size (nm) PI ζ (mV) 
0% magnetite    
5 to 15 (50:50) 54.5±1.6 0.155±0.027 -33.2±7.3 
40 to 75 (50:50) 68.5±0.8 0.146±0.014 -30.9±4.8 
90 to 126 (75:25) 70.3±0.2 0.138±0.007 -33.5±4.6 
4% magnetite    
5 to 15 (50:50) 82.9±1.6 0.261±0.003 -29.2±12.3 
40 to 75 (50:50) 82.6±0.7 0.167±0.003 -30.8±3.3 
90 to 126 (75:25) 82.8±0.7 0.169±0.007 -27.1±4.0 
8% magnetite    
5 to 15 (50:50) 108.4±3.7 0.290±0.007 -42.2±7.4 
40 to 75 (50:50) 95.8±1.1 0.238±0.006 -45.7±7.5 
90 to 126 (75:25) 108.5±3.8 0.246±0.006 -37.7±9.3 
*All samples were run in triplicate, measured after four to 10 hours after formation 
The increase in size, most evident in the low molecular weight PLGA, was 
probably due to the limited coating of the magnetite by the polymer as compared to the 
higher molecular weight PLGA nanoparticles. The polydispersity of the modified 
magnetite could be another factor which could have negatively impacted the 
polydispersity of the system, which was observed when two different sonication times 
were applied to the MAO suspension before nanosphere preparation.  
Medium (40 to 75 kDa) and high (90 to 126 kDa) molecular weight polymer 
proved to be more suitable for magnetite entrapment. The size of the particles only 
increased from 63.3 nm to 81.8 nm for medium M.W. and from 67.1 nm to 78.8 nm for 
high M.W., when 4% of MOA was entrapped. The higher lactide (a more hydrophobic 
component) present in the high M.W. polymer (75:25), as compared to 50:50 
lactide:glycolide for medium M.W., may explain the smaller increase in size for the 
medium MW PLGA nanoparticles in the presence of MOA. 
The nanoparticles were characterized before and after purification. An increase in 
the mean nanoparticle size from 38.6 nm to 54.5 nm (significant difference, p value 
<0.05) was detected after dialysis for the low MW PLGA nanoparticles without 
magnetite (Table 3.4), while the polydispersity index was improved from 0.217 to 0.155 
due to the removal of small nanoparticles and MOA by dialysis. A similar effect, an 
increase in the mean particle size following dialysis, was observed for the medium and 
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high PLGA molecular weights, but the difference was not significant (p value >0.05).. 
The polydispersity index was improved for all samples due to the removal of SDS in 
excess and the SDS trapped over the nanoparticle surface, which limited the nanoparticle 
aggregation. In addition, losses of small nanoparticles during dialysis explain the increase 
in the PLGA nanoparticles mean size without MOA, and the PI improvement. When 4% 
w/w of MOA was added, the difference in size was not significant for the medium 
molecular weight PLGA. It was not conclusive whether the PLGA nanoparticle size was 
affected by dialysis (p value almost 0.05) for low and high PLGA molecular weight with 
4% w/w of MOA. The difference in nanoparticle mean size before and after dialysis was 
not significant when 8% w/w of MOA was added (p value > 0.05). 
3.4.1.3. Yield of Nanoparticles, Entrapment Efficiency of MOA, Remaining SDS, 
and Oleic Acid Amount over Magnetite 
The amount of MOA in the PLGA matrix was measured by a colorimetric 
method, and the SDS left in the sample was calculated from TGA data (Figure 3.11a and 
3.11b) combined with data collected from the colorimetric method (Table 3.5). The 
residue after 600 °C obtained by TGA analysis for the MPNPs was composed of 
magnetite, sulfate, and sodium (from SDS). The SDS residue was determined by 
subtracting the amount of magnetite obtained from the colorimetric method (Table 3.5) 
from the total residue amount obtained by TGA. From Figure 3.11a, a relation between 
SDS residue and total SDS can be obtained (The sodium and sulfate groups are 24.75 
wt.% of SDS). The entrapment efficiency (final weight ratio of MOA in lyophilized 
MPNPs measured by colorimetric method divided by the initial amount of MOA added in 
the formation process) varied from 57.36% to 91.9% for the PLGA with low and high 
PLGA molecular weight nanoparticles, respectively. The differences in the entrapment 
efficiency were not significant between the 4 and 8 %w/w MOA samples for all 
molecular weights (p values > 0.05).  
The medium molecular weight (40 to 75 kDa) PLGA nanoparticles showed 
similar entrapment efficiency for 4% and 8% of MOA theoretical loading, 77.34% and 
78.75%, respectively. The low (5 to 15 kDa) and high (40 to 75 kDa) molecular weight 
PLGA MPNPs presented different entrapment efficiencies for 4 and 8% w/w MOA 
theoretical loading. The entrapment efficiency of MPNPs formed with 5 to 15 kDa PLGA 
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M.W. was 57.36% and 76.27% for 4 and 8% w/w of MOA theoretical loading, 
respectively. 
Table 3.5. Entrapment of magnetite oleic acid and SDS residue in nanoparticles 
  Magnetite with oleic acid (MOA)   Surfactant 
Nanoparticle Theoretical  Nanosphere Entrapment  SDS SDS 
molecular weight loading1 yield2 efficiency3  residue4 removed5 
kDa wt% % %   wt% % 
PLGA 5 to 15 4% 66.8±3.6 57.36±6.8  5.95±1.3 55.34% 
PLGA 5 to 15 8% 61.6±1.8 76.27±11.7  6.59±2.5 48.90% 
PLGA 40 to 75 4% 58.9±9.3 77.34±8.50  1.50±0.4 88.77% 
PLGA 40 to 75 8% 62.7±3.9 78.75±3.80  6.32±1.7 51.02% 
PLGA 90 to 126 4% 66.6±2.6 70.23±18.5  4.80±2.6 64.00% 
PLGA 90 to 126 8% 56.2±3.7 91.90±31.8   4.71±3.1 63.48% 
*All samples in triplicate 
1. Theoretical loading: Initial amount of MOA added to the nanoparticle formation process (wt%) 
2. Nanosphere yield: final weight of sample after freeze drying (mg)/initial weight of sample (mg) 
3. Entrapment efficiency: MOA in samples (wt%)/theoretical loading (wt%) 
4. SDS residue: Total residue (wt%) (from TGA) – magnetite (wt%) (from colorimetric method)  
5. SDS removed: SDS residue (wt%)/total SDS added in the nanoparticle formation process (wt%) 








































































































Figure 3.11. a. SDS profiles acquired by TGA. Temperature was varied from 25 to 
600 °C. A residue of 24.75% composed of sulfate and sodium group of the SDS 
molecule was found at 600 ºC. This residue present in all samples was used to 
calculate the amount of SDS remaining in the nanoparticles. b. A typical curve for 
the MPNPs formed with low molecular weight PLGA (CA64). The residue at 600 °C 
was due to the sodium and sulfate groups of SDS, and magnetite.  
The medium molecular weight (40 to 75 kDa) PLGA nanoparticles showed 
similar entrapment efficiency for 4% and 8% of MOA theoretical loading, 77.34% and 
78.75%, respectively. The low (5 to 15 kDa) and high (40 to 75 kDa) molecular weight 
PLGA MPNPs presented different entrapment efficiencies for 4 and 8% w/w MOA 




M.W. was 57.36% and 76.27% for 4 and 8% w/w of MOA theoretical loading, 
respectively 
The MPNPs yield ranged from 56.2% to 66.8% due to losses during dialysis and 
freeze drying. This data suggested that the dialysis membrane cutoff was high, or 
compatibility between nanoparticles and membrane promoted adsorption of PLGA 
nanoparticles with entrapped MOA on the surface of the dialysis membrane. All 
membranes presented surface areas visibly brown in color (membrane is white prior to 
use) after the samples were removed. No visual difference was observed between MPNPs 
prepared with 4% and 8% of MOA. 
The SDS amount removed by the three washes varied from 51.02% to 88.77%. No 
obvious relationship was found between the SDS removed and the PLGA molecular 
weights, or amount of magnetite added.  
• Oleic acid on magnetite 
The amount of oleic acid was measured by thermogravimetric analysis (TGA) 
(Figure 3.12).  
 
Figure 3.12. TGA data for magnetite and MOA (magnetite plus oleic acid). The 
initial decrease was due to the presence of water (approximately 2 wt% for 
magnetite and 1.15% for MOA). The 2.74 wt% and 3.64 wt% remaining could be 
explained by ammonium used in the magnetite formulation.  
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The TGA residue for MOA at 600 °C was 86.39 wt%. The TGA residue for 
normal magnetite was 95.23%. The 8.84 wt% difference was associated with the oleic 
acid presence. This data correlated well with the colorimetric method for iron detection, 
in which the oleic acid content detected was 10.24 wt% with an error of 0.03 wt%. 
3.5. Conclusions 
Surface modification of magnetite with oleic acid was a useful approach to ensure 
the entrapment of magnetite into a hydrophobic polymer (PLGA) with high entrapment 
efficiency. MPNPs with a final mean size under 100 nm were obtained, at 4% w/w MOA 
theoretical loading. When MOA theoretical loading was increased to 8% w/w, 
nanoparticles mean size under 120 nm were formed. The entrapment efficiency was 
highly different for the low (57%) and high PLGA molecular weight (92%).  
The emulsion evaporation method was a suitable synthesis method for the 
formation of nanoparticles with a mean size under 100 nm. The SDS concentration 
played a critical role in controlling the nanoparticle size. The size and uniformity of the 
MOA suspension was found critical in forming small and uniform MPNPs. With the 
method proposed, it was possible to increase the PLGA concentration by at least three 
times without increasing the nanoparticle size over 100 nm. Stability of MPNPs was 
improved by applying a purification step quickly after synthesis. Dialysis was used as a 
purification step to remove the excess of SDS and avoid aggregation. 
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CHAPTER 4. CONCLUSIONS 
Magnetite was successfully entrapped into PLGA nanoparticles while maintaining 
their size under 100 nm, for 4% w/w MOA theoretical loading. The SDS concentration 
and MOA size and size distribution were found to be the critical factors in controlling the 
nanoparticle size. The entrapment efficiency varied between 57% for low MW PLGA 
and 92% for high MW PLGA. Entrapment of magnetite can be coupled with the 
entrapment and delivery of active components (cancer drug, peptides, DNA, and others) 
to the target by the developed MPNPs.  
It was found that an increase in the PLGA concentration (batch of production) by 
three times was possible with the proposed method, while keeping the nanosphere size 
less than 100 nm. This finding is significant, considering that commercial application of 
the synthesis method is strongly dependent on the nanoparticle yield formation, directly 
proportional to polymer concentration. Lastly, it was found that synthesis must be 
followed by a purification step (i.e. dialysis) to avoid aggregation of the nanoparticles 






CHAPTER 5. FUTURE WORK 
 The main target of the thesis research was to synthesize nanoparticles less than 
100 nm in size, with entrapped magnetite in the polymeric matrix. The study of 
technologies available and the main parameters affecting the final PLGA nanoparticle 
size were the two main parts of this research. Although significant progress was made 
toward understanding the system developed, other areas of research should be addressed 
before the developed MPNPs could be successfully implemented in the drug delivery 
field. The future work should address the following aspects: 
• Test the MPNP system with a suitable drug. The hydrophilic and hydrophobic 
drugs have different behaviors affecting the process parameters and size of the 
nanospheres. Although, the hydrophobic drugs are suitable for single emulsion 
evaporation method, the hydrophilic drugs should be tested. This requires 
switching from the single emulsion-evaporation to double emulsion-evaporation 
method. Some limitations should be addressed for the double emulsion -
evaporation method, such as formation of bigger nanoparticles with lower drug 
entrapment efficiency (losses of active component in the continuous phase due to 
hydrophilic behavior of active component). The addition of some additives can 
improve the entrapment efficiency (i.e. higher viscosity, cationic-anionic 
interaction). 
• Remove or replace SDS by other surfactants. SDS can not be administrated by 
parenteral route. To overcome this limitation two approaches can be followed: 
o Purification of the nanoparticles suspension to remove the SDS associated 
with the nanoparticles. Dialysis is an adequate method for elimination of 
SDS, but ultra-filtration can be used, and it should be tested. 
o Synthesis of a suitable surfactant with high hydrophilic-lipophilic balance 
(HLB) value (over 20), biodegradable, biocompatible, good packing 
number (less than 0.3), and small molecular size to replace SDS. The 
advantage of SDS is the use of electrostatic and steric forces to form small 
micelles that are used to form small nanoparticles. 
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• Optimize the SDS concentration, PLGA concentration, sonication time, 
entrapment efficiency of active component, and purification steps to obtain the 
optimum nanoparticle size by factorial design. 
• Study the effect of sonication on the structure of the LGA chains, especially for 
high molecular weight. The size reduction of polymer chains can affect the 
possible release profiles of the active component entrapped.  
• Conduct stability studies. The aggregation profile should be measured over time 
at different pHs. The nanoparticles aggregation must be avoided at corporal pH 
(neutral) for parenteral administration. 
• Study the release profile of drugs entrapped in the MPNPs, an important step for 
further uses in vivo. 
• Test the cellular uptake of PLGA-SDS nanoparticles to find the toxicity levels, 
and the advantages/disadvantages of the system. This is related with the active 
component bio-distribution, mechanism of cellular uptake and action (i.e. the 
negative and positive charges over the surface of the particle play an important 
role in the cellular uptake of PLGA nanoparticles). 
• Conduct targeting studies required to find the minimum amount of magnetite that 
should be entrapped in the MPNP to obtain a suitable drug delivery system. 
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APPENDIX B. STANDARD CURVE FOR IRON DETECTION 
 
 Iron determination based on Prussian blue reaction. The wavelength used was at 
700 nm. The digestion was made with Hydrochloric acid at 6 N.  
 The standard curve was prepared with iron (III) oxide, 99.999% of purity. 
 
Iron standard curve




































APPENDIX C. SIZE MEASUREMENTS WITH DLS (MALVERN 
ZETASIZER NANOSERIES) 
There were prepared a lot of sample to define the important parameters to obtain 
nanoparticle under 100 nm. The tables presented in this appendix showed the diversity of 
nanoparticle size in function of the parameters tested. Many experiments were design to 
test some theories and procedures.  
Double emulsion method without second sonication (CAR 140, CAR 132), and 
all other parameters were maintained constant. CAR 131 is the standard single emulsion 
evaporation method, but the magnetite entrapped was without oleic acid surface 
modification. CAR 133 was double emulsion method with second sonication. CAR 135 
and CAR 136 were different evaporation rates with single emulsion method (PLGA of 
LMW). The evaporation procedure tested were without injection of nitrogen and high 
vacuum (40 cm Hg), and without nitrogen injection and high vacuum (40 cm Hg). The 
sample CAR 138 was with low vacuum (100 cm Hg) and nitrogen injection. All other 
samples are explained in the table. 
 










1 Size CAR140 DE w/o II sonic 01/26/05 25 201.2 0.212   
2 Size CAR140 DE w/o II sonic 01/26/05 25 204.8 0.198   
3 Size CAR140 DE w/o II sonic 01/26/05 25 204.6 0.226   
4 Size CAR131 Standard Mgn 01/26/05 25 171.6 0.263   
5 Size CAR131 Standard Mgn 01/26/05 25 115.1 0.527   
6 Size CAR131 Standard Mgn 01/26/05 25 100.5 0.598   
7 Size CAR131 Standard Mgn 2pick 01/26/05 25 89.05 0.762   
8 Size CAR131 Standard Mgn 2pick 01/26/05 25 91.3 0.801   
9 Size CAR131 Standard Mgn 2pick 01/26/05 25 99.11 0.512   
10 Size CAR132 DEWOS 01/26/05 25 124 0.364   
11 Size CAR132 DEWOS 01/26/05 25 125.6 0.281   
12 Size CAR132 DEWOS 01/26/05 25 122.8 0.281   
13 Size CAR133 DEWS 01/26/05 25 110.4 0.42   
14 Size CAR133 DEWS 01/26/05 25 99.45 0.524   
15 Size CAR133 DEWS 01/26/05 25 100.9 0.461   
16 Size CAR133 DEWS 2picks 01/26/05 25 93.49 0.464   
17 Size CAR133 DEWS 2picks 01/26/05 25 87.23 0.434   
18 Size CAR133 DEWS 2picks 01/26/05 25 93.32 0.604   
19 Size CAR134 stdb liposurf 01/26/05 25 172.1 0.265   
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20 Size CAR134 stdb liposurf 01/26/05 25 124.3 0.393   
21 Size CAR134 stdb liposurf 01/26/05 25 94.34 0.686   
22 Size CAR134 stdb liposurf 2pick 01/26/05 25 90.47 0.498   
23 Size CAR134 stdb liposurf 2pick 01/26/05 25 85.02 0.625   
24 Size CAR134 stdb liposurf 2pick 01/26/05 25 92.21 0.502   
25 Size CAR 135 Ev rate 01/26/05 25 41.43 0.342   
26 Size CAR 135 Ev rate 01/26/05 25 41.39 0.302   
27 Size CAR 135 Ev rate 01/26/05 25 39.95 0.322   
28 Size CAR 136 Ev rate 01/26/05 25 58.02 0.414   
29 Size CAR 136 Ev rate 01/26/05 25 57.96 0.418   
30 Size CAR 136 Ev rate 01/26/05 25 56.94 0.41   
31 Size CAR 137 DEWOS VE 01/26/05 25 193.2 0.7   
32 Size CAR 137 DEWOS VE 01/26/05 25 136.9 0.959   
33 Size CAR 137 DEWOS VE 01/26/05 25 140.2 0.957   
34 Size CAR 137 DEWOS VE 2pick 01/26/05 25 77.14 0.759   
35 Size CAR 137 DEWOS VE 2pick 01/26/05 25 80.67 0.521   
36 Size CAR 137 DEWOS VE 2pick 01/26/05 25 88.12 0.493   
37 Size CAR 138 Ev Rate low vac 01/26/05 25 66.34 0.212   
38 Size CAR 138 Ev Rate low vac 01/26/05 25 42.57 0.402   
39 Size CAR 138 Ev Rate low vac 01/26/05 25 42.34 0.367   
40 Size CAR 139 DEWOS VE MMW 01/26/05 25 71.66 0.393   
41 Size CAR 139 DEWOS VE MMW 01/26/05 25 70.43 0.388   
42 Size CAR 139 DEWOS VE MMW 01/26/05 25 72.11 0.365   
43 Size CAR Mgn lipo 01/26/05 25 175.3 0.4   
44 Size CAR Mgn lipo 01/26/05 25 179.3 0.417   
45 Size CAR Mgn lipo 01/26/05 25 176.6 0.392   
46 Size CAR Mgn lipo 2pick 01/26/05 25 329.9 0.695   
47 Size CAR Mgn lipo 2pick 01/26/05 25 297 0.535   
48 Size CAR Mgn lipo 2pick 01/26/05 25 248.2 0.664   
49 Size CAR Mgn  01/26/05 25 270.5 0.359   
50 Size CAR Mgn  01/26/05 25 241.9 0.431   
51 Size CAR Mgn  01/26/05 25 237.8 0.418   
52 Size CAR 134 waste 01/26/05 25 51.6 0.443   
53 Size CAR 134 waste 01/26/05 25 50.64 0.416   
54 Size CAR 134 waste 01/26/05 25 48.25 0.418   
55 Size CAR 131 waste 01/26/05 25 67.18 0.463   
56 Size CAR 131 waste 01/26/05 25 67.55 0.464   
57 Size CAR 131 waste 01/26/05 25 65.2 0.478   
58 Size CAR 131 waste 2pick 01/26/05 25 66.86 0.49   
59 Size CAR 131 waste 2pick 01/26/05 25 63.78 0.469   
60 Size CAR 131 waste 2pick 01/26/05 25 67.85 0.464   
61 Size water 01/26/05 25 1639 0.776   
62 Size water 2 01/26/05 25 2609 1   
63 Size water 2 01/26/05 25 1274 0.617   
64 Size water 2 01/26/05 25 875.1 0.568   




Sample CAR 185 and CAR 186 were prepared with different amounts of PLGA. 
The sample CAR 178, CAR 179, and CAR181 were with high molecular weight PLGA. 
The samples CAR 168, CAR 172, CAR 182 and CAR 180 were prepared with more 
surfactant (35 mg). CAR 173 and CAR 174 were formed with medium PLGA molecular 
weight (MMW). In all samples presented in this table, the aqueous phase was prepared 
with a buffer solution (pH 8). They showed a strong precipitation after two hour ended 
the formation process. Strong aggregation was present, which was reflected in the higher 
size measured. 
 










1 Size Car185-100mg May 20, 2005 25 74.43 0.124   
2 Size Car185-100mg May 20, 2005 25 74.11 0.137   
3 Size Car185-100mg May 20, 2005 25 74.72 0.126   
4 Size Car184-150mg May 20, 2005 25 65.02 0.171   
5 Size Car184-150mg May 20, 2005 25 65.36 0.143   
6 Size Car184-150mg May 20, 2005 25 65.16 0.175   
7 Size Car178-HMW May 20, 2005 25 149.8 0.504   
8 Size Car178-HMW May 20, 2005 25 148.5 0.495   
9 Size Car178-HMW May 20, 2005 25 149.5 0.502   
10 Size Car181-HMW May 20, 2005 25 122.6 0.417   
11 Size Car181-HMW May 20, 2005 25 123 0.427   
12 Size Car181-HMW May 20, 2005 25 123.8 0.433   
13 Size Car182-HMW35mg May 20, 2005 25 118.4 0.473   
14 Size Car182-HMW35mg May 20, 2005 25 115.7 0.456   
15 Size Car182-HMW35mg May 20, 2005 25 118.4 0.422   
16 Size Car180-HMW35mg May 20, 2005 25 148.2 0.55   
17 Size Car180-HMW35mg May 20, 2005 25 154.6 0.522   
18 Size Car180-HMW35mg May 20, 2005 25 154.9 0.521   
19 Size Car179-HMW May 20, 2005 25 142.2 0.492   
20 Size Car179-HMW May 20, 2005 25 138.3 0.499   
21 Size Car179-HMW May 20, 2005 25 142.6 0.49   
22 Size Car172-MMW35mg May 20, 2005 25 171 0.523   
23 Size Car172-MMW35mg May 20, 2005 25 173.7 0.537   
24 Size Car172-MMW35mg May 20, 2005 25 166.5 0.584   
25 Size Car173-MMW May 20, 2005 25 211.6 1   
26 Size Car173-MMW May 20, 2005 25 208.7 1   
27 Size Car173-MMW May 20, 2005 25 209.1 1   
28 Size Car174-MMW May 20, 2005 25 215.8 1   
29 Size Car174-MMW May 20, 2005 25 214.8 1   
30 Size Car174-MMW May 20, 2005 25 209.4 0.985   
31 Size Car166-LMW May 20, 2005 25 297.2 0.667   
32 Size Car166-LMW May 20, 2005 25 233.7 1   
33 Size Car166-LMW May 20, 2005 25 287.1 0.655   
34 Size Car168-LMW35mg May 20, 2005 25 201.5 0.637   
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35 Size Car168-LMW35mg May 20, 2005 25 196.2 0.619   
36 Size Car168-LMW35mg May 20, 2005 25 200.7 0.64   
37 Size Car167-LMW May 20, 2005 25 188.1 0.597   
38 Size Car167-LMW May 20, 2005 25 192 0.603   
39 Size Car167-LMW May 20, 2005 25 191.7 0.594   
40 Size Car-MAO May 20, 2005 25 200.6 0.242   
41 Size Car-MAO May 20, 2005 25 198.9 0.225   
42 Size Car-MAO May 20, 2005 25 202.6 0.239   
43 Zeta Car-184Z May 20, 2005 25   -98.5 0.8654 
44 Zeta Car-184Z May 20, 2005 25   -99.18 0.9144 
45 Zeta Car-184Z May 20, 2005 25   -101.5 0.9352 
46 Zeta Car-184Zdup May 20, 2005 25   -99.1 0.8952 
47 Zeta Car-184Zdup May 20, 2005 25   -99.85 0.9099 




The samples CAR 250, CAR 256, CAR 262 were formed with poly(vinyl alcohol) 
(PVA). All other samples were for magnetite entrapment by emulsion evaporation (single 
emulsion).  
 










1 Size CAR250pva May 25, 2005 25 117.8 0.161   
2 Size CAR250pva May 25, 2005 25 120.6 0.16   
3 Size CAR250pva May 25, 2005 25 121.2 0.18   
4 Size CAR250pva May 25, 2005 25 121.6 0.164   
5 Size CAR256pva May 25, 2005 25 135.8 0.135   
6 Size CAR256pva May 25, 2005 25 137.4 0.127   
7 Size CAR256pva May 25, 2005 25 138.1 0.068   
8 Size CAR262pva May 25, 2005 25 149.3 0.073   
9 Size CAR262pva May 25, 2005 25 148.2 0.093   
10 Size CAR262pva May 25, 2005 25 147.3 0.058   
11 Size CAR196magLMW May 25, 2005 25 110.1 0.395   
12 Size CAR196magLMW May 25, 2005 25 107.3 0.433   
13 Size CAR196magLMW May 25, 2005 25 108.7 0.396   
14 Size CAR197magLMW May 25, 2005 25 146 0.269   
15 Size CAR197magLMW May 25, 2005 25 145.3 0.281   
16 Size CAR197magLMW May 25, 2005 25 142.1 0.28   
17 Size CAR198magLMW May 25, 2005 25 130.4 0.281   
18 Size CAR198magLMW May 25, 2005 25 128.1 0.271   
19 Size CAR198magLMW May 25, 2005 25 130.6 0.28   
20 Size CAR199magLMW May 25, 2005 25 149.2 0.229   
21 Size CAR199magLMW May 25, 2005 25 147.1 0.241   
22 Size CAR199magLMW May 25, 2005 25 145.7 0.234   
23 Size CAR200magLMW May 25, 2005 25 91.23 0.371   
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24 Size CAR200magLMW May 25, 2005 25 90.09 0.361   
25 Size CAR200magLMW May 25, 2005 25 89.59 0.373   
26 Size CAR201magLMW May 25, 2005 25 146.7 0.253   
27 Size CAR201magLMW May 25, 2005 25 145.8 0.241   
28 Size CAR201magLMW May 25, 2005 25 144.1 0.246   
29 Size CAR202magMMW May 25, 2005 25 84.67 0.295   
30 Size CAR202magMMW May 25, 2005 25 82.7 0.284   
31 Size CAR202magMMW May 25, 2005 25 82.19 0.284   
32 Size CAR203magMMW May 25, 2005 25 144.1 0.284   
33 Size CAR203magMMW May 25, 2005 25 140.6 0.214   
34 Size CAR203magMMW May 25, 2005 25 139.3 0.207   
35 Size CAR204magMMW May 25, 2005 25 89.9 0.381   
36 Size CAR204magMMW May 25, 2005 25 89.31 0.387   
37 Size CAR204magMMW May 25, 2005 25 86.9 0.374   
38 Size CAR208magHMW May 25, 2005 25 77.04 0.325   
39 Size CAR208magHMW May 25, 2005 25 77.1 0.257   
40 Size CAR208magHMW May 25, 2005 25 75.78 0.263   
41 Size CAR209magHMW May 25, 2005 25 83.38 0.341   
42 Size CAR209magHMW May 25, 2005 25 81.91 0.337   
43 Size CAR209magHMW May 25, 2005 25 81.28 0.327   
44 Size CAR210magHMW May 25, 2005 25 83.44 0.397   
45 Size CAR210magHMW May 25, 2005 25 82.5 0.403   
46 Size CAR210magHMW May 25, 2005 25 79.15 0.365   
47 Size CAR205HmagMMW May 25, 2005 25 101.5 0.285   
48 Size CAR205HmagMMW May 25, 2005 25 102.4 0.299   
49 Size CAR205HmagMMW May 25, 2005 25 101.8 0.281   
50 Size CAR211HmagHMW May 25, 2005 25 99.01 0.356   
51 Size CAR211HmagHMW May 25, 2005 25 95.27 0.371   
52 Size CAR211HmagHMW May 25, 2005 25 94.68 0.387   
 
 
 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. 
 










1 Size CAR238LMWLS May 26, 2005 25 37.91 0.301   
2 Size CAR238LMWLS May 26, 2005 25 39.13 0.304   
3 Size CAR238LMWLS May 26, 2005 25 39.12 0.299   
4 Size CAR238LMWLSB May 26, 2005 25 39.42 0.3   
5 Size CAR238LMWLSB May 26, 2005 25 39.77 0.274   
6 Size CAR238LMWLSB May 26, 2005 25 39.55 0.255   
7 Size CAR239LMWLS May 26, 2005 25 37.89 0.293   
8 Size CAR239LMWLS May 26, 2005 25 38.27 0.296   
9 Size CAR239LMWLS May 26, 2005 25 38.16 0.262   
10 Size CAR240MMWLS May 26, 2005 25 41.15 0.288   
11 Size CAR240MMWLS May 26, 2005 25 41.53 0.261   
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12 Size CAR240MMWLS May 26, 2005 25 41.38 0.257   
13 Size CAR241MMWLS May 26, 2005 25 67.16 0.106   
14 Size CAR241MMWLS May 26, 2005 25 67.49 0.111   
15 Size CAR241MMWLS May 26, 2005 25 66.86 0.111   
16 Size CAR242MMWLS May 26, 2005 25 68.02 0.097   
17 Size CAR242MMWLS May 26, 2005 25 68.38 0.096   
18 Size CAR242MMWLS May 26, 2005 25 68.86 0.1   
19 Size CAR244HMWLS May 26, 2005 25 69.83 0.132   
20 Size CAR244HMWLS May 26, 2005 25 70.4 0.113   
21 Size CAR244HMWLS May 26, 2005 25 70.71 0.114   
22 Size CAR245HMWLS May 26, 2005 25 71.7 0.132   
23 Size CAR245HMWLS May 26, 2005 25 70.53 0.129   
24 Size CAR245HMWLS May 26, 2005 25 69.66 0.134   
25 Size CAR270LMWLS May 26, 2005 25 111.4 0.315   
26 Size CAR270LMWLS May 26, 2005 25 112.5 0.312   
27 Size CAR270LMWLS May 26, 2005 25 111.9 0.313   
28 Size CAR271LMWLS May 26, 2005 25 110.3 0.314   
29 Size CAR271LMWLS May 26, 2005 25 103 0.422   
30 Size CAR271LMWLS May 26, 2005 25 108.3 0.306   
31 Size CAR272LMWLS May 26, 2005 25 108.3 0.304   
32 Size CAR272LMWLS May 26, 2005 25 109.8 0.303   
33 Size CAR272LMWLS May 26, 2005 25 107.6 0.298   
34 Size CAR250LMWPVACentA May 26, 2005 25 131.3 0.19   
35 Size CAR250LMWPVACentA May 26, 2005 25 129.4 0.165   
36 Size CAR250LMWPVACentA May 26, 2005 25 129.9 0.188   
37 Size CAR250LMWPVACentB May 26, 2005 25 134.9 0.218   
38 Size CAR250LMWPVACentB May 26, 2005 25 132.9 0.191   
39 Size CAR250LMWPVACentB May 26, 2005 25 133.7 0.205   
40 Zeta CAR238 May 26, 2005 25   -27.01 0.04717 
41 Zeta CAR238 May 26, 2005 25   -31.68 0.04591 
42 Zeta CAR238 May 26, 2005 25   -28.26 0.04641 
43 Zeta CAR239 May 26, 2005 25   -0.419 0.02604 
44 Zeta CAR239 May 26, 2005 25   -0.39 0.03365 
45 Zeta CAR239 May 26, 2005 25   -0.007 0.02787 
46 Zeta CAR240 May 26, 2005 25   -32.73 0.04691 
47 Zeta CAR240 May 26, 2005 25   -34.34 0.05291 
48 Zeta CAR240 May 26, 2005 25   -25.87 0.04898 
49 Zeta CAR241 May 26, 2005 25   -37.32 0.05661 
50 Zeta CAR241 May 26, 2005 25   -32.94 0.05253 
51 Zeta CAR241 May 26, 2005 25   -28.45 0.0505 
52 Zeta CAR242 May 26, 2005 25   -33.32 0.04405 
53 Zeta CAR242 May 26, 2005 25   -36.94 0.04596 
54 Zeta CAR242 May 26, 2005 25   -35.23 0.04512 
55 Zeta CAR244 May 26, 2005 25   -37.73 0.04893 
56 Zeta CAR244 May 26, 2005 25   -38.21 0.05791 
57 Zeta CAR244 May 26, 2005 25   -33.36 0.05458 
58 Zeta CAR245 May 26, 2005 25   -40.82 0.05726 
59 Zeta CAR245 May 26, 2005 25   -48.45 0.05051 
60 Zeta CAR245 May 26, 2005 25   -36.99 0.04983 
61 Zeta CAR239good May 26, 2005 25   -26.67 0.0492 
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62 Zeta CAR239good May 26, 2005 25   -24.14 0.05313 
63 Zeta CAR239good May 26, 2005 25   -20.9 0.05301 
64 Zeta CAR270 May 26, 2005 25   -38.42 0.04357 
65 Zeta CAR270 May 26, 2005 25   -39.54 0.04467 
66 Zeta CAR270 May 26, 2005 25   -41.52 0.05614 
67 Zeta CAR271 May 26, 2005 25   -40.02 0.05087 
68 Zeta CAR271 May 26, 2005 25   -34.48 0.04217 
69 Zeta CAR271 May 26, 2005 25   -38.64 0.04197 
70 Zeta CAR272 May 26, 2005 25   -39.71 0.05134 
71 Zeta CAR272 May 26, 2005 25   -40.38 0.04539 
72 Zeta CAR272 May 26, 2005 25   -42.87 0.04933 
73 Zeta CAR250 May 26, 2005 25   -23.5 0.01789 
74 Zeta CAR250 May 26, 2005 25   -24.4 0.03051 
75 Zeta CAR250 May 26, 2005 25   -22.29 0.01175 
76 Zeta CAR197 May 26, 2005 25   -35.26 0.09469 
77 Zeta CAR197 May 26, 2005 25   -36.1 0.094 
78 Zeta CAR197 May 26, 2005 25   -35.72 0.0928 
 
 
 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. 
 










1 Size CAR280LMW12S May 27, 2005 25 40.42 0.344   
2 Size CAR280LMW12S May 27, 2005 25 39.79 0.328   
3 Size CAR280LMW12S May 27, 2005 25 39.37 0.319   
4 Size CAR282LMW08S May 27, 2005 25 39.94 0.268   
5 Size CAR282LMW08S May 27, 2005 25 40.68 0.296   
6 Size CAR282LMW08S May 27, 2005 25 41.49 0.3   
7 Size CAR283LMW12Smag May 27, 2005 25 120.7 0.382   
8 Size CAR283LMW12Smag May 27, 2005 25 121.6 0.366   
9 Size CAR283LMW12Smag May 27, 2005 25 122.8 0.376   
10 Size CAR273MMWmag May 27, 2005 25 90.06 0.312   
11 Size CAR273MMWmag May 27, 2005 25 91.53 0.269   
12 Size CAR273MMWmag May 27, 2005 25 90.49 0.266   
13 Size CAR274MMWmag May 27, 2005 25 90.13 0.262   
14 Size CAR274MMWmag May 27, 2005 25 88.95 0.308   
15 Size CAR274MMWmag May 27, 2005 25 87.93 0.271   
16 Size CAR276HMWmag May 27, 2005 25 84.14 0.228   
17 Size CAR276HMWmag May 27, 2005 25 84.36 0.242   
18 Size CAR276HMWmag May 27, 2005 25 82.73 0.226   
19 Size CAR277HMWmag May 27, 2005 25 84.36 0.251   
20 Size CAR277HMWmag May 27, 2005 25 85.37 0.239   
21 Size CAR277HMWmag May 27, 2005 25 84.65 0.233   
22 Zeta CAR280 May 27, 2005 25   -23.61 0.05224 
23 Zeta CAR280 May 27, 2005 25   -35.74 0.04815 
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24 Zeta CAR280 May 27, 2005 25   -29.58 0.05152 
25 Zeta CAR282 May 27, 2005 25   -20.9 0.045 
26 Zeta CAR282 May 27, 2005 25   -26.71 0.05282 
27 Zeta CAR282 May 27, 2005 25   -26.43 0.04728 
28 Zeta CAR283 May 27, 2005 25   -47.24 0.04702 
29 Zeta CAR283 May 27, 2005 25   -46.15 0.05155 
30 Zeta CAR283 May 27, 2005 25   -43.66 0.04594 
31 Zeta CAR273 May 27, 2005 25   -38.31 0.04669 
32 Zeta CAR273 May 27, 2005 25   -40.96 0.05421 
33 Zeta CAR273 May 27, 2005 25   -42.22 0.04773 
34 Zeta CAR274 May 27, 2005 25   -78.11 0.2119 
35 Zeta CAR274 May 27, 2005 25   -81.23 0.2167 
36 Zeta CAR274 May 27, 2005 25   -72.12 0.2184 
37 Zeta CAR276 May 27, 2005 25   -47.2 0.06435 
38 Zeta CAR276 May 27, 2005 25   -48.1 0.06122 
39 Zeta CAR276 May 27, 2005 25   -53.9 0.06464 
40 Zeta CAR277 May 27, 2005 25   -65.88 0.1229 
41 Zeta CAR277 May 27, 2005 25   -54.92 0.1237 
42 Zeta CAR277 May 27, 2005 25   -61.07 0.1224 
43 Size car280B May 27, 2005 25 39.05 0.312   
44 Size car280B May 27, 2005 25 39.54 0.28   
45 Size car280B May 27, 2005 25 38.87 0.257   
46 Size CAR206MMW8mag May 27, 2005 25 96.61 0.365   
47 Size CAR206MMW8mag May 27, 2005 25 98.76 0.289   
48 Size CAR206MMW8mag May 27, 2005 25 98.99 0.281   
49 Size CAR207MMW8mag May 27, 2005 25 89.24 0.274   
50 Size CAR207MMW8mag May 27, 2005 25 90.53 0.273   
51 Size CAR207MMW8mag May 27, 2005 25 90.69 0.279   
52 Size CAR212HMW8mag May 27, 2005 25 101 0.288   
53 Size CAR212HMW8mag May 27, 2005 25 97.37 0.354   
54 Size CAR212HMW8mag May 27, 2005 25 97.06 0.363   
55 Size CAR213HMW8mag May 27, 2005 25 101 0.366   
56 Size CAR213HMW8mag May 27, 2005 25 101 0.382   
57 Size CAR213HMW8mag May 27, 2005 25 102.2 0.371   
 
 
 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. 
 










1 Size car284 June 1, 2005 25 39.74 0.329   
2 Size car284 June 1, 2005 25 41.02 0.285   
3 Size car284 June 1, 2005 25 41.49 0.338   
4 Size car285 June 1, 2005 25 36.79 0.271   
5 Size car285 June 1, 2005 25 36.64 0.265   
6 Size car285 June 1, 2005 25 35.83 0.252   
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7 Size car286 June 1, 2005 25 35.72 0.31   
8 Size car286 June 1, 2005 25 35.26 0.314   
9 Size car286 June 1, 2005 25 34.92 0.305   
10 Size car287 June 1, 2005 25 33.74 0.328   
11 Size car287 June 1, 2005 25 32.87 0.312   
12 Size car287 June 1, 2005 25 32.13 0.287   
13 Size car227 June 1, 2005 25 59.69 0.136   
14 Size car227 June 1, 2005 25 59.28 0.13   
15 Size car227 June 1, 2005 25 59.34 0.129   
16 Size car228 June 1, 2005 25 58.51 0.128   
17 Size car228 June 1, 2005 25 58.64 0.147   
18 Size car228 June 1, 2005 25 58.8 0.126   
19 Size car230 June 1, 2005 25 54.29 0.146   
20 Size car230 June 1, 2005 25 54.66 0.156   
21 Size car230 June 1, 2005 25 54.99 0.147   
22 Size car231 June 1, 2005 25 56.23 0.157   
23 Size car231 June 1, 2005 25 55.54 0.154   
24 Size car231 June 1, 2005 25 56.38 0.136   
25 Size car233 June 1, 2005 25 65.26 0.145   
26 Size car233 June 1, 2005 25 66.01 0.143   
27 Size car233 June 1, 2005 25 65.86 0.106   
28 Size car234 June 1, 2005 25 64.64 0.13   
29 Size car234 June 1, 2005 25 64.35 0.138   
30 Size car234 June 1, 2005 25 64.62 0.098   
31 Size car236 June 1, 2005 25 62.64 0.113   
32 Size car236 June 1, 2005 25 61.84 0.123   
33 Size car236 June 1, 2005 25 62 0.118   
34 Size car237 June 1, 2005 25 62.67 0.108   
35 Size car237 June 1, 2005 25 62.66 0.123   
36 Size car237 June 1, 2005 25 62.81 0.119   
37 Zeta CAR227 June 1, 2005 25   -42.25 0.05356 
38 Zeta CAR227 June 1, 2005 25   -39.85 0.04572 
39 Zeta CAR227 June 1, 2005 25   -48.49 0.04773 
40 Zeta CAR228 June 1, 2005 25   -26.31 0.04532 
41 Zeta CAR228 June 1, 2005 25   -32.21 0.05414 
42 Zeta CAR228 June 1, 2005 25   -40.24 0.05379 
43 Zeta CAR230 June 1, 2005 25   -38.04 0.05605 
44 Zeta CAR230 June 1, 2005 25   -46.52 0.05541 
45 Zeta CAR230 June 1, 2005 25   -33.7 0.04612 
46 Zeta CAR231 June 1, 2005 25   -39.71 0.0532 
47 Zeta CAR231 June 1, 2005 25   -30.69 0.05288 
48 Zeta CAR231 June 1, 2005 25   -40.24 0.04728 
49 Zeta CAR233 June 1, 2005 25   -37.77 0.05128 
50 Zeta CAR233 June 1, 2005 25   -37.49 0.04805 
51 Zeta CAR233 June 1, 2005 25   -34.04 0.04194 
52 Zeta CAR234 June 1, 2005 25   -41.83 0.05085 
53 Zeta CAR234 June 1, 2005 25   -37.96 0.05366 
54 Zeta CAR234 June 1, 2005 25   -40.49 0.05513 
55 Zeta CAR236 June 1, 2005 25   -44.75 0.04805 
56 Zeta CAR236 June 1, 2005 25   -43.62 0.05331 
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57 Zeta CAR236 June 1, 2005 25   -41.81 0.04469 
58 Zeta CAR237 June 1, 2005 25   -40.27 0.04468 
59 Zeta CAR237 June 1, 2005 25   -30.79 0.05193 
60 Zeta CAR237 June 1, 2005 25   -44.99 0.05545 
 
 
 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 















1 Size car305 June 3, 2005 25 42.45 0.245   
2 Size car305 June 3, 2005 25 42.28 0.235   
3 Size car305 June 3, 2005 25 41.65 0.219   
4 Size car306 June 3, 2005 25 45.82 0.226   
5 Size car306 June 3, 2005 25 46.19 0.227   
6 Size car306 June 3, 2005 25 45.95 0.211   
7 Size car307 June 3, 2005 25 50.31 0.214   
8 Size car307 June 3, 2005 25 50.59 0.208   
9 Size car307 June 3, 2005 25 50.33 0.206   
10 Size car308 June 3, 2005 25 71.61 0.146   
11 Size car308 June 3, 2005 25 71.68 0.16   
12 Size car308 June 3, 2005 25 71.17 0.141   
13 Size car220 June 3, 2005 25 50.43 0.43   
14 Size car220 June 3, 2005 25 50.43 0.407   
15 Size car220 June 3, 2005 25 50.6 0.381   
16 Size car221 June 3, 2005 25 46.06 0.338   
17 Size car221 June 3, 2005 25 45.73 0.338   
18 Size car221 June 3, 2005 25 45.37 0.326   
19 Size car222 June 3, 2005 25 54.98 0.4   
20 Size car222 June 3, 2005 25 55.29 0.409   
21 Size car222 June 3, 2005 25 54.93 0.404   
22 Size car223 June 3, 2005 25 45.21 0.329   
23 Size car223 June 3, 2005 25 45.2 0.326   
24 Size car223 June 3, 2005 25 44.5 0.326   
25 Size car224 June 3, 2005 25 48.13 0.363   
26 Size car224 June 3, 2005 25 48.15 0.368   
27 Size car224 June 3, 2005 25 47.93 0.36   
28 Size car225 June 3, 2005 25 45.7 0.347   
29 Size car225 June 3, 2005 25 44.92 0.337   
30 Size car225 June 3, 2005 25 45.98 0.298   
31 Size car278 June 3, 2005 25 85.09 0.239   
32 Size car278 June 3, 2005 25 82.13 0.215   
33 Size car278 June 3, 2005 25 83.19 0.232   
34 Size car298 June 3, 2005 25 94.42 0.255   
35 Size car298 June 3, 2005 25 97.01 0.27   
36 Size car298 June 3, 2005 25 94.58 0.253   
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37 Size car246B June 3, 2005 25 71.21 0.109   
38 Size car246B June 3, 2005 25 70.77 0.109   
39 Size car246B June 3, 2005 25 70.7 0.119   
40 Zeta 305 June 3, 2005 25   -22.79 0.04735 
41 Zeta 305 June 3, 2005 25   -21.41 0.04462 
42 Zeta 305 June 3, 2005 25   -30.68 0.04621 
43 Zeta 306 June 3, 2005 25   -30.49 0.04179 
44 Zeta 306 June 3, 2005 25   -33.5 0.04166 
45 Zeta 306 June 3, 2005 25   -28.08 0.04476 
46 Zeta 307 June 3, 2005 25   -34.34 0.04706 
47 Zeta 307 June 3, 2005 25   -31.02 0.04254 
48 Zeta 307 June 3, 2005 25   -38.75 0.04664 
49 Zeta 308 June 3, 2005 25   -28.79 0.03723 
50 Zeta 308 June 3, 2005 25   -28.87 0.04204 
51 Zeta 308 June 3, 2005 25   -28.89 0.04493 
52 Zeta 220 June 3, 2005 25   -29.28 0.05139 
53 Zeta 220 June 3, 2005 25   -30.57 0.0493 
54 Zeta 220 June 3, 2005 25   -29.12 0.05355 
55 Zeta 221 June 3, 2005 25   -43.6 0.05563 
56 Zeta 221 June 3, 2005 25   -36.31 0.05485 
57 Zeta 221 June 3, 2005 25   -32.76 0.04848 
58 Zeta 221 June 3, 2005 25   -37.38 0.05555 
59 Zeta 221 June 3, 2005 25   -45.27 0.05616 
60 Zeta 221 June 3, 2005 25   -47.66 0.05769 
61 Zeta car222 June 3, 2005 25   -28.31 0.05764 
62 Zeta car222 June 3, 2005 25   -31.09 0.0509 
63 Zeta car222 June 3, 2005 25   -32.73 0.05893 
64 Zeta car224 June 3, 2005 25   -41.64 0.06209 
65 Zeta car224 June 3, 2005 25   -38.75 0.05962 
66 Zeta car224 June 3, 2005 25   -36.83 0.05459 
67 Zeta car225 June 3, 2005 25   -33.29 0.0526 
68 Zeta car225 June 3, 2005 25   -35.63 0.05361 
69 Zeta car225 June 3, 2005 25   -31.65 0.06025 
70 Zeta car278 June 3, 2005 25   -39.8 0.05376 
71 Zeta car278 June 3, 2005 25   -37.75 0.05196 
72 Zeta car278 June 3, 2005 25   -37.74 0.04382 
73 Zeta car298 June 3, 2005 25   -40.16 0.04919 
74 Zeta car298 June 3, 2005 25   -42.54 0.04754 
75 Zeta car298 June 3, 2005 25   -41.52 0.05034 
76 Zeta car246B June 3, 2005 25   -41.94 0.06332 
77 Zeta car246B June 3, 2005 25   -42.72 0.06383 
78 Zeta car246B June 3, 2005 25   -37.01 0.06173 
79 Zeta car290 June 3, 2005 25   -39.09 0.05605 
80 Zeta car290 June 3, 2005 25   -40.2 0.05033 
81 Zeta car290 June 3, 2005 25   -37.92 0.04803 
82 Zeta car291 June 3, 2005 25   -35.57 0.04945 
83 Zeta car291 June 3, 2005 25   -36.68 0.0434 
84 Zeta car291 June 3, 2005 25   -36.67 0.04517 
85 Zeta car292 June 3, 2005 25   -41.85 0.04898 
86 Zeta car292 June 3, 2005 25   -39.76 0.04906 
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87 Zeta car292 June 3, 2005 25   -42.32 0.04582 
88 Zeta car294 June 3, 2005 25   -36.1 0.05677 
89 Zeta car294 June 3, 2005 25   -35.98 0.05735 
90 Zeta car294 June 3, 2005 25   -41.99 0.05419 
91 Zeta car295 June 3, 2005 25   -36.26 0.04908 
92 Zeta car295 June 3, 2005 25   -36.45 0.05581 
93 Zeta car295 June 3, 2005 25   -34.19 0.04544 
94 Zeta car281 June 3, 2005 25   -16.26 0.05288 
95 Zeta car281 June 3, 2005 25   -22.89 0.05259 
96 Zeta car281 June 3, 2005 25   -27.3 0.05847 
97 Zeta car284 June 3, 2005 25   -46.72 0.05927 
98 Zeta car284 June 3, 2005 25   -48.39 0.06012 
99 Zeta car284 June 3, 2005 25   -47.27 0.06056 
100 Zeta car297 June 3, 2005 25   -39.78 0.06191 
101 Zeta car297 June 3, 2005 25   -39.57 0.0657 
102 Zeta car297 June 3, 2005 25   -35.74 0.06543 
103 Zeta car267D June 3, 2005 25   -21 0.01114 
104 Zeta car267D June 3, 2005 25   -22.63 0.03553 
105 Zeta car267D June 3, 2005 25   -22.16 0.03242 
106 Zeta car285 June 3, 2005 25   -22.37 0.05831 
107 Zeta car285 June 3, 2005 25   -21.55 0.05001 
108 Zeta car285 June 3, 2005 25   -19.88 0.05926 
109 Zeta car286 June 3, 2005 25   -20.47 0.07439 
110 Zeta car286 June 3, 2005 25   -21.63 0.0766 
111 Zeta car286 June 3, 2005 25   -33.98 0.0734 
112 Zeta car287 June 3, 2005 25   -28.58 0.07888 
113 Zeta car287 June 3, 2005 25   -15.81 0.07966 
114 Zeta car287 June 3, 2005 25   -23.97 0.08622 
 
 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. The symbol D in the 















1 Size car309 June 7, 2005 25 46.32 0.22   
2 Size car309 June 7, 2005 25 46.99 0.223   
3 Size car309 June 7, 2005 25 47 0.229   
4 Size car310 June 7, 2005 25 38.39 0.239   
5 Size car310 June 7, 2005 25 38.38 0.249   
6 Size car310 June 7, 2005 25 38.49 0.251   
7 Size car311 June 7, 2005 25 41.53 0.242   
8 Size car311 June 7, 2005 25 41.48 0.239   
9 Size car311 June 7, 2005 25 41.82 0.225   
10 Size car312 June 7, 2005 25 52.67 0.199   
11 Size car312 June 7, 2005 25 52.38 0.213   
12 Size car312 June 7, 2005 25 52.95 0.196   
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13 Size car310B June 7, 2005 25 38.26 0.243   
14 Size car310B June 7, 2005 25 38.52 0.242   
15 Size car310B June 7, 2005 25 38.45 0.236   
16 Size car295B June 7, 2005 25 98.2 0.269   
17 Size car295B June 7, 2005 25 98.71 0.274   
18 Size car295B June 7, 2005 25 96.59 0.238   
19 Size car322 June 7, 2005 25 80.42 0.257   
20 Size car322 June 7, 2005 25 81.54 0.268   
21 Size car322 June 7, 2005 25 81.39 0.287   
22 Size car323 June 7, 2005 25 81.14 0.254   
23 Size car323 June 7, 2005 25 79.85 0.227   
24 Size car323 June 7, 2005 25 79.63 0.212   
25 Size car227 June 7, 2005 25 65.8 0.212   
26 Size car227 June 7, 2005 25 65.6 0.209   
27 Size car227 June 7, 2005 25 65.02 0.215   
28 Size car292 June 7, 2005 25 119.4 0.252   
29 Size car292 June 7, 2005 25 120.1 0.248   
30 Size car292 June 7, 2005 25 119.2 0.255   
31 Size car291 June 7, 2005 25 116.8 0.237   
32 Size car291 June 7, 2005 25 118.2 0.262   
33 Size car291 June 7, 2005 25 116.9 0.252   
34 Size car271 June 7, 2005 25 105.3 0.291   
35 Size car271 June 7, 2005 25 104.9 0.287   
36 Size car271 June 7, 2005 25 104.8 0.296   
37 Size car270 June 7, 2005 25 107.3 0.291   
38 Size car270 June 7, 2005 25 106.4 0.28   
39 Size car270 June 7, 2005 25 106.8 0.276   
40 Size car293 June 7, 2005 25 96.1 0.216   
41 Size car293 June 7, 2005 25 96.24 0.19   
42 Size car293 June 7, 2005 25 94.16 0.213   
43 Size car236D June 7, 2005 25 68.75 0.119   
44 Size car236D June 7, 2005 25 68.51 0.115   
45 Size car236D June 7, 2005 25 68.8 0.095   
46 Size car294D June 7, 2005 25 95.97 0.213   
47 Size car294D June 7, 2005 25 96.29 0.198   
48 Size car294D June 7, 2005 25 94.67 0.211   
49 Size car274D June 7, 2005 25 87.45 0.198   
50 Size car274D June 7, 2005 25 87.02 0.187   
51 Size car274D June 7, 2005 25 85.13 0.207   
52 Size car297 June 7, 2005 25 87.44 0.193   
53 Size car297 June 7, 2005 25 86.63 0.193   
54 Size car297 June 7, 2005 25 87.34 0.197   
55 Size car226D June 7, 2005 25 67.08 0.15   
56 Size car226D June 7, 2005 25 67.89 0.119   
57 Size car226D June 7, 2005 25 67.55 0.103   
58 Size car290D June 7, 2005 25 111.4 0.247   
59 Size car290D June 7, 2005 25 111.9 0.256   
60 Size car290D June 7, 2005 25 113.6 0.241   
61 Size car276D June 7, 2005 25 81.97 0.177   
62 Size car276D June 7, 2005 25 81.43 0.197   
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63 Size car276D June 7, 2005 25 81.94 0.192   
64 Size car244D June 7, 2005 25 75.07 0.115   
65 Size car244D June 7, 2005 25 75.11 0.104   
66 Size car244D June 7, 2005 25 75.16 0.123   
67 Size car240D June 7, 2005 25 50.51 0.31   
68 Size car240D June 7, 2005 25 50.85 0.269   
69 Size car240D June 7, 2005 25 50.55 0.276   
70 Size car277D June 7, 2005 25 80.06 0.194   
71 Size car277D June 7, 2005 25 79.45 0.18   
72 Size car277D June 7, 2005 25 78.07 0.187   
73 Size car243D June 7, 2005 25 70.89 0.183   
74 Size car243D June 7, 2005 25 70.18 0.176   
75 Size car243D June 7, 2005 25 70.6 0.17   
76 Zeta car295B June 7, 2005 25   -44.34 0.05961 
77 Zeta car295B June 7, 2005 25   -44.42 0.05544 
78 Zeta car295B June 7, 2005 25   -45.08 0.05587 
79 Zeta car323 June 7, 2005 25   -41.11 0.04982 
80 Zeta car323 June 7, 2005 25   -39.99 0.04692 
81 Zeta car323 June 7, 2005 25   -36.61 0.05343 
82 Zeta car227D June 7, 2005 25   -38.45 0.01142 
83 Zeta car227D June 7, 2005 25   -36.13 0.03206 
84 Zeta car227D June 7, 2005 25   -30.63 0.03136 
85 Zeta car292D June 7, 2005 25   -30.87 0.0338 
86 Zeta car292D June 7, 2005 25   -32.12 0.03201 
87 Zeta car292D June 7, 2005 25   -32.89 0.03613 
88 Zeta car271D June 7, 2005 25   -35.94 0.0408 
89 Zeta car271D June 7, 2005 25   -45.65 0.0403 
90 Zeta car271D June 7, 2005 25   -31.3 0.03191 
91 Zeta car240D June 7, 2005 25   -38.86 0.01368 
92 Zeta car240D June 7, 2005 25   -24.2 0.02971 
93 Zeta car240D June 7, 2005 25   -26.85 0.02055 
94 Zeta car243D June 7, 2005 25   -41.66 0.03599 
95 Zeta car243D June 7, 2005 25   -48.75 0.0348 
96 Zeta car243D June 7, 2005 25   -38.25 0.03574 
97 Zeta car226D June 7, 2005 25   -29.73 0.0322 
98 Zeta car226D June 7, 2005 25   -29.31 0.03894 
99 Zeta car226D June 7, 2005 25   -32.48 0.02884 
100 Zeta car310 June 7, 2005 25   -45.63 0.1611 
101 Zeta car310 June 7, 2005 25   -43.63 0.1635 
102 Zeta car310 June 7, 2005 25   -46.17 0.168 
103 Zeta car312 June 7, 2005 25   -39.38 0.05628 
104 Zeta car312 June 7, 2005 25   -36.82 0.05124 
105 Zeta car312 June 7, 2005 25   -37.6 0.04674 
106 Zeta car249D June 7, 2005 25   -39.44 0.02625 
107 Zeta car249D June 7, 2005 25   -40.31 0.03019 
108 Zeta car249D June 7, 2005 25   -42.8 0.02894 
109 Zeta car277D June 7, 2005 25   -41.84 0.06295 
110 Zeta car277D June 7, 2005 25   -33.74 0.05501 





 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. The amplitude used was 
39%. The evaporation time was 7 min. The amount of MOA was 4% w/w and 8%w/w. 
 










1 Size CA64 July 5, 2005 25 38.81 0.233   
2 Size CA64 July 5, 2005 25 39.01 0.212   
3 Size CA64 July 5, 2005 25 38.86 0.214   
4 Size CA65 July 5, 2005 25 38.47 0.226   
5 Size CA65 July 5, 2005 25 38.62 0.245   
6 Size CA65 July 5, 2005 25 38.61 0.23   
7 Size CA66 July 5, 2005 25 52.72 0.385   
8 Size CA66 July 5, 2005 25 53.59 0.364   
9 Size CA66 July 5, 2005 25 54.77 0.399   
10 Size CA67 July 5, 2005 25 63.61 0.135   
11 Size CA67 July 5, 2005 25 63.39 0.132   
12 Size CA67 July 5, 2005 25 63.74 0.121   
13 Size CA68 July 5, 2005 25 63.35 0.117   
14 Size CA68 July 5, 2005 25 63.05 0.118   
15 Size CA68 July 5, 2005 25 62.91 0.148   
16 Size CA69 July 5, 2005 25 63.55 0.119   
17 Size CA69 July 5, 2005 25 62.94 0.126   
18 Size CA69 July 5, 2005 25 62.92 0.124   
19 Size CA70 July 5, 2005 25 66.06 0.13   
20 Size CA70 July 5, 2005 25 66.58 0.117   
21 Size CA70 July 5, 2005 25 66.75 0.128   
22 Size CA71 July 5, 2005 25 67.65 0.125   
23 Size CA71 July 5, 2005 25 67.27 0.118   
24 Size CA71 July 5, 2005 25 66.87 0.127   
25 Size CA72 July 5, 2005 25 68.05 0.156   
26 Size CA72 July 5, 2005 25 66.95 0.13   
27 Size CA72 July 5, 2005 25 67.47 0.111   
28 Size CAR324B July 5, 2005 25 83.27 0.169   
29 Size CAR324B July 5, 2005 25 84.46 0.165   
30 Size CAR324B July 5, 2005 25 84.95 0.204   
31 Size CAR324Bd July 5, 2005 25 76.41 0.17   
32 Size CAR324Bd July 5, 2005 25 76.97 0.164   
33 Size CAR324Bd July 5, 2005 25 76.41 0.154   
34 Size CAR325B July 5, 2005 25 92.94 0.168   
35 Size CAR325B July 5, 2005 25 92.32 0.203   
36 Size CAR325B July 5, 2005 25 90.89 0.183   
37 Size CAR325Bd July 5, 2005 25 87.11 0.21   
38 Size CAR325Bd July 5, 2005 25 86.32 0.207   
39 Size CAR325Bd July 5, 2005 25 85.56 0.202   
40 Zeta CA64 July 5, 2005 25   -12.91 0.06245 
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41 Zeta CA64 July 5, 2005 25   -9.807 0.06122 
42 Zeta CA64 July 5, 2005 25   -23.13 0.06295 
43 Zeta CA65 July 5, 2005 25   -20.57 0.05185 
44 Zeta CA65 July 5, 2005 25   -15.61 0.0536 
45 Zeta CA65 July 5, 2005 25   -18.51 0.05874 
46 Zeta CA66 July 5, 2005 25   -21.27 0.05534 
47 Zeta CA66 July 5, 2005 25   -25.83 0.05911 
48 Zeta CA66 July 5, 2005 25   -25.59 0.06282 
49 Zeta CA67 July 5, 2005 25   -25.64 0.06076 
50 Zeta CA67 July 5, 2005 25   -18.51 0.05591 
51 Zeta CA67 July 5, 2005 25   -30.33 0.05918 
52 Zeta CA68 July 5, 2005 25   -21.49 0.05441 
53 Zeta CA68 July 5, 2005 25   -30.42 0.0583 
54 Zeta CA68 July 5, 2005 25   -30.31 0.05497 
55 Zeta CA69 July 5, 2005 25   -25.83 0.05436 
56 Zeta CA69 July 5, 2005 25   -26.66 0.05299 
57 Zeta CA69 July 5, 2005 25   -27.58 0.06211 
58 Zeta CA70 July 5, 2005 25   -33.42 0.06064 
59 Zeta CA70 July 5, 2005 25   -29.55 0.0613 
60 Zeta CA70 July 5, 2005 25   -24.87 0.06363 
61 Zeta CA71 July 5, 2005 25   -26.76 0.05636 
62 Zeta CA71 July 5, 2005 25   -22.09 0.05531 
63 Zeta CA71 July 5, 2005 25   -22.4 0.06397 
64 Zeta CA72 July 5, 2005 25   -32.47 0.05571 
65 Zeta CA72 July 5, 2005 25   -27.75 0.06102 
66 Zeta CA72 July 5, 2005 25   -24.19 0.05908 
67 Zeta CAR324B July 5, 2005 25   -34.2 0.04592 
68 Zeta CAR324B July 5, 2005 25   -39.53 0.04942 
69 Zeta CAR324B July 5, 2005 25   -38.91 0.04601 
70 Zeta CAR324Bd July 5, 2005 25   -25.59 0.03581 
71 Zeta CAR324Bd July 5, 2005 25   -24.94 0.03331 
72 Zeta CAR324Bd July 5, 2005 25   -22.89 0.02498 
73 Zeta CAR325B July 5, 2005 25   -40.11 0.04227 
74 Zeta CAR325B July 5, 2005 25   -37.64 0.04801 
75 Zeta CAR325B July 5, 2005 25   -38.79 0.03533 
76 Zeta CAR325Bd July 5, 2005 25   -34.66 0.02218 
77 Zeta CAR325Bd July 5, 2005 25   -22.75 0.03844 





 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. The amplitude used was 














1 Size CA46 July 12, 2005 25 87.85 0.312   
2 Size CA46 July 12, 2005 25 86.56 0.297   
3 Size CA46 July 12, 2005 25 84.91 0.298   
4 Size CA47 July 12, 2005 25 86.7 0.299   
5 Size CA47 July 12, 2005 25 87.94 0.297   
6 Size CA47 July 12, 2005 25 86.36 0.296   
7 Size CA48 July 12, 2005 25 88.3 0.295   
8 Size CA48 July 12, 2005 25 86.79 0.288   
9 Size CA48 July 12, 2005 25 89.19 0.291   
10 Size CA52 July 12, 2005 25 89.39 0.295   
11 Size CA52 July 12, 2005 25 88.59 0.306   
12 Size CA52 July 12, 2005 25 88.42 0.272   
13 Size CA53 July 12, 2005 25 80.98 0.198   
14 Size CA53 July 12, 2005 25 78.88 0.188   
15 Size CA53 July 12, 2005 25 78.12 0.181   
16 Size CA54 July 12, 2005 25 77.05 0.195   
17 Size CA54 July 12, 2005 25 77.6 0.183   
18 Size CA54 July 12, 2005 25 77.37 0.18   
19 Size CA58 July 12, 2005 25 78.76 0.173   
20 Size CA58 July 12, 2005 25 79.56 0.188   
21 Size CA58 July 12, 2005 25 79.07 0.166   
22 Size CA59 July 12, 2005 25 77.95 0.168   
23 Size CA59 July 12, 2005 25 79.16 0.139   
24 Size CA59 July 12, 2005 25 78.96 0.154   
25 Size CA60 July 12, 2005 25 79.37 0.189   
26 Size CA60 July 12, 2005 25 78.3 0.19   
27 Size CA60 July 12, 2005 25 78.15 0.181   
28 Size CA64 July 12, 2005 25 53.38 0.154   
29 Size CA64 July 12, 2005 25 53.68 0.153   
30 Size CA64 July 12, 2005 25 53.47 0.154   
31 Size CA65 July 12, 2005 25 54.11 0.118   
32 Size CA65 July 12, 2005 25 53.35 0.142   
33 Size CA65 July 12, 2005 25 53.58 0.129   
34 Size CA66 July 12, 2005 25 57.22 0.192   
35 Size CA66 July 12, 2005 25 56.08 0.185   
36 Size CA66 July 12, 2005 25 55.61 0.172   
37 Size CA67AD July 12, 2005 25 68.46 0.149   
38 Size CA67AD July 12, 2005 25 68.31 0.137   
39 Size CA67AD July 12, 2005 25 68.44 0.128   
40 Size CA68AD July 12, 2005 25 70.21 0.153   
41 Size CA68AD July 12, 2005 25 69.44 0.166   
42 Size CA68AD July 12, 2005 25 68.55 0.169   
43 Size CA69AD July 12, 2005 25 69.03 0.138   
44 Size CA69AD July 12, 2005 25 67.28 0.127   
45 Size CA69AD July 12, 2005 25 66.88 0.147   
46 Size CA70AD July 12, 2005 25 70.89 0.14   
47 Size CA70AD July 12, 2005 25 69.61 0.128   
48 Size CA70AD July 12, 2005 25 69.98 0.12   
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49 Size CA71AD July 12, 2005 25 70.83 0.137   
50 Size CA71AD July 12, 2005 25 70.45 0.143   
51 Size CA71AD July 12, 2005 25 70.21 0.148   
52 Size CA72AD July 12, 2005 25 70.6 0.143   
53 Size CA72AD July 12, 2005 25 70.11 0.143   
54 Size CA72AD July 12, 2005 25 69.99 0.136   
55 Size CA46AD July 12, 2005 25 81.3 0.272   
56 Size CA46AD July 12, 2005 25 82.33 0.255   
57 Size CA46AD July 12, 2005 25 82.19 0.255   
58 Size CA47AD July 12, 2005 25 85.85 0.262   
59 Size CA47AD July 12, 2005 25 84.95 0.263   
60 Size CA47AD July 12, 2005 25 83.37 0.268   
61 Size CA48AD July 12, 2005 25 81.71 0.259   
62 Size CA48AD July 12, 2005 25 81.62 0.259   
63 Size CA48AD July 12, 2005 25 82.88 0.257   
64 Size CA52AD July 12, 2005 25 83.3 0.181   
65 Size CA52AD July 12, 2005 25 83.74 0.17   
66 Size CA52AD July 12, 2005 25 83.27 0.15   
67 Size CA53AD July 12, 2005 25 82.29 0.157   
68 Size CA53AD July 12, 2005 25 82.69 0.176   
69 Size CA53AD July 12, 2005 25 81.56 0.175   
70 Size CA54AD July 12, 2005 25 81.68 0.174   
71 Size CA54AD July 12, 2005 25 82.68 0.146   
72 Size CA54AD July 12, 2005 25 82.13 0.172   
73 Size CA58AD July 12, 2005 25 82.57 0.181   
74 Size CA58AD July 12, 2005 25 82.35 0.164   
75 Size CA58AD July 12, 2005 25 82.47 0.164   
76 Size CA59AD July 12, 2005 25 81.44 0.172   
77 Size CA59AD July 12, 2005 25 82.92 0.16   
78 Size CA59AD July 12, 2005 25 82.58 0.153   
79 Size CA60AD July 12, 2005 25 84.64 0.182   
80 Size CA60AD July 12, 2005 25 83.04 0.175   
81 Size CA60AD July 12, 2005 25 82.88 0.171   
82 Zeta CA64AD July 12, 2005 25   -29.52 0.03673 
83 Zeta CA64AD July 12, 2005 25   -31.71 0.03312 
84 Zeta CA64AD July 12, 2005 25   -33.99 0.02105 
85 Zeta CA65AD July 12, 2005 25   -28.67 0.03486 
86 Zeta CA65AD July 12, 2005 25   -25.85 0.02822 
87 Zeta CA65AD July 12, 2005 25   -25.55 0.02596 
88 Zeta CA66AD July 12, 2005 25   -41.61 0.01139 
89 Zeta CA66AD July 12, 2005 25   -38.18 0.03504 
90 Zeta CA66AD July 12, 2005 25   -43.41 0.03109 
91 Zeta CA67AD July 12, 2005 25   -32.31 0.02989 
92 Zeta CA67AD July 12, 2005 25   -32.16 0.01203 
93 Zeta CA67AD July 12, 2005 25   -31.04 0.03462 
94 Zeta CA68AD July 12, 2005 25   -34.72 0.0114 
95 Zeta CA68AD July 12, 2005 25   -33.48 0.02884 
96 Zeta CA68AD July 12, 2005 25   -36.98 0.03461 
97 Zeta CA69AD July 12, 2005 25   -23.02 0.01207 
98 Zeta CA69AD July 12, 2005 25   -29.77 0.02555 
 
120 
99 Zeta CA69AD July 12, 2005 25   -24.23 0.0297 
100 Zeta CA70AD July 12, 2005 25   -25.97 0.03194 
101 Zeta CA70AD July 12, 2005 25   -31.58 0.01207 
102 Zeta CA70AD July 12, 2005 25   -33.4 0.01913 
103 Zeta CA71AD July 12, 2005 25   -36.35 0.01369 
104 Zeta CA71AD July 12, 2005 25   -39.24 0.02446 
105 Zeta CA71AD July 12, 2005 25   -40.65 0.02406 
106 Zeta CA72AD July 12, 2005 25   -34.67 0.03526 
107 Zeta CA72AD July 12, 2005 25   -26.06 0.03188 
108 Zeta CA72AD July 12, 2005 25   -33.2 0.01604 
109 Zeta CA46AD July 12, 2005 25   -23.52 0.01603 
110 Zeta CA46AD July 12, 2005 25   -24.21 0.0302 
111 Zeta CA46AD July 12, 2005 25   -24.1 0.01675 
112 Zeta CA47AD July 12, 2005 25   -43.38 0.03603 
113 Zeta CA47AD July 12, 2005 25   -42.63 0.03764 
114 Zeta CA47AD July 12, 2005 25   -43.82 0.02526 
 
 
 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. The amplitude used was 
39%. The evaporation time was 7 min. The amount of MOA was 4% w/w and 8%w/w. 
 
Record Type Sample Date T (°C) 
Z-Ave 
(nm) 
PDI ZP (mV) 
Cond 
(mS/cm) 
1 Size CA49 July 15, 2005 24 118 0.309   
2 Size CA49 July 15, 2005 24 115.2 0.365   
3 Size CA49 July 15, 2005 24 115.3 0.297   
4 Size CA50 July 15, 2005 24 113.6 0.342   
5 Size CA50 July 15, 2005 24 114.8 0.367   
6 Size CA50 July 15, 2005 24 115.7 0.304   
7 Size CA51 July 15, 2005 24 115 0.306   
8 Size CA51 July 15, 2005 24 114.3 0.298   
9 Size CA51 July 15, 2005 24 113.8 0.296   
10 Size CA49AD July 15, 2005 24 106.7 0.285   
11 Size CA49AD July 15, 2005 24 106.9 0.277   
12 Size CA49AD July 15, 2005 24 106.2 0.286   
13 Size CA50AD July 15, 2005 24 113.9 0.291   
14 Size CA50AD July 15, 2005 24 112.2 0.295   
15 Size CA50AD July 15, 2005 24 111.6 0.291   
16 Size CA51AD July 15, 2005 24 107.7 0.296   
17 Size CA51AD July 15, 2005 24 104.4 0.302   
18 Size CA51AD July 15, 2005 24 105.6 0.288   
19 Size CA55 July 15, 2005 24 92.62 0.23   
20 Size CA55 July 15, 2005 24 91.51 0.242   
21 Size CA55 July 15, 2005 24 91.91 0.241   
22 Size CA56 July 15, 2005 24 92.61 0.265   
23 Size CA56 July 15, 2005 24 92.29 0.25   
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24 Size CA56 July 15, 2005 24 92.18 0.239   
25 Size CA57 July 15, 2005 24 94.65 0.259   
26 Size CA57 July 15, 2005 24 94.7 0.257   
27 Size CA57 July 15, 2005 24 94.32 0.257   
28 Size CA55AD July 15, 2005 24 96.65 0.249   
29 Size CA55AD July 15, 2005 24 95.45 0.224   
30 Size CA55AD July 15, 2005 24 93.38 0.234   
31 Size CA56AD July 15, 2005 24 97.31 0.242   
32 Size CA56AD July 15, 2005 24 93.97 0.236   
33 Size CA56AD July 15, 2005 24 94.27 0.219   
34 Size CA57AD July 15, 2005 24 97.76 0.257   
35 Size CA57AD July 15, 2005 24 97.17 0.246   
36 Size CA57AD July 15, 2005 24 96.12 0.231   
37 Size CA61 July 15, 2005 24 111.2 0.251   
38 Size CA61 July 15, 2005 24 111.3 0.257   
39 Size CA61 July 15, 2005 24 111.5 0.254   
40 Size CA62 July 15, 2005 24 102.1 0.258   
41 Size CA62 July 15, 2005 24 102.1 0.262   
42 Size CA62 July 15, 2005 24 101.4 0.255   
43 Size CA63 July 15, 2005 24 110.9 0.267   
44 Size CA63 July 15, 2005 24 108.6 0.256   
45 Size CA63 July 15, 2005 24 107.2 0.263   
46 Size CA61AD July 15, 2005 24 110.1 0.228   
47 Size CA61AD July 15, 2005 24 109.1 0.25   
48 Size CA61AD July 15, 2005 24 108.7 0.239   
49 Size CA62AD July 15, 2005 24 105.3 0.248   
50 Size CA62AD July 15, 2005 24 105.2 0.255   
51 Size CA62AD July 15, 2005 24 102.7 0.244   
52 Size CA63AD July 15, 2005 24 110.6 0.259   
53 Size CA63AD July 15, 2005 24 112 0.246   
54 Size CA63AD July 15, 2005 24 112.9 0.245   
55 Size CA63ADT July 15, 2005 25 115.1 0.261   
56 Size CA63ADT July 15, 2005 25 115.6 0.258   
57 Size CA63ADT July 15, 2005 25 113.1 0.255   
58 Zeta CA49 July 15, 2005 25   -28.87 0.04323 
59 Zeta CA49 July 15, 2005 25   -31.17 0.04672 
60 Zeta CA49 July 15, 2005 25   -34.76 0.04642 
61 Zeta CA50 July 15, 2005 25   -34.93 0.05304 
62 Zeta CA50 July 15, 2005 25   -36.48 0.05332 
63 Zeta CA50 July 15, 2005 25   -37.35 0.05282 
64 Zeta CA51 July 15, 2005 25   -40.45 0.04901 
65 Zeta CA51 July 15, 2005 25   -41.48 0.04936 
66 Zeta CA51 July 15, 2005 25   -39.01 0.05645 
67 Zeta CA49AD July 15, 2005 25   -41.38 0.02754 
68 Zeta CA49AD July 15, 2005 25   -43.95 0.03569 
69 Zeta CA49AD July 15, 2005 25   -41.24 0.02272 
70 Zeta CA50AD July 15, 2005 25   -34.82 0.0348 
71 Zeta CA50AD July 15, 2005 25   -35.08 0.03603 
72 Zeta CA50AD July 15, 2005 25   -34.41 0.01709 
73 Zeta CA51AD July 15, 2005 25   -49.81 0.01232 
74 Zeta CA51AD July 15, 2005 25   -49.2 0.0168 
75 Zeta CA51AD July 15, 2005 25   -49.76 0.03254 
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76 Zeta CA55 July 15, 2005 25   -29.59 0.04544 
77 Zeta CA55 July 15, 2005 25   -31.16 0.03277 
78 Zeta CA55 July 15, 2005 25   -30.48 0.0339 
79 Zeta CA56 July 15, 2005 25   -36.54 0.04697 
80 Zeta CA56 July 15, 2005 25   -33.83 0.03484 
81 Zeta CA56 July 15, 2005 25   -36.25 0.03411 
82 Zeta CA57 July 15, 2005 25   -35.92 0.04955 
83 Zeta CA57 July 15, 2005 25   -33.4 0.05804 
84 Zeta CA57 July 15, 2005 25   -39.5 0.05686 
85 Zeta CA55D July 15, 2005 25   -42.79 0.03703 
86 Zeta CA55D July 15, 2005 25   -44.05 0.01857 
87 Zeta CA55D July 15, 2005 25   -48.3 0.03593 
88 Zeta CA56D July 15, 2005 25   -52.03 0.03032 
89 Zeta CA56D July 15, 2005 25   -51.25 0.02136 
90 Zeta CA56D July 15, 2005 25   -57.2 0.01252 
91 Zeta CA57D July 15, 2005 25   -37.83 0.01333 
92 Zeta CA57D July 15, 2005 25   -39.23 0.03353 
93 Zeta CA57D July 15, 2005 25   -38.38 0.01364 
94 Zeta CA61 July 15, 2005 25   -41.51 0.03602 
95 Zeta CA61 July 15, 2005 25   -37.65 0.0474 
96 Zeta CA61 July 15, 2005 25   -44.16 0.04636 
97 Zeta CA62 July 15, 2005 25   -34.9 0.04585 
98 Zeta CA62 July 15, 2005 25   -35.7 0.04746 
99 Zeta CA62 July 15, 2005 25   -36.08 0.04751 
100 Zeta CA63 July 15, 2005 25   -37.74 0.04386 
101 Zeta CA63 July 15, 2005 25   -35.24 0.04193 
102 Zeta CA63 July 15, 2005 25   -35.28 0.04543 
103 Zeta CA61d July 15, 2005 25   -26.78 0.03368 
104 Zeta CA61d July 15, 2005 25   -27.03 0.01376 
105 Zeta CA61d July 15, 2005 25   -27.08 0.02994 
106 Zeta CA62d July 15, 2005 25   -41.93 0.03316 
107 Zeta CA62d July 15, 2005 25   -39.23 0.01798 
108 Zeta CA62d July 15, 2005 25   -48.8 0.01908 
109 Zeta CA63d July 15, 2005 25   -40.16 0.03061 
110 Zeta CA63d July 15, 2005 25   -44.62 0.0335 
111 Zeta CA63d July 15, 2005 25   -43.7 0.03591 
112 Zeta CA48d July 15, 2005 25   -18.73 0.03706 
113 Zeta CA48d July 15, 2005 25   -20.29 0.036 
114 Zeta CA48d July 15, 2005 25   -22.26 0.03334 
115 Zeta CA52d July 15, 2005 25   -29.83 0.02918 
116 Zeta CA52d July 15, 2005 25   -31.95 0.01571 
117 Zeta CA52d July 15, 2005 25   -29.56 0.01591 
118 Zeta CA53d July 15, 2005 25   -34.32 0.03804 
119 Zeta CA53d July 15, 2005 25   -32.85 0.03811 
120 Zeta CA53d July 15, 2005 25   -35.72 0.03805 
121 Zeta CA54d July 15, 2005 25   -31.29 0.03255 
122 Zeta CA54d July 15, 2005 25   -24.45 0.01913 
123 Zeta CA54d July 15, 2005 25   -27.42 0.03508 
124 Zeta CA58d July 15, 2005 25   -28.33 0.01526 
125 Zeta CA58d July 15, 2005 25   -21.29 0.01581 
126 Zeta CA58d July 15, 2005 25   -29.2 0.03316 
127 Zeta CA59d July 15, 2005 25   -33.44 0.0172 
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128 Zeta CA59d July 15, 2005 25   -31.54 0.02946 
129 Zeta CA59d July 15, 2005 25   -29.23 0.03231 
130 Zeta CA60d July 15, 2005 25   -26.36 0.03619 
131 Zeta CA60d July 15, 2005 25   -21.51 0.01768 
132 Zeta CA60d July 15, 2005 25   -22.77 0.02739 
133 Zeta CA46 July 15, 2005 25   -23.53 0.05858 
134 Zeta CA46 July 15, 2005 25   -26.56 0.06197 
135 Zeta CA46 July 15, 2005 25   -24.98 0.06733 
136 Zeta CA47 July 15, 2005 25   -26.51 0.05669 
137 Zeta CA47 July 15, 2005 25   -28.95 0.05978 
138 Zeta CA47 July 15, 2005 25   -27.72 0.05673 
139 Zeta CA48 July 15, 2005 25   -27.56 0.05657 
140 Zeta CA48 July 15, 2005 25   -36.56 0.06527 
141 Zeta CA48 July 15, 2005 25   -33.94 0.06606 
142 Zeta CA52 July 15, 2005 25   -28.73 0.06249 
143 Zeta CA52 July 15, 2005 25   -29.87 0.05929 
144 Zeta CA52 July 15, 2005 25   -31.98 0.05971 
145 Zeta CA53 July 15, 2005 25   -25.2 0.09448 
146 Zeta CA53 July 15, 2005 25   -26.15 0.09667 
147 Zeta CA53 July 15, 2005 25   -23.58 0.09639 
148 Zeta CA54 July 15, 2005 25   -25.46 0.05217 
149 Zeta CA54 July 15, 2005 25   -25.27 0.05263 
150 Zeta CA54 July 15, 2005 25   -25.78 0.05351 
151 Zeta CA58 July 15, 2005 25   -34.38 0.05817 
152 Zeta CA58 July 15, 2005 25   -32.91 0.05886 
153 Zeta CA58 July 15, 2005 25   -31.59 0.06233 
154 Zeta CA59 July 15, 2005 25   -38.18 0.07735 
155 Zeta CA59 July 15, 2005 25   -34.96 0.07765 
156 Zeta CA59 July 15, 2005 25   -34.03 0.078 
157 Zeta CA60 July 15, 2005 25   -31.96 0.05438 
158 Zeta CA60 July 15, 2005 25   -31.93 0.05455 
159 Zeta CA60 July 15, 2005 25   -32.56 0.0565 
 
 
 All sample were prepared with emulsion evaporation method (SDS of 2 mg/ml), 
and with the three PLGA molecular weight used in this research. The amplitude used was 
39%. The evaporation time was 7 min. The amount of MOA was 4% w/w and 8%w/w. 
 










1 Size CA66b July 26, 2005 25 42.36 0.136   
2 Size CA66b July 26, 2005 25 36.85 0.247   
3 Size CA66b July 26, 2005 25 36.13 0.212   
4 Size CA1 July 26, 2005 25 66.14 0.18   
5 Size CA1 July 26, 2005 25 67.14 0.201   
6 Size CA1 July 26, 2005 25 66.68 0.192   
7 Size CA4 July 26, 2005 25 45.64 0.234   
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8 Size CA4 July 26, 2005 25 44.97 0.232   
9 Size CA4 July 26, 2005 25 44.76 0.234   
10 Size CA7 July 26, 2005 25 34.2 0.243   
11 Size CA7 July 26, 2005 25 34.98 0.242   
12 Size CA7 July 26, 2005 25 34.99 0.24   
13 Size CA10 July 26, 2005 25 32.52 0.274   
14 Size CA10 July 26, 2005 25 32.13 0.27   
15 Size CA10 July 26, 2005 25 31.8 0.274   
16 Size CA13 July 26, 2005 25 31.23 0.294   
17 Size CA13 July 26, 2005 25 30.68 0.271   
18 Size CA13 July 26, 2005 25 30.24 0.258   
19 Size TCA1 July 26, 2005 25 87.18 0.218   
20 Size TCA1 July 26, 2005 25 87.28 0.21   
21 Size TCA1 July 26, 2005 25 85.15 0.211   
22 Size TCA2 July 26, 2005 25 81.43 0.191   
23 Size TCA2 July 26, 2005 25 79.26 0.195   
24 Size TCA2 July 26, 2005 25 79.52 0.199   
25 Size TCA3 July 26, 2005 25 95.33 0.391   
26 Size TCA3 July 26, 2005 25 94.86 0.309   
27 Size TCA3 July 26, 2005 25 94.08 0.391   
28 Size CA62RS July 26, 2005 25 872.2 0.703   
29 Size CA62RS July 26, 2005 25 850 0.683   
30 Size CA62RS July 26, 2005 25 937.3 0.764   
31 Size CA62TRS July 26, 2005 25 1036 0.666   
32 Size CA62TRS July 26, 2005 25 1165 0.673   
33 Size CA62TRS July 26, 2005 25 1239 0.805   
34 Size CA65RS July 26, 2005 25 976.5 0.779   
35 Size CA65RS July 26, 2005 25 801.5 0.661   
36 Size CA65RS July 26, 2005 25 429.9 0.641   
37 Size CA65TRS July 26, 2005 25 2103 1   
38 Size CA65TRS July 26, 2005 25 1363 0.848   
39 Size CA65TRS July 26, 2005 25 687 0.642   
40 Size CA65RS2 July 26, 2005 25 981.8 0.757   
41 Size CA65RS2 July 26, 2005 25 1011 0.789   
42 Size CA65RS2 July 26, 2005 25 414.9 0.741   
43 Zeta CA66b July 26, 2005 25   -27.31 0.04447 
44 Zeta CA66b July 26, 2005 25   -35.92 0.03059 
45 Zeta CA66b July 26, 2005 25   -29.38 0.04481 
46 Zeta CA1 July 26, 2005 25   -32.02 0.02929 
47 Zeta CA1 July 26, 2005 25   -28.15 0.03035 
48 Zeta CA1 July 26, 2005 25   -35.93 0.01985 
49 Zeta CA4 July 26, 2005 25   -27.53 0.02218 
50 Zeta CA4 July 26, 2005 25   -29.69 0.02354 
51 Zeta CA4 July 26, 2005 25   -22.71 0.04021 
52 Zeta CA7 July 26, 2005 25   -38.59 0.03356 
53 Zeta CA7 July 26, 2005 25   -48.12 0.04156 
54 Zeta CA7 July 26, 2005 25   -38.45 0.04042 
55 Zeta CA10 July 26, 2005 25   -36.28 0.03359 
56 Zeta CA10 July 26, 2005 25   -30.14 0.04715 
57 Zeta CA10 July 26, 2005 25   -48.55 0.03741 
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58 Zeta CA13 July 26, 2005 25   -32.16 0.05517 
59 Zeta CA13 July 26, 2005 25   -27.43 0.0535 
60 Zeta CA13 July 26, 2005 25   -30.97 0.05652 
61 Zeta TCA1 July 26, 2005 25   -24.26 0.03499 
62 Zeta TCA1 July 26, 2005 25   -23.23 0.04819 
63 Zeta TCA1 July 26, 2005 25   -24.41 0.0491 
64 Zeta TCA2 July 26, 2005 25   -22.07 0.03822 
65 Zeta TCA2 July 26, 2005 25   -21.93 0.03767 
66 Zeta TCA2 July 26, 2005 25   -22.34 0.04373 
67 Zeta TCA3 July 26, 2005 25   -23.85 0.04753 
68 Zeta TCA3 July 26, 2005 25   -22.39 0.03561 
69 Zeta TCA3 July 26, 2005 25   -23.49 0.03684 
70 Zeta CA62RS July 26, 2005 25   -41.4 0.02966 
71 Zeta CA62RS July 26, 2005 25   -41.5 0.02326 
72 Zeta CA62RS July 26, 2005 25   -37.58 0.02265 
73 Zeta CA62TRS July 26, 2005 25   -43.33 0.02563 
74 Zeta CA62TRS July 26, 2005 25   -47.49 0.0171 
75 Zeta CA62TRS July 26, 2005 25   -48.52 0.03385 
76 Zeta CA65RS July 26, 2005 25   -32.12 0.02134 
77 Zeta CA65RS July 26, 2005 25   -35.79 0.03574 
78 Zeta CA65RS July 26, 2005 25   -37.82 0.03545 
79 Zeta CA65TRS July 26, 2005 25   -50.64 0.02522 
80 Zeta CA65TRS July 26, 2005 25   -48.32 0.01853 





APPENDIX D. STATISTICS ANALYSIS OF DATA 
Analysis by SAS software using proc mixed procedure (α = 0.05). The results 
showed the effect of active component (AC), PLGA molecular weight (MW), and 
dialysis (Dys) in nanoparticle size is significant.   
 
Randomize complete design (one-way anova) 
Effect of PLGA molecular weight, MOA, and dialysis in Np size 
List of Data        SIN GROUP DIALSYSIS 
 
Obs     Size    Dys    AC    MW    Rep 
 
  1     38.9     1      1     1     1 
  2     38.6     1      1     1     2 
  3     38.4     1      1     1     3 
  4     63.6     1      1     2     1 
  5     63.1     1      1     2     2 
  6     63.1     1      1     2     3 
  7     66.5     1      1     3     1 
  8     67.3     1      1     3     2 
  9     67.5     1      1     3     3 
 10     86.4     1      2     1     1 
 11     87.0     1      2     1     2 
 12     88.1     1      2     1     3 
 13     88.8     1      2     2     1 
 14     79.3     1      2     2     2 
 15     77.3     1      2     2     3 
 16     79.1     1      2     3     1 
 17     78.7     1      2     3     2 
 18     78.6     1      2     3     3 
 19    116.2     1      3     1     1 
 20    114.7     1      3     1     2 
 21    114.4     1      3     1     3 
 22     92.0     1      3     2     1 
 23     92.4     1      3     2     2 
 24     94.6     1      3     2     3 
 25    111.3     1      3     3     1 
 26    101.9     1      3     3     2 
 27    108.9     1      3     3     3 
 28     53.5     2      1     1     1 
 29     53.7     2      1     1     2 
 30     56.3     2      1     1     3 
 31     68.4     2      1     2     1 
 32     69.4     2      1     2     2 
 33     67.7     2      1     2     3 
 34     70.2     2      1     3     1 
 35     70.5     2      1     3     2 
 36     70.2     2      1     3     3 
 37     81.9     2      2     1     1 
 38     84.7     2      2     1     2 
 39     82.1     2      2     1     3 
 40     88.8     2      2     2     1 
 41     82.2     2      2     2     2 
 42     82.2     2      2     2     3 
 43     82.5     2      2     3     1 
 44     82.3     2      2     3     2 
 45     83.5     2      2     3     3 
 46    106.6     2      3     1     1 
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 47    112.6     2      3     1     2 
 48    105.9     2      3     1     3 
 49     95.2     2      3     2     1 
 50     95.2     2      3     2     2 
 51     97.0     2      3     2     3 
 52    109.3     2      3     3     1 
 53    104.4     2      3     3     2 





Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed       SIN GROUP DIALSYSIS 
 
The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.NANOPARTICLES 
Dependent Variable           Size 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
             Class Level Information 
 
Class    Levels    Values 
 
AC            3    1 2 3 
MW            3    1 2 3 
Dys           2    1 2 
Rep           3    1 2 3 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                     48 
Columns in Z                     27 
Subjects                          1 
Max Obs Per Subject              54 
 
 
          Number of Observations 
 
Number of Observations Read              54 
Number of Observations Used              54 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       188.74031456 
        1              1       178.18514374      0.00000000 
 
 








 Covariance Parameter 
       Estimates 
 
Cov Parm       Estimate 
 
Rep(AC*MW)       4.2600 
Residual         2.1356 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           178.2 
AIC (smaller is better)         182.2 
AICC (smaller is better)        182.5 
BIC (smaller is better)         184.8 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
AC              2      18     829.10    <.0001 
MW              2      18      12.37    0.0004 
AC*MW           4      18      59.33    <.0001 
Dys             1      18      44.21    <.0001 
AC*Dys          2      18      48.56    <.0001 
MW*Dys          2      18       1.97    0.1684 
AC*MW*Dys       4      18      31.21    <.0001 
 
 
                                Least Squares Means 
 
                                            Standard 
Effect       AC    MW    Dys    Estimate       Error      DF    t Value    Pr > |t| 
 
AC           1                   60.3833      0.7694      18      78.48      <.0001 
AC           2                   82.9722      0.7694      18     107.84      <.0001 
AC           3                    104.69      0.7694      18     136.07      <.0001 
MW                 1             81.1111      0.7694      18     105.42      <.0001 
MW                 2             81.1278      0.7694      18     105.44      <.0001 
MW                 3             85.8056      0.7694      18     111.52      <.0001 
AC*MW        1     1             46.5667      1.3326      18      34.94      <.0001 
AC*MW        1     2             65.8833      1.3326      18      49.44      <.0001 
AC*MW        1     3             68.7000      1.3326      18      51.55      <.0001 
AC*MW        2     1             85.0333      1.3326      18      63.81      <.0001 
AC*MW        2     2             83.1000      1.3326      18      62.36      <.0001 
AC*MW        2     3             80.7833      1.3326      18      60.62      <.0001 
AC*MW        3     1              111.73      1.3326      18      83.84      <.0001 
AC*MW        3     2             94.4000      1.3326      18      70.84      <.0001 
AC*MW        3     3              107.93      1.3326      18      80.99      <.0001 
Dys                      1       81.3593      0.4867      18     167.17      <.0001 
Dys                      2       84.0037      0.4867      18     172.60      <.0001 
AC*Dys       1           1       56.3333      0.8430      18      66.83      <.0001 
AC*Dys       1           2       64.4333      0.8430      18      76.44      <.0001 
AC*Dys       2           1       82.5889      0.8430      18      97.97      <.0001 
AC*Dys       2           2       83.3556      0.8430      18      98.88      <.0001 
AC*Dys       3           1        105.16      0.8430      18     124.74      <.0001 
AC*Dys       3           2        104.22      0.8430      18     123.64      <.0001 
MW*Dys             1     1       80.3000      0.8430      18      95.26      <.0001 
MW*Dys             1     2       81.9222      0.8430      18      97.18      <.0001 
MW*Dys             2     1       79.3556      0.8430      18      94.14      <.0001 
MW*Dys             2     2       82.9000      0.8430      18      98.34      <.0001 
MW*Dys             3     1       84.4222      0.8430      18     100.15      <.0001 
MW*Dys             3     2       87.1889      0.8430      18     103.43      <.0001 
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AC*MW*Dys    1     1     1       38.6333      1.4601      18      26.46      <.0001 
AC*MW*Dys    1     1     2       54.5000      1.4601      18      37.33      <.0001 
AC*MW*Dys    1     2     1       63.2667      1.4601      18      43.33      <.0001 
AC*MW*Dys    1     2     2       68.5000      1.4601      18      46.92      <.0001 
AC*MW*Dys    1     3     1       67.1000      1.4601      18      45.96      <.0001 
AC*MW*Dys    1     3     2       70.3000      1.4601      18      48.15      <.0001 
AC*MW*Dys    2     1     1       87.1667      1.4601      18      59.70      <.0001 
AC*MW*Dys    2     1     2       82.9000      1.4601      18      56.78      <.0001 
AC*MW*Dys    2     2     1       81.8000      1.4601      18      56.02      <.0001 
AC*MW*Dys    2     2     2       84.4000      1.4601      18      57.80      <.0001 
AC*MW*Dys    2     3     1       78.8000      1.4601      18      53.97      <.0001 
AC*MW*Dys    2     3     2       82.7667      1.4601      18      56.69      <.0001 
AC*MW*Dys    3     1     1        115.10      1.4601      18      78.83      <.0001 
AC*MW*Dys    3     1     2        108.37      1.4601      18      74.22      <.0001 
AC*MW*Dys    3     2     1       93.0000      1.4601      18      63.69      <.0001 
AC*MW*Dys    3     2     2       95.8000      1.4601      18      65.61      <.0001 
AC*MW*Dys    3     3     1        107.37      1.4601      18      73.53      <.0001 





                                                Differences of Least Squares Means 
 
                                                                  Standard 
Effect       AC    MW    Dys    _AC    _MW    _Dys    Estimate       Error      DF    t Value    Pr > |t|    Adjustment       Adj P 
 
AC           1                  2                     -22.5889      1.0881      18     -20.76      <.0001    Tukey           <.0001 
AC           1                  3                     -44.3056      1.0881      18     -40.72      <.0001    Tukey           <.0001 
AC           2                  3                     -21.7167      1.0881      18     -19.96      <.0001    Tukey           <.0001 
MW                 1                   2              -0.01667      1.0881      18      -0.02      0.9879    Tukey           0.9999 
MW                 1                   3               -4.6944      1.0881      18      -4.31      0.0004    Tukey           0.0012 
MW                 2                   3               -4.6778      1.0881      18      -4.30      0.0004    Tukey           0.0012 
AC*MW        1     1            1      2              -19.3167      1.8846      18     -10.25      <.0001    Tukey           <.0001 
AC*MW        1     1            1      3              -22.1333      1.8846      18     -11.74      <.0001    Tukey           <.0001 
AC*MW        1     1            2      1              -38.4667      1.8846      18     -20.41      <.0001    Tukey           <.0001 
AC*MW        1     1            2      2              -36.5333      1.8846      18     -19.38      <.0001    Tukey           <.0001 
AC*MW        1     1            2      3              -34.2167      1.8846      18     -18.16      <.0001    Tukey           <.0001 
AC*MW        1     1            3      1              -65.1667      1.8846      18     -34.58      <.0001    Tukey           <.0001 
AC*MW        1     1            3      2              -47.8333      1.8846      18     -25.38      <.0001    Tukey           <.0001 
AC*MW        1     1            3      3              -61.3667      1.8846      18     -32.56      <.0001    Tukey           <.0001 
AC*MW        1     2            1      3               -2.8167      1.8846      18      -1.49      0.1524    Tukey           0.8442 
AC*MW        1     2            2      1              -19.1500      1.8846      18     -10.16      <.0001    Tukey           <.0001 
AC*MW        1     2            2      2              -17.2167      1.8846      18      -9.14      <.0001    Tukey           <.0001 
AC*MW        1     2            2      3              -14.9000      1.8846      18      -7.91      <.0001    Tukey           <.0001 
AC*MW        1     2            3      1              -45.8500      1.8846      18     -24.33      <.0001    Tukey           <.0001 
AC*MW        1     2            3      2              -28.5167      1.8846      18     -15.13      <.0001    Tukey           <.0001 
AC*MW        1     2            3      3              -42.0500      1.8846      18     -22.31      <.0001    Tukey           <.0001 
AC*MW        1     3            2      1              -16.3333      1.8846      18      -8.67      <.0001    Tukey           <.0001 
AC*MW        1     3            2      2              -14.4000      1.8846      18      -7.64      <.0001    Tukey           <.0001 
AC*MW        1     3            2      3              -12.0833      1.8846      18      -6.41      <.0001    Tukey           0.0001 
AC*MW        1     3            3      1              -43.0333      1.8846      18     -22.83      <.0001    Tukey           <.0001 
AC*MW        1     3            3      2              -25.7000      1.8846      18     -13.64      <.0001    Tukey           <.0001 
AC*MW        1     3            3      3              -39.2333      1.8846      18     -20.82      <.0001    Tukey           <.0001 
AC*MW        2     1            2      2                1.9333      1.8846      18       1.03      0.3186    Tukey           0.9779 
AC*MW        2     1            2      3                4.2500      1.8846      18       2.26      0.0368    Tukey           0.4145 
AC*MW        2     1            3      1              -26.7000      1.8846      18     -14.17      <.0001    Tukey           <.0001 
AC*MW        2     1            3      2               -9.3667      1.8846      18      -4.97      <.0001    Tukey           0.0025 
AC*MW        2     1            3      3              -22.9000      1.8846      18     -12.15      <.0001    Tukey           <.0001 
AC*MW        2     2            2      3                2.3167      1.8846      18       1.23      0.2348    Tukey           0.9390 
AC*MW        2     2            3      1              -28.6333      1.8846      18     -15.19      <.0001    Tukey           <.0001 
AC*MW        2     2            3      2              -11.3000      1.8846      18      -6.00      <.0001    Tukey           0.0003 
AC*MW        2     2            3      3              -24.8333      1.8846      18     -13.18      <.0001    Tukey           <.0001 
AC*MW        2     3            3      1              -30.9500      1.8846      18     -16.42      <.0001    Tukey           <.0001 
AC*MW        2     3            3      2              -13.6167      1.8846      18      -7.23      <.0001    Tukey           <.0001 
AC*MW        2     3            3      3              -27.1500      1.8846      18     -14.41      <.0001    Tukey           <.0001 
AC*MW        3     1            3      2               17.3333      1.8846      18       9.20      <.0001    Tukey           <.0001 
AC*MW        3     1            3      3                3.8000      1.8846      18       2.02      0.0589    Tukey           0.5519 
AC*MW        3     2            3      3              -13.5333      1.8846      18      -7.18      <.0001    Tukey           <.0001 
Dys                      1                    2        -2.6444      0.3977      18      -6.65      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           1      1             2        -8.1000      0.6889      18     -11.76      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           1      2             1       -26.2556      1.1922      18     -22.02      <.0001    Tukey-Kramer    <.0001 
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AC*Dys       1           1      2             2       -27.0222      1.1922      18     -22.67      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           1      3             1       -48.8222      1.1922      18     -40.95      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           1      3             2       -47.8889      1.1922      18     -40.17      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           2      2             1       -18.1556      1.1922      18     -15.23      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           2      2             2       -18.9222      1.1922      18     -15.87      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           2      3             1       -40.7222      1.1922      18     -34.16      <.0001    Tukey-Kramer    <.0001 
AC*Dys       1           2      3             2       -39.7889      1.1922      18     -33.38      <.0001    Tukey-Kramer    <.0001 
AC*Dys       2           1      2             2        -0.7667      0.6889      18      -1.11      0.2804    Tukey-Kramer    0.8698 
AC*Dys       2           1      3             1       -22.5667      1.1922      18     -18.93      <.0001    Tukey-Kramer    <.0001 
AC*Dys       2           1      3             2       -21.6333      1.1922      18     -18.15      <.0001    Tukey-Kramer    <.0001 
AC*Dys       2           2      3             1       -21.8000      1.1922      18     -18.29      <.0001    Tukey-Kramer    <.0001 
AC*Dys       2           2      3             2       -20.8667      1.1922      18     -17.50      <.0001    Tukey-Kramer    <.0001 
AC*Dys       3           1      3             2         0.9333      0.6889      18       1.35      0.1922    Tukey-Kramer    0.7518 
MW*Dys             1     1             1      2        -1.6222      0.6889      18      -2.35      0.0301    Tukey-Kramer    0.2237 
MW*Dys             1     1             2      1         0.9444      1.1922      18       0.79      0.4386    Tukey-Kramer    0.9653 
MW*Dys             1     1             2      2        -2.6000      1.1922      18      -2.18      0.0427    Tukey-Kramer    0.2933 
MW*Dys             1     1             3      1        -4.1222      1.1922      18      -3.46      0.0028    Tukey-Kramer    0.0285 
MW*Dys             1     1             3      2        -6.8889      1.1922      18      -5.78      <.0001    Tukey-Kramer    0.0002 
MW*Dys             1     2             2      1         2.5667      1.1922      18       2.15      0.0451    Tukey-Kramer    0.3057 
MW*Dys             1     2             2      2        -0.9778      1.1922      18      -0.82      0.4228    Tukey-Kramer    0.9599 
MW*Dys             1     2             3      1        -2.5000      1.1922      18      -2.10      0.0504    Tukey-Kramer    0.3317 
MW*Dys             1     2             3      2        -5.2667      1.1922      18      -4.42      0.0003    Tukey-Kramer    0.0038 
MW*Dys             2     1             2      2        -3.5444      0.6889      18      -5.15      <.0001    Tukey-Kramer    0.0008 
MW*Dys             2     1             3      1        -5.0667      1.1922      18      -4.25      0.0005    Tukey-Kramer    0.0054 
MW*Dys             2     1             3      2        -7.8333      1.1922      18      -6.57      <.0001    Tukey-Kramer    <.0001 
MW*Dys             2     2             3      1        -1.5222      1.1922      18      -1.28      0.2179    Tukey-Kramer    0.7933 
MW*Dys             2     2             3      2        -4.2889      1.1922      18      -3.60      0.0021    Tukey-Kramer    0.0214 
MW*Dys             3     1             3      2        -2.7667      0.6889      18      -4.02      0.0008    Tukey-Kramer    0.0089 
AC*MW*Dys    1     1     1      1      1      2       -15.8667      1.1932      18     -13.30      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      1      2      1       -24.6333      2.0649      18     -11.93      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      1      2      2       -29.8667      2.0649      18     -14.46      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      1      3      1       -28.4667      2.0649      18     -13.79      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      1      3      2       -31.6667      2.0649      18     -15.34      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      2      1      1       -48.5333      2.0649      18     -23.50      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      2      1      2       -44.2667      2.0649      18     -21.44      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      2      2      1       -43.1667      2.0649      18     -20.91      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      2      2      2       -45.7667      2.0649      18     -22.16      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      2      3      1       -40.1667      2.0649      18     -19.45      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      2      3      2       -44.1333      2.0649      18     -21.37      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      3      1      1       -76.4667      2.0649      18     -37.03      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      3      1      2       -69.7333      2.0649      18     -33.77      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      3      2      1       -54.3667      2.0649      18     -26.33      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      3      2      2       -57.1667      2.0649      18     -27.69      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      3      3      1       -68.7333      2.0649      18     -33.29      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     1      3      3      2       -69.8667      2.0649      18     -33.84      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      1      2      1        -8.7667      2.0649      18      -4.25      0.0005    Tukey-Kramer    0.0326 
AC*MW*Dys    1     1     2      1      2      2       -14.0000      2.0649      18      -6.78      <.0001    Tukey-Kramer    0.0002 
AC*MW*Dys    1     1     2      1      3      1       -12.6000      2.0649      18      -6.10      <.0001    Tukey-Kramer    0.0008 
AC*MW*Dys    1     1     2      1      3      2       -15.8000      2.0649      18      -7.65      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      2      1      1       -32.6667      2.0649      18     -15.82      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      2      1      2       -28.4000      2.0649      18     -13.75      <.0001    Tukey-Kramer    <.0001 
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AC*MW*Dys    1     1     2      2      2      1       -27.3000      2.0649      18     -13.22      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      2      2      2       -29.9000      2.0649      18     -14.48      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      2      3      1       -24.3000      2.0649      18     -11.77      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      2      3      2       -28.2667      2.0649      18     -13.69      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      3      1      1       -60.6000      2.0649      18     -29.35      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      3      1      2       -53.8667      2.0649      18     -26.09      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      3      2      1       -38.5000      2.0649      18     -18.65      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      3      2      2       -41.3000      2.0649      18     -20.00      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      3      3      1       -52.8667      2.0649      18     -25.60      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     1     2      3      3      2       -54.0000      2.0649      18     -26.15      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      1      2      2        -5.2333      1.1932      18      -4.39      0.0004    Tukey-Kramer    0.0248 
AC*MW*Dys    1     2     1      1      3      1        -3.8333      2.0649      18      -1.86      0.0798    Tukey-Kramer    0.8954 
AC*MW*Dys    1     2     1      1      3      2        -7.0333      2.0649      18      -3.41      0.0031    Tukey-Kramer    0.1524 
AC*MW*Dys    1     2     1      2      1      1       -23.9000      2.0649      18     -11.57      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      2      1      2       -19.6333      2.0649      18      -9.51      <.0001    Tukey-Kramer    <.0001 




Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
 
The Mixed Procedure 
 
                                                Differences of Least Squares Means 
 
                                                                  Standard 
Effect       AC    MW    Dys    _AC    _MW    _Dys    Estimate       Error      DF    t Value    Pr > |t|    Adjustment       Adj P 
 
AC*MW*Dys    1     2     1      2      2      2       -21.1333      2.0649      18     -10.23      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      2      3      1       -15.5333      2.0649      18      -7.52      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      2      3      2       -19.5000      2.0649      18      -9.44      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      3      1      1       -51.8333      2.0649      18     -25.10      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      3      1      2       -45.1000      2.0649      18     -21.84      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      3      2      1       -29.7333      2.0649      18     -14.40      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      3      2      2       -32.5333      2.0649      18     -15.76      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      3      3      1       -44.1000      2.0649      18     -21.36      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     1      3      3      2       -45.2333      2.0649      18     -21.91      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      1      3      1         1.4000      2.0649      18       0.68      0.5064    Tukey-Kramer    1.0000 
AC*MW*Dys    1     2     2      1      3      2        -1.8000      2.0649      18      -0.87      0.3948    Tukey-Kramer    1.0000 
AC*MW*Dys    1     2     2      2      1      1       -18.6667      2.0649      18      -9.04      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      2      1      2       -14.4000      2.0649      18      -6.97      <.0001    Tukey-Kramer    0.0002 
AC*MW*Dys    1     2     2      2      2      1       -13.3000      2.0649      18      -6.44      <.0001    Tukey-Kramer    0.0004 
AC*MW*Dys    1     2     2      2      2      2       -15.9000      2.0649      18      -7.70      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      2      3      1       -10.3000      2.0649      18      -4.99      <.0001    Tukey-Kramer    0.0075 
AC*MW*Dys    1     2     2      2      3      2       -14.2667      2.0649      18      -6.91      <.0001    Tukey-Kramer    0.0002 
AC*MW*Dys    1     2     2      3      1      1       -46.6000      2.0649      18     -22.57      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      3      1      2       -39.8667      2.0649      18     -19.31      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      3      2      1       -24.5000      2.0649      18     -11.87      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      3      2      2       -27.3000      2.0649      18     -13.22      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      3      3      1       -38.8667      2.0649      18     -18.82      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     2     2      3      3      2       -40.0000      2.0649      18     -19.37      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      1      3      2        -3.2000      1.1932      18      -2.68      0.0152    Tukey-Kramer    0.4501 
AC*MW*Dys    1     3     1      2      1      1       -20.0667      2.0649      18      -9.72      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      2      1      2       -15.8000      2.0649      18      -7.65      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      2      2      1       -14.7000      2.0649      18      -7.12      <.0001    Tukey-Kramer    0.0001 
AC*MW*Dys    1     3     1      2      2      2       -17.3000      2.0649      18      -8.38      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      2      3      1       -11.7000      2.0649      18      -5.67      <.0001    Tukey-Kramer    0.0020 
AC*MW*Dys    1     3     1      2      3      2       -15.6667      2.0649      18      -7.59      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      3      1      1       -48.0000      2.0649      18     -23.25      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      3      1      2       -41.2667      2.0649      18     -19.99      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      3      2      1       -25.9000      2.0649      18     -12.54      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      3      2      2       -28.7000      2.0649      18     -13.90      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      3      3      1       -40.2667      2.0649      18     -19.50      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     1      3      3      2       -41.4000      2.0649      18     -20.05      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     2      2      1      1       -16.8667      2.0649      18      -8.17      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     2      2      1      2       -12.6000      2.0649      18      -6.10      <.0001    Tukey-Kramer    0.0008 
AC*MW*Dys    1     3     2      2      2      1       -11.5000      2.0649      18      -5.57      <.0001    Tukey-Kramer    0.0024 
 
134 
AC*MW*Dys    1     3     2      2      2      2       -14.1000      2.0649      18      -6.83      <.0001    Tukey-Kramer    0.0002 
AC*MW*Dys    1     3     2      2      3      1        -8.5000      2.0649      18      -4.12      0.0006    Tukey-Kramer    0.0418 
AC*MW*Dys    1     3     2      2      3      2       -12.4667      2.0649      18      -6.04      <.0001    Tukey-Kramer    0.0010 
AC*MW*Dys    1     3     2      3      1      1       -44.8000      2.0649      18     -21.70      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     2      3      1      2       -38.0667      2.0649      18     -18.44      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     2      3      2      1       -22.7000      2.0649      18     -10.99      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     2      3      2      2       -25.5000      2.0649      18     -12.35      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     2      3      3      1       -37.0667      2.0649      18     -17.95      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    1     3     2      3      3      2       -38.2000      2.0649      18     -18.50      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     1      2      1      2         4.2667      1.1932      18       3.58      0.0022    Tukey-Kramer    0.1135 
AC*MW*Dys    2     1     1      2      2      1         5.3667      2.0649      18       2.60      0.0181    Tukey-Kramer    0.4972 
AC*MW*Dys    2     1     1      2      2      2         2.7667      2.0649      18       1.34      0.1970    Tukey-Kramer    0.9927 
AC*MW*Dys    2     1     1      2      3      1         8.3667      2.0649      18       4.05      0.0007    Tukey-Kramer    0.0472 
AC*MW*Dys    2     1     1      2      3      2         4.4000      2.0649      18       2.13      0.0471    Tukey-Kramer    0.7707 
AC*MW*Dys    2     1     1      3      1      1       -27.9333      2.0649      18     -13.53      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     1      3      1      2       -21.2000      2.0649      18     -10.27      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     1      3      2      1        -5.8333      2.0649      18      -2.83      0.0112    Tukey-Kramer    0.3738 
AC*MW*Dys    2     1     1      3      2      2        -8.6333      2.0649      18      -4.18      0.0006    Tukey-Kramer    0.0369 
AC*MW*Dys    2     1     1      3      3      1       -20.2000      2.0649      18      -9.78      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     1      3      3      2       -21.3333      2.0649      18     -10.33      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     2      2      2      1         1.1000      2.0649      18       0.53      0.6007    Tukey-Kramer    1.0000 
AC*MW*Dys    2     1     2      2      2      2        -1.5000      2.0649      18      -0.73      0.4769    Tukey-Kramer    1.0000 
AC*MW*Dys    2     1     2      2      3      1         4.1000      2.0649      18       1.99      0.0625    Tukey-Kramer    0.8426 
AC*MW*Dys    2     1     2      2      3      2         0.1333      2.0649      18       0.06      0.9492    Tukey-Kramer    1.0000 
AC*MW*Dys    2     1     2      3      1      1       -32.2000      2.0649      18     -15.59      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     2      3      1      2       -25.4667      2.0649      18     -12.33      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     2      3      2      1       -10.1000      2.0649      18      -4.89      0.0001    Tukey-Kramer    0.0091 
AC*MW*Dys    2     1     2      3      2      2       -12.9000      2.0649      18      -6.25      <.0001    Tukey-Kramer    0.0006 
AC*MW*Dys    2     1     2      3      3      1       -24.4667      2.0649      18     -11.85      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     1     2      3      3      2       -25.6000      2.0649      18     -12.40      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     1      2      2      2        -2.6000      1.1932      18      -2.18      0.0429    Tukey-Kramer    0.7445 
AC*MW*Dys    2     2     1      2      3      1         3.0000      2.0649      18       1.45      0.1635    Tukey-Kramer    0.9843 
AC*MW*Dys    2     2     1      2      3      2        -0.9667      2.0649      18      -0.47      0.6453    Tukey-Kramer    1.0000 
AC*MW*Dys    2     2     1      3      1      1       -33.3000      2.0649      18     -16.13      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     1      3      1      2       -26.5667      2.0649      18     -12.87      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     1      3      2      1       -11.2000      2.0649      18      -5.42      <.0001    Tukey-Kramer    0.0032 
AC*MW*Dys    2     2     1      3      2      2       -14.0000      2.0649      18      -6.78      <.0001    Tukey-Kramer    0.0002 
AC*MW*Dys    2     2     1      3      3      1       -25.5667      2.0649      18     -12.38      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     1      3      3      2       -26.7000      2.0649      18     -12.93      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     2      2      3      1         5.6000      2.0649      18       2.71      0.0143    Tukey-Kramer    0.4334 
AC*MW*Dys    2     2     2      2      3      2         1.6333      2.0649      18       0.79      0.4392    Tukey-Kramer    1.0000 
AC*MW*Dys    2     2     2      3      1      1       -30.7000      2.0649      18     -14.87      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     2      3      1      2       -23.9667      2.0649      18     -11.61      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     2      3      2      1        -8.6000      2.0649      18      -4.16      0.0006    Tukey-Kramer    0.0380 
AC*MW*Dys    2     2     2      3      2      2       -11.4000      2.0649      18      -5.52      <.0001    Tukey-Kramer    0.0026 
AC*MW*Dys    2     2     2      3      3      1       -22.9667      2.0649      18     -11.12      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     2     2      3      3      2       -24.1000      2.0649      18     -11.67      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     1      2      3      2        -3.9667      1.1932      18      -3.32      0.0038    Tukey-Kramer    0.1749 
AC*MW*Dys    2     3     1      3      1      1       -36.3000      2.0649      18     -17.58      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     1      3      1      2       -29.5667      2.0649      18     -14.32      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     1      3      2      1       -14.2000      2.0649      18      -6.88      <.0001    Tukey-Kramer    0.0002 
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AC*MW*Dys    2     3     1      3      2      2       -17.0000      2.0649      18      -8.23      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     1      3      3      1       -28.5667      2.0649      18     -13.83      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     1      3      3      2       -29.7000      2.0649      18     -14.38      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     2      3      1      1       -32.3333      2.0649      18     -15.66      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     2      3      1      2       -25.6000      2.0649      18     -12.40      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     2      3      2      1       -10.2333      2.0649      18      -4.96      0.0001    Tukey-Kramer    0.0080 
AC*MW*Dys    2     3     2      3      2      2       -13.0333      2.0649      18      -6.31      <.0001    Tukey-Kramer    0.0006 
AC*MW*Dys    2     3     2      3      3      1       -24.6000      2.0649      18     -11.91      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    2     3     2      3      3      2       -25.7333      2.0649      18     -12.46      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    3     1     1      3      1      2         6.7333      1.1932      18       5.64      <.0001    Tukey-Kramer    0.0021 
AC*MW*Dys    3     1     1      3      2      1        22.1000      2.0649      18      10.70      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    3     1     1      3      2      2        19.3000      2.0649      18       9.35      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    3     1     1      3      3      1         7.7333      2.0649      18       3.75      0.0015    Tukey-Kramer    0.0837 
AC*MW*Dys    3     1     1      3      3      2         6.6000      2.0649      18       3.20      0.0050    Tukey-Kramer    0.2156 
AC*MW*Dys    3     1     2      3      2      1        15.3667      2.0649      18       7.44      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    3     1     2      3      2      2        12.5667      2.0649      18       6.09      <.0001    Tukey-Kramer    0.0009 
AC*MW*Dys    3     1     2      3      3      1         1.0000      2.0649      18       0.48      0.6340    Tukey-Kramer    1.0000 
AC*MW*Dys    3     1     2      3      3      2        -0.1333      2.0649      18      -0.06      0.9492    Tukey-Kramer    1.0000 
AC*MW*Dys    3     2     1      3      2      2        -2.8000      1.1932      18      -2.35      0.0306    Tukey-Kramer    0.6474 
AC*MW*Dys    3     2     1      3      3      1       -14.3667      2.0649      18      -6.96      <.0001    Tukey-Kramer    0.0002 
AC*MW*Dys    3     2     1      3      3      2       -15.5000      2.0649      18      -7.51      <.0001    Tukey-Kramer    <.0001 
AC*MW*Dys    3     2     2      3      3      1       -11.5667      2.0649      18      -5.60      <.0001    Tukey-Kramer    0.0022 
AC*MW*Dys    3     2     2      3      3      2       -12.7000      2.0649      18      -6.15      <.0001    Tukey-Kramer    0.0008 





Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
post hoc adjustment with macro by Arnold Saxton 
 
Effect=AC ADJUSTMENT=Tukey(P<0.05) bygroup=1 
 
Obs    AC    MW    Dys    Estimate      StdErr    MSGROUP 
 
  1    3     _      _       104.69      0.7694       A 
  2    2     _      _      82.9722      0.7694       B 
  3    1     _      _      60.3833      0.7694       C 
 
 
Effect=MW ADJUSTMENT=Tukey(P<0.05) bygroup=2 
 
Obs    AC    MW    Dys    Estimate      StdErr    MSGROUP 
 
  4    _     3      _      85.8056      0.7694       A 
  5    _     2      _      81.1278      0.7694       B 
  6    _     1      _      81.1111      0.7694       B 
 
 
Effect=AC*MW ADJUSTMENT=Tukey(P<0.05) bygroup=3 
 
Obs    AC    MW    Dys    Estimate      StdErr    MSGROUP 
 
  7    3     1      _       111.73      1.3326       A 
  8    3     3      _       107.93      1.3326       A 
  9    3     2      _      94.4000      1.3326       B 
 10    2     1      _      85.0333      1.3326       C 
 11    2     2      _      83.1000      1.3326       C 
 12    2     3      _      80.7833      1.3326       C 
 13    1     3      _      68.7000      1.3326       D 
 14    1     2      _      65.8833      1.3326       D 
 15    1     1      _      46.5667      1.3326       E 
 
 
Effect=Dys ADJUSTMENT=Tukey-Kramer(P<0.05) bygroup=4 
 
Obs    AC    MW    Dys    Estimate      StdErr    MSGROUP 
 
 16    _     _      2      84.0037      0.4867       A 
 17    _     _      1      81.3593      0.4867       B 
 
 
Effect=AC*Dys ADJUSTMENT=Tukey-Kramer(P<0.05) bygroup=5 
 
Obs    AC    MW    Dys    Estimate      StdErr    MSGROUP 
 
 18    3     _      1       105.16      0.8430       A 
 19    3     _      2       104.22      0.8430       A 
 20    2     _      2      83.3556      0.8430       B 
 21    2     _      1      82.5889      0.8430       B 
 22    1     _      2      64.4333      0.8430       C 
 23    1     _      1      56.3333      0.8430       D 
 
 
Effect=MW*Dys ADJUSTMENT=Tukey-Kramer(P<0.05) bygroup=6 
 
Obs    AC    MW    Dys    Estimate      StdErr    MSGROUP 
 
 24    _     3      2      87.1889      0.8430      A 
 25    _     3      1      84.4222      0.8430      B 
 26    _     2      2      82.9000      0.8430      BC 
 27    _     1      2      81.9222      0.8430      BCD 
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 28    _     1      1      80.3000      0.8430      CD 
 29    _     2      1      79.3556      0.8430      D 
 
 
Effect=AC*MW*Dys ADJUSTMENT=Tukey-Kramer(P<0.05) bygroup=7 
 
Obs    AC    MW    Dys    Estimate      StdErr    MSGROUP 
 
 30    3     1      1       115.10      1.4601      A 
 31    3     3      2       108.50      1.4601      AB 
 32    3     1      2       108.37      1.4601      B 
 33    3     3      1       107.37      1.4601      AB 
 34    3     2      2      95.8000      1.4601      C 
 35    3     2      1      93.0000      1.4601      CD 
 36    2     1      1      87.1667      1.4601      DE 
 37    2     2      2      84.4000      1.4601      EF 
 38    2     1      2      82.9000      1.4601      EF 
 39    2     3      2      82.7667      1.4601      EF 
 40    2     2      1      81.8000      1.4601      EF 
 41    2     3      1      78.8000      1.4601      F 
 42    1     3      2      70.3000      1.4601      GH 
 43    1     2      2      68.5000      1.4601      G 
 44    1     3      1      67.1000      1.4601      GH 
 45    1     2      1      63.2667      1.4601      H 
 46    1     1      2      54.5000      1.4601      I 




Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
Univariate analysis of residuals 
 
The UNIVARIATE Procedure 
Variable:  Resid 
 
                            Moments 
 
N                          54    Sum Weights                 54 
Mean                        0    Sum Observations             0 
Std Deviation      0.93308206    Variance            0.87064214 
Skewness           0.61780823    Kurtosis            1.30643015 
Uncorrected SS     46.1440334    Corrected SS        46.1440334 
Coeff Variation             .    Std Error Mean      0.12697639 
 
 
              Basic Statistical Measures 
 
    Location                    Variability 
 
Mean      0.00000     Std Deviation            0.93308 
Median   -0.12025     Variance                 0.87064 
Mode       .          Range                    4.63333 
                      Interquartile Range      0.89214 
 
 
           Tests for Location: Mu0=0 
 
Test           -Statistic-    -----p Value------ 
 
Student's t    t         0    Pr > |t|    1.0000 
Sign           M        -2    Pr >= |M|   0.6835 
Signed Rank    S     -54.5    Pr >= |S|   0.6432 
 
 
                   Tests for Normality 
 
Test                  --Statistic---    -----p Value------ 
 
Shapiro-Wilk          W     0.953407    Pr < W      0.0351 
Kolmogorov-Smirnov    D     0.114721    Pr > D      0.0762 
Cramer-von Mises      W-Sq  0.156856    Pr > W-Sq   0.0198 
Anderson-Darling      A-Sq    0.8974    Pr > A-Sq   0.0215 
 
 
Quantiles (Definition 5) 
 
Quantile       Estimate 
 
100% Max       2.700799 
99%            2.700799 
95%            2.040987 
90%            1.173660 
75% Q3         0.478603 
50% Median    -0.120250 
25% Q1        -0.413535 
10%           -1.092346 
5%            -1.641995 
1%            -1.932534 







           Extreme Observations 
 
------Lowest-----        -----Highest----- 
 
   Value      Obs           Value      Obs 
 
-1.93253       20         1.36653       19 
-1.82140       15         1.36767       54 
-1.64200       26         2.04099       25 
-1.50014       46         2.44238       13 
-1.20066       48         2.70080       47 
 
 
   Stem Leaf                     #  Boxplot                        Normal Probability Plot 
     26 0                        1     0         2.7+                                                * 
     24 4                        1     0            |                                            * 
     22                                             |                                                 ++ 
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 The analysis of sonication amplitude was performed with the same 
program, but the parameters tested were in molecular weight without addition of MOA 
and sonication amplitude. The proc mixed procedure (α = 0.05) was used.    
 
 
Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
List of Data         SONICATION 
EFFECT 
 
Obs    Size    Son    MW    Rep 
 
  1    38.7     1      1     1 
  2    38.1     1      1     2 
  3    41.4     1      1     3 
  4    67.2     1      2     1 
  5    68.4     1      2     2 
  6    64.9     1      2     3 
  7    70.3     1      3     1 
  8    70.6     1      3     2 
  9    67.1     1      3     3 
 10    38.9     2      1     1 
 11    38.6     2      1     2 
 12    38.4     2      1     3 
 13    63.6     2      2     1 
 14    63.1     2      2     2 
 15    63.1     2      2     3 
 16    66.5     2      3     1 
 17    67.3     2      3     2 
 18    67.5     2      3     3 
 
Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.NANOPARTICLES 
Dependent Variable           Size 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
             Class Level Information 
 
Class    Levels    Values 
 
Son           2    1 2 
MW            3    1 2 3 
Rep           3    1 2 3 
 
 
            Dimensions 
 
Covariance Parameters             2 
 
141 
Columns in X                     12 
Columns in Z                     18 
Subjects                          1 
Max Obs Per Subject              18 
 
 
          Number of Observations 
 
Number of Observations Read              18 
Number of Observations Used              18 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1        47.29665069 
        1              4        47.29665069      0.00000000 
 
 
                   Convergence criteria met. 
 
  Covariance Parameter 
       Estimates 
 
Cov Parm        Estimate 
 
Rep(Son*MW)            0 
Residual          1.7406 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood            47.3 
AIC (smaller is better)          49.3 
AICC (smaller is better)         49.7 
BIC (smaller is better)          50.2 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Son             1      12      12.39    0.0042 
MW              2      12     885.01    <.0001 
Son*MW          2      12       1.69    0.2255 
 
 
                           Least Squares Means 
 
                                   Standard 
Effect    Son    MW    Estimate       Error      DF    t Value    Pr > |t| 
 
Son       1             58.5222      0.4398      12     133.08      <.0001 
Son       2             56.3333      0.4398      12     128.10      <.0001 
MW               1      39.0167      0.5386      12      72.44      <.0001 
MW               2      65.0500      0.5386      12     120.78      <.0001 
MW               3      68.2167      0.5386      12     126.65      <.0001 
Son*MW    1      1      39.4000      0.7617      12      51.73      <.0001 
Son*MW    1      2      66.8333      0.7617      12      87.74      <.0001 
Son*MW    1      3      69.3333      0.7617      12      91.02      <.0001 
Son*MW    2      1      38.6333      0.7617      12      50.72      <.0001 
Son*MW    2      2      63.2667      0.7617      12      83.06      <.0001 






                                        Differences of Least Squares Means 
 
                                                  Standard 
Effect    Son    MW    _Son    _MW    Estimate       Error      DF    t Value    Pr > |t|    Adjustment       Adj P 
 
Son       1            2                2.1889      0.6219      12       3.52      0.0042    Tukey           0.0042 
MW               1             2      -26.0333      0.7617      12     -34.18      <.0001    Tukey           <.0001 
MW               1             3      -29.2000      0.7617      12     -38.34      <.0001    Tukey           <.0001 
MW               2             3       -3.1667      0.7617      12      -4.16      0.0013    Tukey           0.0035 
Son*MW    1      1     1       2      -27.4333      1.0772      12     -25.47      <.0001    Tukey           <.0001 
Son*MW    1      1     1       3      -29.9333      1.0772      12     -27.79      <.0001    Tukey           <.0001 
Son*MW    1      1     2       1        0.7667      1.0772      12       0.71      0.4902    Tukey           0.9768 
Son*MW    1      1     2       2      -23.8667      1.0772      12     -22.16      <.0001    Tukey           <.0001 
Son*MW    1      1     2       3      -27.7000      1.0772      12     -25.71      <.0001    Tukey           <.0001 
Son*MW    1      2     1       3       -2.5000      1.0772      12      -2.32      0.0387    Tukey           0.2577 
Son*MW    1      2     2       1       28.2000      1.0772      12      26.18      <.0001    Tukey           <.0001 
Son*MW    1      2     2       2        3.5667      1.0772      12       3.31      0.0062    Tukey           0.0542 
Son*MW    1      2     2       3       -0.2667      1.0772      12      -0.25      0.8087    Tukey           0.9998 
Son*MW    1      3     2       1       30.7000      1.0772      12      28.50      <.0001    Tukey           <.0001 
Son*MW    1      3     2       2        6.0667      1.0772      12       5.63      0.0001    Tukey           0.0012 
Son*MW    1      3     2       3        2.2333      1.0772      12       2.07      0.0603    Tukey           0.3605 
Son*MW    2      1     2       2      -24.6333      1.0772      12     -22.87      <.0001    Tukey           <.0001 
Son*MW    2      1     2       3      -28.4667      1.0772      12     -26.43      <.0001    Tukey           <.0001 





Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
post hoc adjustment with macro by Arnold Saxton 
 
Effect=Son ADJUSTMENT=Tukey(P<0.05) bygroup=1 
 
Obs    Son    MW    Estimate      StdErr    MSGROUP 
 
  1     1     _      58.5222      0.4398       A 
  2     2     _      56.3333      0.4398       B 
 
 
Effect=MW ADJUSTMENT=Tukey(P<0.05) bygroup=2 
 
Obs    Son    MW    Estimate      StdErr    MSGROUP 
 
  3     _     3      68.2167      0.5386       A 
  4     _     2      65.0500      0.5386       B 
  5     _     1      39.0167      0.5386       C 
 
 
Effect=Son*MW ADJUSTMENT=Tukey(P<0.05) bygroup=3 
 
Obs    Son    MW    Estimate      StdErr    MSGROUP 
 
  6     1     3      69.3333      0.7617      A 
  7     2     3      67.1000      0.7617      A 
  8     1     2      66.8333      0.7617      AB 
  9     2     2      63.2667      0.7617      B 
 10     1     1      39.4000      0.7617      C 
 11     2     1      38.6333      0.7617      C 
 
 
Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
Univariate analysis of residuals 
 
The UNIVARIATE Procedure 
Variable:  Resid 
 
                            Moments 
 
N                          18    Sum Weights                 18 
Mean                        0    Sum Observations             0 
Std Deviation      1.10843469    Variance            1.22862745 
Skewness           -0.3005744    Kurtosis            0.14206577 
Uncorrected SS     20.8866667    Corrected SS        20.8866667 
Coeff Variation             .    Std Error Mean      0.26126056 
 
 
              Basic Statistical Measures 
 
    Location                    Variability 
 
Mean      0.00000     Std Deviation            1.10843 
Median    0.08333     Variance                 1.22863 
Mode     -0.16667     Range                    4.23333 










           Tests for Location: Mu0=0 
 
Test           -Statistic-    -----p Value------ 
 
Student's t    t         0    Pr > |t|    1.0000 
Sign           M         0    Pr >= |M|   1.0000 
Signed Rank    S       5.5    Pr >= |S|   0.8234 
 
 
                   Tests for Normality 
 
Test                  --Statistic---    -----p Value------ 
 
Shapiro-Wilk          W     0.968394    Pr < W      0.7670 
Kolmogorov-Smirnov    D     0.138858    Pr > D     >0.1500 
Cramer-von Mises      W-Sq   0.05184    Pr > W-Sq  >0.2500 
Anderson-Darling      A-Sq  0.293812    Pr > A-Sq  >0.2500 
 
Quantiles (Definition 5) 
 
Quantile        Estimate 
 
100% Max       2.0000000 
99%            2.0000000 
95%            2.0000000 
90%            1.5666667 
75% Q3         0.4000000 
50% Median     0.0833333 
25% Q1        -0.6000000 
10%           -1.9333333 
5%            -2.2333333 
1%            -2.2333333 
0% Min        -2.2333333 
 
            Extreme Observations 
 
------Lowest-----        ------Highest----- 
 
   Value      Obs            Value      Obs 
 
-2.23333        9         0.400000       18 
-1.93333        6         0.966667        7 
-1.30000        2         1.266667        8 
-0.70000        1         1.566667        5 
-0.60000       16         2.000000        3 
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The analysis of entrapment efficiency (EE) was performed with the same 
program, but the parameters tested were in molecular weight (MW), and MOA (AC). The 
proc mixed procedure (α = 0.05) was used with Tukey adjustment.    
 
Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
List of Data 
 
Obs      EE     AC    MW    Rep 
 
  1     68.3     2     1     1 
  2     49.1     2     1     2 
  3     54.7     2     1     3 
  4     82.2     2     2     1 
  5     72.0     2     2     2 
  6     77.8     2     2     3 
  7     62.8     2     3     1 
  8     93.2     2     3     2 
  9     54.6     2     3     3 
 10     71.7     3     1     1 
 11     64.8     3     1     2 
 12     92.3     3     1     3 
 13     69.2     3     2     1 
 14     84.3     3     2     2 
 15     82.7     3     2     3 
 16    125.0     3     3     1 
 17     58.4     3     3     2 
 18     92.2     3     3     3 
 
 
Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
 
The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.NANOPARTICLES 
Dependent Variable           EE 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
             Class Level Information 
 
Class    Levels    Values 
 
AC            2    2 3 
MW            3    1 2 3 
Rep           3    1 2 3 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                     12 
Columns in Z                     18 
Subjects                          1 
 
146 





          Number of Observations 
 
Number of Observations Read              18 
Number of Observations Used              18 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       109.86421701 
        1              2       109.86421700      0.00000000 
 
 
                   Convergence criteria met. 
 
 
 Covariance Parameter 
       Estimates 
 
Cov Parm       Estimate 
 
Rep(AC*MW)       319.94 
Residual       0.007751 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           109.9 
AIC (smaller is better)         113.9 
AICC (smaller is better)        115.2 
BIC (smaller is better)         115.6 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
AC              1      12       2.75    0.1230 
MW              2      12       1.05    0.3790 
AC*MW           2      12       0.57    0.5821 
 
 
                           Least Squares Means 
 
                                  Standard 
Effect    AC    MW    Estimate       Error      DF    t Value    Pr > |t| 
 
AC        2            68.3000      5.9624      12      11.46      <.0001 
AC        3            82.2889      5.9624      12      13.80      <.0001 
MW              1      66.8167      7.3024      12       9.15      <.0001 
MW              2      78.0333      7.3024      12      10.69      <.0001 
MW              3      81.0333      7.3024      12      11.10      <.0001 
AC*MW     2     1      57.3667     10.3272      12       5.55      0.0001 
AC*MW     2     2      77.3333     10.3272      12       7.49      <.0001 
AC*MW     2     3      70.2000     10.3272      12       6.80      <.0001 
AC*MW     3     1      76.2667     10.3272      12       7.39      <.0001 
AC*MW     3     2      78.7333     10.3272      12       7.62      <.0001 





                                       Differences of Least Squares Means 
 
                                                Standard 
Effect    AC    MW    _AC    _MW    Estimate       Error      DF    t Value    Pr > |t|    Adjustment       Adj P 
 
AC        2           3             -13.9889      8.4321      12      -1.66      0.1230    Tukey           0.1230 
MW              1            2      -11.2167     10.3272      12      -1.09      0.2988    Tukey           0.5401 
MW              1            3      -14.2167     10.3272      12      -1.38      0.1938    Tukey           0.3830 
MW              2            3       -3.0000     10.3272      12      -0.29      0.7764    Tukey           0.9547 
AC*MW     2     1     2      2      -19.9667     14.6048      12      -1.37      0.1966    Tukey           0.7446 
AC*MW     2     1     2      3      -12.8333     14.6048      12      -0.88      0.3968    Tukey           0.9447 
AC*MW     2     1     3      1      -18.9000     14.6048      12      -1.29      0.2200    Tukey           0.7829 
AC*MW     2     1     3      2      -21.3667     14.6048      12      -1.46      0.1692    Tukey           0.6917 
AC*MW     2     1     3      3      -34.5000     14.6048      12      -2.36      0.0359    Tukey           0.2429 
AC*MW     2     2     2      3        7.1333     14.6048      12       0.49      0.6341    Tukey           0.9957 
AC*MW     2     2     3      1        1.0667     14.6048      12       0.07      0.9430    Tukey           1.0000 
AC*MW     2     2     3      2       -1.4000     14.6048      12      -0.10      0.9252    Tukey           1.0000 
AC*MW     2     2     3      3      -14.5333     14.6048      12      -1.00      0.3393    Tukey           0.9109 
AC*MW     2     3     3      1       -6.0667     14.6048      12      -0.42      0.6852    Tukey           0.9980 
AC*MW     2     3     3      2       -8.5333     14.6048      12      -0.58      0.5699    Tukey           0.9902 
AC*MW     2     3     3      3      -21.6667     14.6048      12      -1.48      0.1637    Tukey           0.6801 
AC*MW     3     1     3      2       -2.4667     14.6048      12      -0.17      0.8687    Tukey           1.0000 
AC*MW     3     1     3      3      -15.6000     14.6048      12      -1.07      0.3065    Tukey           0.8848 




Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
post hoc adjustment with macro by Arnold Saxton 
 
Effect=AC ADJUSTMENT=Tukey(P<0.05) bygroup=1 
 
Obs    AC    MW    Estimate      StdErr    MSGROUP 
 
  1    3     _      82.2889      5.9624       A 
  2    2     _      68.3000      5.9624       A 
 
 
Effect=MW ADJUSTMENT=Tukey(P<0.05) bygroup=2 
 
Obs    AC    MW    Estimate      StdErr    MSGROUP 
 
  3    _     3      81.0333      7.3024       A 
  4    _     2      78.0333      7.3024       A 
  5    _     1      66.8167      7.3024       A 
 
 
Effect=AC*MW ADJUSTMENT=Tukey(P<0.05) bygroup=3 
 
Obs    AC    MW    Estimate      StdErr    MSGROUP 
 
  6    3     3      91.8667     10.3272       A 
  7    3     2      78.7333     10.3272       A 
  8    2     2      77.3333     10.3272       A 
  9    3     1      76.2667     10.3272       A 
 10    2     3      70.2000     10.3272       A 




Randomize complete design (one-way anova) 
effect of PLGA molecular weight, MOA, and dialysis in Np size 
 CRD with proc mixed 
Univariate analysis of residuals 
 
The UNIVARIATE Procedure 
Variable:  Resid 
 
                            Moments 
 
N                          18    Sum Weights                 18 
Mean                -8.29E-15    Sum Observations    -1.492E-13 
Std Deviation      0.00036405    Variance            1.32536E-7 
Skewness           0.18387008    Kurtosis            1.17850428 
Uncorrected SS     2.25311E-6    Corrected SS        2.25311E-6 
Coeff Variation    -4.3917E12    Std Error Mean      0.00008581 
 
 
              Basic Statistical Measures 
 
    Location                    Variability 
 
Mean     -0.00000     Std Deviation          0.0003641 
Median   -0.00003     Variance              1.32536E-7 
Mode       .          Range                    0.00161 









           Tests for Location: Mu0=0 
 
Test           -Statistic-    -----p Value------ 
 
Student's t    t  -966E-13    Pr > |t|    1.0000 
Sign           M         0    Pr >= |M|   1.0000 
Signed Rank    S      -4.5    Pr >= |S|   0.8650 
 
 
                   Tests for Normality 
Test                  --Statistic---    -----p Value------ 
 
Shapiro-Wilk          W     0.969305    Pr < W      0.7845 
Kolmogorov-Smirnov    D     0.133315    Pr > D     >0.1500 
Cramer-von Mises      W-Sq  0.050249    Pr > W-Sq  >0.2500 
Anderson-Darling      A-Sq  0.318331    Pr > A-Sq  >0.2500 
 
 
 Quantiles (Definition 5) 
 
Quantile          Estimate 
100% Max       8.02645E-04 
99%            8.02645E-04 
95%            8.02645E-04 
90%            5.57168E-04 
75% Q3         1.34851E-04 
50% Median    -2.82622E-05 
25% Q1        -2.00258E-04 
10%           -3.77905E-04 
5%            -8.10720E-04 
1%            -8.10720E-04 
0% Min        -8.10720E-04 
 
 
               Extreme Observations 
--------Lowest-------        -------Highest------- 
       Value      Obs               Value      Obs 
 
-0.000810720       17         0.000134851       14 
-0.000377905        9         0.000264857        1 
-0.000277777       11         0.000388403       12 
-0.000230942       13         0.000557168        8 
-0.000200258        2         0.000802645       16 
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